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In the following work, nanoparticle quantum dot (QD) fluorophores have been 
exploited to measure biologically relevant analytes via a miniaturized sensor ensemble to 
provide key diagnostic and prognostic information in a rapid, yet sensitive manner—data 
essential for effective treatment of many diseases including HIV/AIDS and cancer. At the 
heart of this ―nano-bio-chip‖ (NBC) sensor is a modular chemical/cellular processing unit 
consisting of either a polycarbonate membrane filter for cell-based assays, or an agarose 
bead array for detection of biomarkers in serum or saliva. Two applications of the NBC 
sensor system are described herein, both exhibiting excellent correlation to reference 
methods (R
2
 above 0.94), with analysis times under 30 minutes and sample volumes 
below 50 µL.   
First, the NBC sensor was employed for the sequestration and enumeration of T 
lymphocytes, cells specifically targeted by HIV, from whole blood samples. Several 
different conjugation methods linking QDs to recognition biomolecules were extensively 
characterized by biological and optical methods, with a thiol-linked secondary antibody 
labeling scheme yielding intense, specific signal. Using this technique, the photostability 
 viii 
of QDs was exploited, as was the ability to simultaneously visualize different color QDs 
via a single light pathway, effectively reducing optical requirements by half. Further, T-
cell counts were observed well below the 200/µL discriminator between HIV and AIDS 
and across the common testing region, demonstrating the first reported example of cell 
counting via QDs in an enclosed, disposable device.   
Next, multiplexed bead-based detection of cancer protein biomarkers CEA, Her-
2/Neu, and CA125 in serum and saliva was examined using a sandwich immunoassay 
with detecting antibodies covalently bound to QDs. This nano-based signal was amplified 
30 times versus molecular fluorophores and cross talk in multiplexed experiments was 
less than 5%. In addition, molecular-level tuning of recognition elements (size, 
concentration) and agarose porosity resulted in NBC limits of detection two orders of 
magnitude lower than ELISA, values competitive with the most sensitive methods yet 
reported (0.021 ng/mL CEA). Taken together, these efforts serve to establish the valuable 
role of QDs in miniaturized diagnostic devices with potential for delivering biomedical 
information rapidly, reliably, and robustly.  
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 AF – Alexa Fluor; trademarked brand name for a series of molecular fluorophores 
 Agn. – Antigen; often synonymous with the analyte in immunoassay 
 AIDS – Acquired Immunodeficiency Syndrome 
 B – Background; signal present at a zero analyte concentration 
 BSA – Bovine Serum Albumin; a common protein used to stabilize other 
polypeptides  
 c.Ab. – Capture Antibody; immobilization ligand in sandwich immunoassay 
 CA125 – Cancer Antigen 125; a cancer biomarker 
 CAOI – Circular Area of Interest; describes a collection of pixels 
 CCD – Charge Coupled Device; array of photosensitive elements; heart of digital 
photography 
 CD – Cluster of Differentiation or Complementarity Domain; cell surface epitope 
that defines cellular function and development 
 CD3 – a common lymphocyte CD 
 CD4 – a CD present in lymphocytes and monocytes 
 CD8 – a CD specific to killer lymphocytes 
 CEA – Carcinoembryonic Antigen; a common epithelial cancer biomarker 
 CFD – Computational Fluid Dynamics; in silico approach used to model and 
optimize reagent transport and liquid delivery in microfluidic systems 
 CP – Circular Profile; a collection of pixels defined by deconvolution macro 
 CPU – Central Processing Unit or Cellular Processing Unit or Chemical 
Processing Unit; the reactive core of computers or nano-bio-chip assemblages  
 CRP – C-Reactive Protein; a well-studied marker of inflammation  
 Ctrl. – Control 
 CV – Coefficient of Variation; descriptor of deviation within a collection of 
measurements 
 D – Doughnut; a collection of pixels defined by deconvolution macro 
 d.Ab. – Detecting Antibody; the transduction element in sandwich immunoassay 
 DTT – Dithiothreitol; a powerful reducing agent 
 EDC – 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide; a popular zero-length 
cross-linker used to link carboxyls to primary amines.   
 ELISA – Enzyme Linked Immunosorbent Assay; well-established approach for 
protein measurements using a sandwich arrangement of antibodies and a color-
changing substrate  
 xiv 
 F(ab’)2 – Fragment of whole IgG without Fc region containing both antigen 
recognition regions 
 Fab – Fragment of whole IgG without Fc region containing one antigen 
recognition region 
 Fc – Fragment Crystallizable; portion of IgG forming non-antigen binding stem 
 FC – Flow Cytometry; a common bioanalytical technique to counting and sort 
cells  
 FDA – Food and Drug Administration; a government body charged with 
regulating safety  
 FITC – Fluorescein Isothiocyanate; a common green fluorescing molecule  
 FOV – Field of View; the amount of space a microscope may view at any given 
time with a given objective of defined magnification  
 FRET – Fluorescence (also Förster) Resonance Energy Transfer; optical 
phenomenon of non-radiative energy transfer energy from an excited donor 
molecule to an acceptor, causing emission  
 FWHM – Full Width at Half Maximum; descriptor of uniformity in a collection 
of measurements  
 GLP – Good Laboratory Practice; systemic effort to improve the quality of 
technique 
 Her-2/Neu (Her-2 or C-erbB-2) – Human Epithelial Growth Factor Receptor 2;  
indicator of aberrant smooth tissue growth 
 HIV – Human Immunodeficiency Virus; precursor to AIDS; infects CD3+CD4+ 
lymphocytes  
 IgG – Immunoglobulin G; protein used for immunity  
 IgG1 – Immunoglobulin G in mouse; protein used for murine immunity 
 IL-1ß – Interleukin 1-beta; cytokine used by circulating WBCs for 
communication  
 ISE – Ion Selective Electrode; chemical/mechanical ensemble for measurement of 
charged atomic species 
 LOC – Lab on a Chip; any type of small, novel analytical tool replacing many 
aspects of bench-based laboratory 
 LOD – Limit of Detection; the lowest amount of analyte that may be reliably 
measured with a given technique  
 LP – Line Profile; a collection of pixels defined by deconvolution macro 
 MEMS – Microelectromeachnical Structures; micrometer-scale machines 
 MW – Molecular Weight; mass of one mole of a substance  
 xv 
 N – Noise; any type of variation in signal  
 NBC – Nano-Bio-Chip; an integrated measurement assemblage for medically 
themed analyte classes  
 NHS – N-hydroxy succinimide; carboxylic acid activator and EDC stabilizer 
 NK – Natural Killer; class of cytotoxic lymphocytes  
 PBS – Phosphate Buffered Saline; a common laboratory diluents; isotonic with 
serum 
 PCR – Polymerase Chain Reaction; nucleic acid amplification procedure  
 PDB – Protein Database; repository for polypeptide structures  
 PDMS – Poly-dimethylsiloxane; a silicon based organic polymer; plastic 
 PEG – Poly-ethyleneglycol; a hydrophilic plastic  
 PEO – Poly-ethyleneoxide; synonym for PEG 
 PMMA – Poly-methyl-methacrylate; a strong plastic; Plexiglass® 
 POC – Point-of-Care; a health paradigm focusing on treatment and diagnostic 
events moving to patient not vice versa  
 PVC – Poly-vinyl-chloride; a common, sometimes brittle plastic 
 QD – Quantum Dot; a class of fluorescent semiconductor nanoparticles  
 QD XXX – QD with emission maximum; e.g. QD 565 has emission peak at 565 
nm 
 S – Signal; transduction output specific to the analyte in question 
 SBR – Signal to Background Ratio; a measure of analyte-specific transduction 
output quality versus the system’s ambient output 
 SEM – Scanning Electron Microscopy; powerful technique for gleaning 3D 
surface imagery  
 SERS – Surface Enhanced Raman Spectroscopy; a scatter-based technique  
 SMCC - succinimidyl 4-(N-maleimidomethyl) cyclohexanecarboxylate; a PEG-
amino activator  
 SNR – Signal to Noise Ratio; a measure of analyte-specific transduction output 
quality versus the system’s variation in output 
 TAT – Turnaround Time; the temporal difference between iniation of analytical 
procedure and results 
 TEM – Transmission Electron Microscopy; analytical technique with ultra-
sensitive resolution  
 TIFF (TIF) – Top Image File Format; a data storage paradigm typical of images 
 µTAS – Micro Total Analysis System; any assemblage combing various facets of 
the analytical process into a small device footprint 
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150
 (PDB ID = 1igy) recognition element remains nearly identical in size (B).  D)  The 
larger size of CEA results from its increased molecular weight (* indicates glycosolated 
weight) and larger number of amino acids.  (Images reprinted in accordance with the 
policies of the Research Collaboratory for Structural Bioinformatics’ Protein Data Base 
at Brookhaven National Laboratory.
265
) ......................................................................... 160 
 
Figure 4.17.  Analyte Size Affects Bead Behavior.   (A)  Three-color identification 
approach is used for two different size analytes.  (B) Signal from the larger CEA 
molecules (27 nm) signal remains on the exterior.  (C)  IL-1ß is a smaller, globular 
protein (5 nm) and allows for deeper penetration of immunoassay components.  (D) 
Regardless of bead porosity, all CEA antigen and detecting antibody remains in the thin 
layer on the bead exterior, unlike IL-1ß behavior (E) in which a gradual decrease in 
analyte is seen from exterior to interior.  (Please see Figure 4.15 for optical settings.) 162 
 
Figure 4.18.  Concentration affects bead behavior.   (A)  The three-color identification 
approach from Figure 4.2 is retained for two concentrations of CEA detecting antibody.  
(B) At high concentrations, signal remains on the exterior; however, at lower 
concentrations (C) the distance between capture elements increases allowing deeper 
penetration of immunoassay components.  (Please see Figure 4.20 for optical settings.)
......................................................................................................................................... 165 
 
Figure 4.19.  Line profiles of immunoassay components from Figure 4.18.  The 
behavior of detecting antibody is confined to the bead exterior at higher concentrations of 
capture antibody (A) than the isotopic distribution seen at lower concentrations (B). (C) 
This accumulation of detection body on the periphery of A is in sharp contrast to the 
capture antibody distribution seen in the same system.  (D)  At lower concentrations of 
capture antibody, the differences in bead potency may be seen.  In the 1% beads, there is 
an excess of capture reagent, allowing this signal to penetrate all the way to center.  In 
contrast, the 4% beads have more active sites, effectively depleting all of the reagent 
before penetration to center is possible. .......................................................................... 166 
 xxx 
Figure 4.20.  Chip Design Considerations.  Computational fluid dynamic (CFD) studies 
indicate that the vast majority of NBC flow when using the silicon MEMS chip is around 
the bead.  Red arrows in A (xz plane), B (xy plane), and E (xz plane expanded) indicate 
the most flow at 0.3 mL/min passes through the openings between bead and bottom of the 
well.  Indeed the convective flow indicated by red in D is in contrast to the mostly 
diffusive transport in the bead, shown in blue.  Although no CFD work has been done 
modeling the stainless steel support (C), observations made with the NBC suggest that it 
behaves very differently than the etched silicon chip (D). ............................................. 168 
 
Figure 4.21.  Optical Settings Experiment for Verification of Signal.  In A, the same 
image is seen as in Figure 4.14B along with the optical settings needed for all three 
photomultiplier tubes on the confocal microscope.  B) Here also is the same specimen 
imaged at the more sensitive optical settings required for the lower concentration 
specimen from Figure 4.14C.  The similarity of the two images implies that the 
distribution differences seen in Figure 4.14 are not due to increased gain (sensitivity) or 
offset of confocal optical settings as penetration depths do not increase. ...................... 170 
 
Figure 4.22.  Cross Talk Negative Control.  Beads only functionalized to capture 
antibody imaged at the optical settings detailed in Figure 4.14B with all three 
photomultiplier tubes.  That absence of signal in the green and blue channels implies that 
the presence of signal in the above experiments is genuine. .......................................... 171 
 
Figure 4.23. Occlusion of Nano-Channels. A and B) Agarose pore channels coated with 
detecting antibody.  Smaller bodies, however, such as IL-1ß (35 nm) shown in C, allow 
penetration deeper into the bead interior.  D) Larger immunocompelxes however, such as 
CEA (57nm) may block reagent transport in the agarose pores. .................................... 173 
 
Figure 4.24.  Reagent Usage in Sandwich Immunoassay Systems.  The above 
comparison illustrates the fundamental differences between ELISA and the bead-based 
NBC for protein measurements.  By using a 3D versus 2D reaction vessel (A) and an 
intricate lattice of immobilization moieties versus a planar system (B), the NBC allows 
for a much higher density of reagent capture centers and thus a high capacity for 
reporting the presence of analyte (C).............................................................................. 178 
 
Figure D.1.  Horizontal Cross Section of Compact NBC Labcard.  A variety of 
components condense to create the integrated NBC.  These include the buffer storage 
blister packs, fluid direction cavities, waste disposal reservoirs, and the analysis chamber.
......................................................................................................................................... 184 
 xxxi 
Figure D.2.  Complete Assembly of Working Parts.  Many different components 
condense to create the integrated NBC (B), which contains the buffer storage blister 
packs, fluid direction cavities, waste disposal reservoirs, and the analysis chamber.  The 
two processor types (C) cited above (ii – Chapter 2, ii – Chapter 2 and 3) include the 
membrane-based, cellular processing unit (upper scheme i), for cellular assays, while the 
bead-based, chemical processing unit (lower scheme ii), is typified by protein assays.  
Both must bridge nanometer scale gaps between bioligand and signaling probe (E and F) 
to create bioconjugates for analyte fluorescence labeling (D) within the CPU.  Data 
contained in the samples and processed by the labcard is transcribed by a portable, self-
contained analyzer (A). ................................................................................................... 185 
 
Figure D.3.  Scaling and Moore’s Law Behavior.  The ability to bridge different gaps 
in scale (A) and combine the attributes of different layers results in an increasing number 
of analysis events on a small device footprint advances at a rate reminiscent of Moore‘s 
Law in the microelectronics industry (B). ...................................................................... 186 
 
Figure A.1.  Optimization of Excitation and Emission Optics.  These experiments 
reveals the importance of considering and evaluating carefully all optical assemblages 
used in conjucation with the NBC. ................................................................................. 188 
 
Figure A.2.  Optimization of Primary and Secondary Antibody Concentrations.  A) 
A constant volume secondary antibody was used in tandem with increasing volumes of 
primary.  Collected were total cell counts as well as non-specific (NS) aggregates outside 
of the cellular analysis parameters.  This NS value was used in tandem with background 
(B) counts to give a ratio of these events versus authentic cell counts.  Concentrations of 
reagents that minimized this parameter were needed.  B)  After 10 µg/mL was identified 
as the optimal quantity of primary antibody, the secondary antibody was similarly 
optimized.  Future experiments used 10 nM secondary antibody.  Two different camera 




Chapter 1: Background for and Introduction to Nano-Bio-Chip 
Approach to Point-of-Care Diagnostics  
1.1 OVERVIEW 
This dissertation research focuses on developments occurring in the nanomaterial, 
microfluidic, and clinical communities by integrating semiconductor nanoparticle 
quantum dots (QDs) into miniaturized sensor systems as a new labeling and detection 
modality for ―nano-bio-chip‖ (NBC) applications. These efforts have resulted in a 
superior fluorescent transduction signal with reduced optical requirements for 
multianalyte assays targeting cellular and protein-based disease biomarkers relevant to 
cancer diagnosis and staging as well as HIV monitoring.  Implications of such QD 
applications include enhanced potential for miniaturization of sensor components toward 
development of portable, point-of-care devices which could increase access to diagnostic 
testing in remote or unconventional locations as well as decreased limits of detection due 
to QD signal strength.      
This introductory chapter will serve to define the general problems addressed by 
the dissertation as well as to detail key terms used throughout the remainder of the 
document.    In addition, a brief account of nanotechnology, miniaturized microfluidic 
hardware, and molecular diagnostic biomarkers will demonstrate the trend towards 
coherent and integrated assemblages.  After highlighting some of the work of leaders in 
these fields, a summary will paint a picture of the research landscape in 2003, when this 
investigation was initiated.  Such a précis will expose some of the fundamental 
shortcomings associated with previous work and orient the reader to the laboratory 
infrastructure used in these studies. Finally, brief synopses of the following three chapters 
will outline their role in making this study of nano-bio-chip systems complete.   
 
A    A 
 2 
1.1 STATEMENT OF PROBLEM  
Two core deficiencies in existing biomedical infrastructure and technologies 
motivated this work with NBC systems. First among these unmet clinical needs, is a lack 
of access to diagnostic testing, and hence results, to dictate the proper course of treatment 
for HIV positive individuals.
1, 2
  The majority of the world‘s population lives in the 
developing world where there is little, if any, regular access to a healthcare provider, 
much less a well-equipped clinical laboratory.  In these environments, pharmacologic 
therapeutic interventions may exist due to humanitarian efforts, but a lack of diagnostic 
equipment prevents these drugs from being appropriately dispensed, as information on 
HIV disease state progression to AIDS is unavailable.  Lack of access to HIV appropriate 
prognostics, namely T lymphocyte counts, in these environments results in patients being 
staged with AIDS by opportunistic infections (symptoms), not cell counts.  In these 
resource-scarce settings, rapid and cheap diagnostic and prognostic tests create the ability 
to identify individuals who may be best helped by the available therapeutics and work to 
delay the HIV to AIDS process.   
Alternatively, in more affluent regions, the most prominent causes of death 
change to heart disease and cancer as life expectancy is increased.  Here, the unmet 
clinical need is no longer accessibility, but rather diagnostics that identify the disease in 
its early stages with sensitivity and selectivity.  Similar to resource-scare settings, tests 
that are inexpensive and rapid remain important, but these diagnostic schemes must also 
meet additional requirements.  First, they must monitor many different analytes 
concurrently—this so called ―disease fingerprinting‖ allows clinicians to make much 
more timely and accurate diagnoses.  A second requirement is portable tests that can be 
used in the doctor‘s office or ambulance, that is, the point-of-care.  These decrease the 
time from diagnosis to therapy which has the potential to improve overall patient 
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outcomes.  The approach to making rapid, reliable, rugged, multiplexed, portable, and 
inexpensive diagnostic aids, detailed in this dissertation, builds upon previous work.   
1.2 BACKGROUND 
Traditional approaches to testing clinical biological samples involve a well-
appointed centralized laboratory, serviced by technicians and coupled to patients through 
various staff including nurses, aids, and phlebotomists.  The physician‘s laboratory orders 
relate to the lab also through nursing and support staff.  In this arrangement, laboratory 
diagnostic medicine is effectively three degrees of separation removed from the patient 
and this hierarchy introduces a number of critical junctures in which errors may be 
introduced and delay incurred.  To simplify, a push has been made toward devices that 
give results at the point-of-care (POC), i.e. bedside, ambulance, or remote location, a 
situation advantageous to patient, provider, and nursing.
3-6
  The POC solution used in this 
work, the NBC, utilizes components from the three areas detailed below.  Figure 1.1 
illustrates that the evolution of work leading to the nano-bio-chip proceeded along three 
main avenues.  First, nanoparticle quantum dots have been better characterized, more 
biocompatible, and eventually commercially available.  Second, biological markers of 
disease whether cellular, proteomic, or genetic have increased in number and relevance.  
Third, microfluidics and other miniaturization schemes have led to a rapid decrease in 
instrument size and an increase in chip-based, hand-held approaches to biological 
determinations.   
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Figure 1.1. Trends Toward Coherent POC Biomedical Devices.  Triumvirate 
advances in areas essential to development of the current NBC design: molecular 
diagnostic biomarkers, miniaturization of laboratory components via microfluidics, and 
nanoparticle quantum dots.   
1.3.1 Biomarkers of Disease 
Critical to the NBC are two key types of elements found in (or inspired by) nature 
or else synthesized in living organisms.  First, is the biological recognition element. 
Common to nearly all approaches of disease monitoring is the presence of some type of 
molecule or other moiety, tasked with specifically isolating the analyte from the larger, 
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more complex sample.  Lechtins for carbohydrates, oligos for nucleic acids, and 
aptamers, peptides, antibodies, and scFv fragments for proteins are all commonly used to 
achieve this task.
7
   Typically, this arrangement demands that each analyte be segregated 
by a unique recognition body and advances in dense arrays, especially genomic, has 
increased dramatically the density of such patterns as evidenced by such companies as 
Affymetrix.
8
  Emerging schema propose molecular recognition, without prior knowledge 
of the exact structure and identity of the target.
9-11
  
The second ―bio‖ entity in the NBC is the malady-specific indicator, or 
biomarker.  Beginning with protein studies at the turn of the last century, to the 
elucidation of DNA structure in 1953, and the advent of biomarker panels in the 1990s, 
clinical laboratory science has advanced substantially to increase both the number of 
molecular diagnostics tests, but also their impact on treatment.
12-14
 From CEA‘s 
identification as the first biomarker, to later broad acceptance of proteomic PSA and 
genomic BRCA1 as cancer indicators, to emerging molecules for stroke, Alzheimer‘s, 
cardiac, and pancreatic monitoring, the importance and relevance of these markers has 
been drastic.
15
  As a larger number of proteins and cell types were able to be routinely 
analyzed, more studies into their role in disease could be performed, which in turn 
increased the importance of monitoring these analytes after their implication in disease 
prediction or response to therapy was established.   
With the commercialization of monoclonal antibodies, matched immunoassay 
antibody pairs, and modern instrumentation a new generation of experiments were 
possible to measure proteins and large numbers of cells and cell populations.  By the 
1980s extensive laboratory panels including complete blood counts as well as chemical, 
coagulation, immunology, and microbiology information were possible.  Later, the next 
generation of the genetic revolution—completion of the human genome project in 
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2003—added yet another layer of complexity to the variety of components necessary to 
arrive at an accurate diagnosis.
16
 No longer were single assays acceptable to diagnosis 
patients, rather, the requirements for disease identification moved to a battery of analyses.  
Here, disease fingerprinting utilizes large information pools while companion diagnostics 
further defines disease subsets.
17, 18
  Ultimately, these advances in the number and use of 
genetic and proteomic biomarkers have begun to transform health care into personalized 
medicine.
19, 20
  More detailed descriptions of the proteins and cells analyzed by the NBC 
will be given in the introductions of the respective chapters.   
1.3.2 Instrumentation Evolves via Microfluidics 
Early chemical analysis was not amenable to biological systems.  These classical 
methods isolated the analyte from the sample through some type of chemical 
transformation, i.e. precipitation, distillation and/or the compound of interest was titrated 
with a secondary reagent.  A change in physical property such as color, refractive index, 
boiling point, etc. then determined the amount of analyte present.  Near the turn of the 
last century, scientists moved beyond these easily monitored physical properties to more 
difficult characteristics including absorption or emission of radiation, conductivity, and 
mass-to-charge ratio.  In addition, more evolved separation methods such as 
electrophoresis and chromatography began to supplant extraction and other less 
sophisticated  isolation methods.  As more reliable tools were engineered to use advanced 
physical properties for transduction, in tandem with advanced separation schemes, 
instrumental analysis was born.   
Still, biological analysis was not easily performed with the vast majority of 
instrumental techniques for reasons of sensitivity, selectivity, and the destructive nature 
of sample preparation.  Nevertheless, from such humble beginnings as Coulter counting 
and ion selective electrodes, clinical chemistry began to have a profound impact on the 
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way physicians treated their patients.
21, 22
  Similar to the history of the biomarkers 
themselves, a positive feedback loop emerged in which the importance of the disease 
indicators fed a need for instrumentation to study the biomarker, in turn uncovering more 
information about its role in disease.  The 1980s saw a true coming of age of clinical 
instrumentation with the advent of large scale commercially available flow cytometers, 
hematology instruments, as well as automated benchtop immunoassay and clinical 
chemistry analyzers.
23
  During this same time, however, researchers began to shrink these 
room-sized pieces of equipment into smaller spaces for ease of both patient and provider.   
The first commonly accepted ―lab-on-a-chip‖ (LOC) type study dates to Terry‘s 
work with miniaturized gas chromatography in the late 1970s.
24
 For the next decade, 
miniaturization researchers focused mainly on the electronics industry, although a few 
key innovations were introduced for biomedical applications.  Importantly, the 1980s saw 
the handheld glucose meter become one of the first pieces of miniaturized diagnostic 
equipment to enjoy any commercial success.
25
  As diabetics must frequently monitor 
their blood glucose and dose insulin accordingly, having a device for frequent home use 
was critical.  Another huge commercial success was the home pregnancy test—a slightly 
more elegant piece of engineering and science that began to use biological components 
such as lateral flow immunoassay.
26
  Still, these devices analyzed one biomarker per 
handheld unit; the next steps in evolution would seek to perform many analyses on a 
small device footprint.   
The term micro total analysis systems (µTAS) was coined by Manz in 1990 for 
systems in which chip-based analyzers incorporating on-board sample pretreatment, 
separation, and detection played a fundamental role.
27, 28
   While µTAS or LOC systems 
perform similar tasks as their larger, benchtop counterparts, they offer several advantages 
including decreased volume of sample and analyte, reduced turnaround times, greater 
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sensitivity, reduced cost leading to disposable devices, and finally a portability leading to 
POC capable systems.
28-32
   Key to the sample and reagent handling capabilities of µTAS 
is a miniaturized circuitry of valves, channels, pumps, filters, and reservoirs to 
manipulate the fluidic and gas components of the system, that is, a microfluidic design. 
By definition, microfluidic structures manipulate small fluidic volumes through various 
analysis and sensing steps.
33
  Table 1.1 illustrates the dramatic improvements that are 
possible for a representative measurement.  Here, the concentration of 250 molecules of 
sample X is listed as a function of typical volumes encountered in the laboratory bench, 
the microfluidic chamber, and human cells.  Importantly, as the volume progressively 
decreases, the concentration of the same 250 molecules increases to levels amenable to 
measurement.  Indeed, when these volumes decrease to the nL, pL, or fL regimes, 
concentrations increase into picomolar range—values commonly observed in the 
bioanalytical chemistry laboratory.  
 
 
Table 1.1.  Concentration as a Function of Volume.  For a sample type with 250 
molecules of analyte, measurement is impossible when volumes are on the order of the 
benchtop.  As the same number of analyte molecules are concentrated into a smaller 
microfluidic volume, analysis becomes much more realistic as concentrations increase.   
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Due to the reduced requirements of microfluidic sampling and reagent usage, 
costs decrease drastically and assay times cut substantially.  Rapid prototyping, 
assembly-line compatible designs, and extremely low-cost materials lead to further 
reductions of costs versus instruments that require individual assembly.
34
  Furthermore, 
the contributions of microfluidics to analyte isolation and concentration as well as their 
capacity for mixing, allotment, and fluid focusing, rapidly decrease the number of 
required sample-handling steps.
33, 35
  Below are some commonly used dimensionless 
parameters for microfluidic description as recently highlighted in a Nature Insight
36
: 
 Péclet number, ν, describes the ratio of axial bulk flow to diffusion mass 
transport (rate of transport due to advection over rate of diffusion).  Values 
less than unity imply a linear, diffusion-transported system while values above 
imply that concentration gradients may exist.   
 Fourier number, η, describes the average number of times a molecule contacts 
the wall of a fluid containing channel    
 Bodenstein number, Л, characterizes the back mixing within a system  
 Reynolds number, Re, represents the ratio of intertial forces to viscous forces; 
Re characterizes the degree to which a flow is laminar or turbulent.  Re less 
than 2,300 characterizes laminar flow, above 4,000 is turbulent with values in 
between considered transient.
37
   
Although not all of these descriptors are applicable to the NBC, optimization of these 
parameters has lead to microfluidic architectures with the ability to perform separations, 
with detection elements designed in-stream, all on a small size scale, which make them 
highly compatible with next-generation analysis platforms.
4, 5
  
Microfluidics has followed a path roughly analogous to the microelectronics 
industry.  In this arena, beginning with vacuum tubes, work to create intricate circuitry 
was initially extremely expensive, bulky, and inefficient.  The creation of the transistor 
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effectively eliminated vacuum tubes, but because connections between transistors were 
still manually soldered, and these links were prone to failures.
38
  In fact, the failure of 
even a single hand-soldered connection within the cascade could effectively paralyze the 
entire system; a situation analogous to the single burned out bulb on a strand of lights.  
To overcome this hurdle, the new paradigm of photolithography allowed transistors, as 
well as other resistors and capacitors, to be fabricated along with their respective 
connections, from single piece of substrate, earning Kilby the 2000 Nobel Prize in 
Physics.
39
  While many researchers originally believed this paradigm could be neatly 
replicated for microfluidic structures, devices fabricated with silicon for biological 
applications were usually unnecessary or inappropriate. 
40
 Many teams discovered that 
the expense of silicon, even when mass fabricated, were difficult to reconcile with µTAS 
systems.  In addition, silicon is optically incompatible with the spectral regions usually 
employed for microanalytical systems.  The cost, ease of fabrication, and elastomeric 
properties of plastics have ultimately made them the preferred underlying material for 
construction of POC devices.   In addition, plastics such as poly-dimethylsiloxane 
(PDMS) are highly permeable to gases such as oxygen and carbon dioxide required for 
cell culture in micro.
41
 
Microfluidics has yet to see a similar breakthrough piece of work as 
photolithography, or a ―killer app‖ with highly profitable commercial success, although a 
number of critical advances and applications have demonstrated utility in a variety of 
experiments.
35, 42
  The scope of the field disallows any type of comprehensive review in 
this chapter, however a few key groups deserve mention.  Whitesides‘ work, beginning 
with fundamental studies of self-assembled monolayers,
43





 and designs needed to create microchannels and manipulate 
fluids, creating the potential to do a variety of chemical and biological analysis.  The 
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identification of (PDMS) and poly(methylmethacylate) (PMMA) as elastomeric materials 
for the underlying skeleton of microfluidic devices, and  knowledge on handling of this 
material was critical to future successes.
32
   
Quake‘s work with microfluidics, leading to the formation of the Fluidigm 
corporation,  has advanced the ―large scale integration‖ of microfluidics, analogous to the 
electronics field.
38, 45
  By designing some of the first microfluidic devices with many 
integrated valves and other connections, this work has improved the capabilities of 
microfluidics for high throughput automation.
38
  Micromechanical valves, created via 
multilayer soft lithography, allowed the binary positions of open and closed, but also a 
variety of positions in between which could be exploited as a peristaltic pump, or for 
mixing and sample/reagent volume allotment purposes.
45
  This experimental design has 




 applications as well as the biophysical 
properties of single molecules.  Quake‘s group was the first to successfully sequence a 
single DNA molecule.
48
     
Thus, a significant body of work created by these and other researchers, result in 
LOC systems that could perform biological assays on a miniaturized system.   Section 
1.4 will describe some approaches that have further incorporated microfluidics with 
additional components of the laboratory such as signal transduction, including the few 
that have become compatible with clinical samples to glean meaningful information. 
Unfortunately, most applications are not fully freestanding and require extensive support 
networks of compressed gases and liquids, syringes and external pumps, as well as any 
necessary optics and light handling hardware.  These systems are best described as ―chips 
in a lab‖, rather than true labs on a chip.   
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1.3.3 Nanotechnology 
Although nature has been creating elegantly controlled nanomaterials such as 
small molecules, antibodies, biomarkers, and the other life-inspired components 
described in Section 1.3.1 for eons, it was not until approximately the last 20 years that 
the ability to design, synthesize, measure, characterize, and further manipulate materials 
below 100 nm has been fully realized.
49
  One of the first and most popular types of 
nanoscale preparations are silver or gold nanoparticles.
50, 51
 These have found use in 
Raman scattering and surface plasmon resonance experiments, and numerous reports of 
nucleic acid conjugated nanoparticles appear in the literature.
52, 53
 Magnetic nanoparticles 
have also garnered attention as contrast agents in medical imaging experiments as well as 
underlying support for bio-barcoding designs.
54, 55
     
For the signaling requirements of the NBC, semiconductor nanoparticle quantum 
dots (QDs) have stood out as next generation fluorescent probes and one of the best 
examples of practical nanomaterials.
56, 57
 These inorganic compounds are synthesized 
from group II-VI elements through a number of synthetic routes with CdSe particles 
being the most common.
58, 59 
One or more passivation layers are generally coated around 
the fluorescent core serving to increase hydrophilicity, reduce agglomeration and increase 
fluorescence intensity, resulting in particles with diameters between 5-20 nm depending 
on the size of the original core semiconductor.
60-64
 Figure 1.2A shows the cross section 
of a typical commericially available QD and its onion-like structure resulting from the 
layers of core, clad, and coat.  Attributes such as long-term photostability, high quantum 
yield, resistance to quenching, and narrow emission profile have made QDs a popular 
alternative to traditional organic fluorophores, which often suffer from photobleaching, 
broad bandwidth emission, and specific excitation ranges.
65, 66  
In contrast, QDs possess a 
broad excitation spectrum spanning the UV and near visible range, and their emission 
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wavelength is dependant solely on the size of the inorganic core with larger particles 
fluorescing closer to the IR and the smaller at shorter wavelengths (Fig. 1.2D).    
 
Figure 1.2. Quantum Dot Essentials.
67
  A) Commercially available hydrophilic QDs 
consist of the fluorescent core semiconductor followed by a shell of passivation material 
designed to preserve structural integrity of the core and increase fluorescent signal and 
quantum yield.  This is capped by an additional coat of polymer or other material to 
increase hydrophilicity and allow coordination of any additional chemistry.  B) TEM 
images of QDs with peak emission at 495 nm show smaller nanoparticles than those in C 
with λem of 655 nm.  D)  QDs size determines their λem with larger particles emitting more 
red shifted light.  Nevertheless, all particles are easily excited in the UV, an ideal 
arrangement for multiplexed experiments. (Units in relative fluorescence units, RFU.)   
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Thus, QD‘s extremely long Stokes shift, combined with intense, narrow emission 
profiles and the ability to simultaneously excite a number of different size nanoparticles 
with characteristic emission wavelengths, have made them especially attractive for 
multiplexed experiments.  In 2003, few designs harnessed the full capability of QDs, and 
those that did used them for qualitative imaging, rather than quantitative analysis.  
Nevertheless, these particles were gaining traction as strong candidates for signal 
generation in devices dedicated to a number of important diagnostic applications.  The 
above listed attributes of QDs, well established in 2003, yet not fully utilized in a 
biosensing platform, was a key motivator for their inclusion in the work detailed herein.  
Parameters that needed empirical optimization include: the best method to conjugate QD 
to recognition elements, approaches to reduce non-specific binding and background while 
retaining high fluorescent signal in cellular and protein arrays, and schemes that reduce 
aggregation of the inherently hydrophobic QD material.   
Nanoparticles with structures resembling today‘s definition of QDs were first 
described in the literature by Brus in the early 1980s.
68-70
    The term quantum dot was 
later coined in 1988 by Mark Reed of Texas Instruments because of the quantum 
confinement of the particles, that is, their behavior mimics many aspects of molecular 
and atomic systems, unlike bulk semiconductors.
71
  Figure 1.3 explains this behavior 
graphically.  Succinctly, the small size of QDs change the continuous energy levels found 
in bulk semiconductor material (Fig 1.3A), to a larger bandgap, and thus alters the 
distribution of energy levels found in nanoparticles to a discrete arrangement, similar to 
an atomic system. (Fig. 1.3B).  Importantly, another physical definition of QDs is 
particles smaller than the Böhr exciton radius (Fig. 1.3C).  The exciton is most simply 
defined as an excited state electron and the hypothetical, positively-charged hole particle.  
Coulomb forces attract electron and hole forming the short-lived exciton that disappears 
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upon collapse of electron from excited to ground state and subsequent release of a 
photon.  To be consisered QDs, the particles must have a diameter smaller than the 
distance between electron and hole.   
Later research found that core/shell QDs behaved differently that their core 
counterparts with an increase in signal and stability all resulting from a coat of secondary 
semiconductor.  Hines and Guyot-Sionnest found a ZnS layer to be particularly useful as 
its‘ bandgap energy is higher than CdSe and thus can preserve the excited state of the 
CdSe core and prevent non-radiative relaxation.
64
  Two breakthrough papers in 1998 
published independently by Nie and Alivisatos opened the door for biological 
experiments—these demonstrations added an additional layer to the core/shell composite 
to create water soluble QDs, followed by scaffolding chemistry to attach a biological 
recognition element.
72, 73
  These nanoparticles have demonstrated use in such 







 and protein assays; 
80, 81 
however it was not until 2004 
that investigators, led by Mattoussi, from the Naval Research Lab published some of the 
first quantitative, multiplexed work with QDs.
82




 Figure 1.3.  Quantum Dot Electronic Structure. A) Bulk semiconductor materials have 
a small bandgap and closely spaced, continuous energy levels both in the valence and 
conduction bands.  B)  As the physical dimensions of semiconductor materials are 
decreased, not only does the bandgap energy increases, but so does the differences 
between energy levels within valence and conduction bands.  These increases eventually 
make the energy levels discreet, rather than continuous. C)  The QDs have physical 
dimensions smaller than the Böhr exciton radius, creating a quantum confined situation.   
A common scheme is seen in these biological QD applications.  The first step in 
the pathway between signaling moiety and bioligand, is solubilization of the hydrophobic 
inorganic nanoparticle in an aqueous environment, which is usually accomplished via a 
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passivation layer, frequently a polymer coating, such as PEG or other charged moieties.
60, 
83, 84
 As a colloidal suspension, any disorder in the monodispersity of this passivation 
layer creates flocculation and sedimentation of the QDs out of solution. Next, the 
hydrophilic QD is coupled to biological recognition moieties, such as antibodies, with all 
schemes emphasizing the importance of maintaining biological activity in the ligand, 
while simultaneously retaining the fluorescent advantages of the quantum particle.
85
  





 and a variety of covalent 
techniques.
88,89
   
Of the latter, conjugation schemes abound, including 1-ethyl-3-[3-
dimethylaminopropyl]carbodiimide/N-hydroxysulfosuccinimide (EDC/NHS) coupling of 
carboxyl coated QDs to free antibody amines,
90
 creating free sulfhydryl on the 
biomolecule with succinimidyl 4-(N-maleimidomethyl)cyclohexanecarboxylate (SMCC)  
facilitating QD linkage,
91
 and hydrazine modified QDs with periodate oxidized 
antibodies.
92
  Common to all covalent conjugation schemes is a modification of both the 
antibody structure and of the QD surface, with an inherent risk to alter the recognition 
specificity of the biomolecule and fluorescence characteristics of the nanoparticle. The 
most appropriate method has shown to be dependent upon the specific end application 
and one important goal of this dissertation is to define the optimal conditions for 
inclusion of QDs into the NBC sensor array.   
1.4 INTEGRATED SYSTEMS 
Although the discovery of new biomarkers, advances in microfluidic 
condensation, and simpler synthetic approaches for nanoparticle bioconjugates are all 
valuable additions to the bioanalytical chemist‘s palette, the individual contributions of 
these unique elements pale when contrasted with the cogent elegance of rational, 
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integrated designs.  As Ligler sagaciously observes in her recent perspective, ideal system 
designs are best described as Gestalt—the configuration of the whole possesses attributes 
unattainable by the summation of the individual parts.
93
  Advances in design and 
molecular-level engineering that suggest certain systems are nearing singularity—
complete unification of working parts for rapid, previously unattainable, advances in 
diagnostic relevance and access.  Interestingly, this approach to systems building is in 
sharp contrast to many of the scientific and engineering challenges of decades past.  Here, 
much work was on ―scaling up‖ systems to synthesize or measure large amounts of 
material, while POC, microfluidic devices require scaling down.   
Although this dissertation focuses on an optical, fluorescence-based approach to 
coherent medical sensors, researchers such as Corn and Van Duyne have done exemplary 
work with label-free techniques using the surface plasmon resonance (SPR)
94
 and surface 
enhanced Raman spectroscopy (SERS).
95
  There is also a large body of work using 
electrical and electrochemical signaling for biosensing.
96
  In addition, a number of non-
medical applications exist.  Indeed, since 2001 the role of POC-type sensors as screening 
tools for chemical, biological, and radiological threats has increased dramatically.
97
  
Food, environmental, and narcotics applications expand further the contributions of 
integrated sensors and ever evolving advances continue to decrease assay requirements.
98
   
Despite the excitement of these other areas, the remainder of this treatise will focus on 





Sensors themed around human health, designed intelligently and rationally, 
command quality results.  The easily remembered acronym COMMAND QUALS 
summarizes the most commonly cited attributes of coherently designed sensors and 
serves as wish list when designing POC diagnostic systems.  All integrated approaches 
for use in both developed and resource-scare settings seek to create devices and assay 
platforms that are:  
 Cheap - keeping costs low increases access to diagnostic testing 
 Obvious - simple and easy user-interfaces allows use by unskilled operators  
 Miniaturized - devices with reduced footprint are amenable to POC use  
 Multiplexed - the ability to quantitate a number of different analytes 
concurrently increases the ability to effectively make diagnoses 
 Automated - built-in sample processing, reagent handling, and data 
interpretation further promotes widespread access of diagnostic aides  
 Non-perishable - rugged designs survive difficult storage, shipping, and 
handling as well as extreme temperatures; eliminating the so-called ‗cold-
chain‘ also increases access to such systems; 1 year half-lives are desirable  
 Dependable - the design should have an extremely low rate of failure and be 
highly reproducible, similar to six sigma and GLP quality control designs   
 Quick - short turnaround time (TAT) gives information to physicians quickly 
which is especially important in emergency room environments 
 Unobtrusive - non-invasive diagnostic specimens and sampling procedures 
reduces patient testing antipathy, making regular screening events possible 
 Adaptable – modular devices have the ability to quantitate a variety of 
analytes (cells, proteins, nucleic acids, small molecules, ions)  
 Limited - small reagent and sample volumes decrease costs and minimize 
requirements of biohazard waste disposal and environmental impact 
 Self-contained - reagent and power integration makes for a smaller device 
footprint;  a closed system prevents exposure to biohazard waste  
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A variety of proposed systems meld nano, bio, and chip-based components into 
working systems with a high level of integration while featuring the above attibutes. 
Several pioneers have performed landmark studies in the area.  Whitesides‘ later work 
served to integrate advances in nanotechnology into existing systems and later proposed 
microfluidic structures constructed only of paper and tape.
34, 49
  Groups such as Mirkin‘s 
and Lieber‘s began to use nanowires,
99
 precious metal nanoparticles,
52
 and 
nanolithographic techniques to measure diverse sample types and create a variety of 
assembly types.
100
  Other designs, in which a capillary tube serves to not only direct fluid 
flow and serve as attachment point for bioligands, but also serve as a waveguide for 
excitation beam and conduit for emission signal, illustrate the potential of high level 
integration.
101
   
While the i-STAT
®
 platform was the first sensor array to be microfabricated and 
vended commercially as a whole-blood diagnostic tool, it has had problems in 
establishing a dedicated manufacturing program and designing device packing in a 
reliable, user-friendly format.
102
  With a handheld analyzer costs between $6,000 –






, BUN, glucose, pH, pO2, and pCO2) 
approximately $15 apiece, this scheme remains inaccessible to the most disadvantaged 
regions.  In addition, the i-STAT system has yet to be approved for more complex 
analytes such as protein biomarkers and lymphocyte discrimination.  
Other assembled systems, while nearing completion, have not yet been released 
commercially.  Work by Madou and others has resulted in the LabCD
TM
 which eliminates 
traditional valves and pumps by using centrifugal and centripetal force to perform fluid 
movements.
103
  Similar, to audio and data compact disks, this model divides the 
diagnostics scheme into the disposable component (disk) and the instrument component, 
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the reader.  As the LabCD
TM
, is solid state, injection molding and other standard 
manufacturing techniques offer rapid prototyping at low cost.
104
   
Other relevant prior work for this dissertation research includes the contributions 
of Walt and coworkers.  Walt‘s work with ―electronic noses‖ in which arrays of optical 
fibers serve as the underlying infrastructure for biological sensing systems.
105
  With this 
underlying fiber substrate in place, a variety of secondary schemes can be used including 
the placement of beads for analysis arrays.
106
  Live cells can be loaded into the arrays, 
and their unique response monitored over time, enabling cytotoxicitiy screening of 
biologically active substances.  Alternatively, individual enzymes immobilized on the 
fiber substrate allow detection of single molecules via enzyme-catalyzed signal 
amplification.
107
    
Despite this plethora of advances, the field of usable and FDA-approved 
miniaturized biological sensors is still in its infancy and experience many challenges, 
mostly because only a small part of the analysis scheme is actually ‗micro‘ in nature.  
 Upon moving from microfluidic components to analysis systems the success of 
microscale fluid handling may disintegrate.  Actual clinical analysis via microfluid 
ensembles frequently require external pumps, valves, and fluid handling and these 
systems are best described as ―chips in a lab‖ versus true labs on a chip.
108
   
 The pumps, values, and other fluid manipulators with demonstrated capacity, used in 
conjuction with other external support structures, are frequently only validated with 
highly controlled fluids, not the diverse range of samples likely to be encountered in 
routine testing. 
93
   
 Modular systems, attuned to the requirements of diverse samples types (whole blood, 
plasma, urine) and analyte forms (cells, ions, proteins, nucleic acids), have yet to 
emerge.
109
  These LOC systems generally have one analyte (or small number of 
similar analyte types, i.e. ions) per chip.  Improving the number of applications that 
may be performed on a single system is key.   
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 The lack of unified sample metering and processing, within the confines of the LOC 
structure, retards the development of deployable systems. Methods to selectively 
isolate plasma, specific cell types, or cell lysate from a sample are incomplete and are 
nearly always performed off-chip.
110
   
 Refuse handling remains ill defined and the engineering of disposable LOC 
components is needed to prevent exposure of healthcare workers and the citizenry at 
large to the potentially dangerous waste of biomedical testing.
111
   
 Finally, very few integrated systems are sensitive to the increasingly budget-
conscious nature of health care both in the developed world and in resource-scarce 





Indeed, POC diagnostic devices need be cheap in both developed and developing 
reasons.  Currently, nearly 90% of global healthcare expenditures are spent on 
approximately 10% of the population.  In the United States, per capita health care costs 
are $7,439 annually, while in certain African nations, this expenditure drops below ten 
US dollars.
113
   Furthermore, this rate is increasing at a rate of between 7 and 8 percent 
annually, a unsustainable percentage much higher than that of inflation.
114
  Even within 
the resource-heavy US population, a tiny subset of the population consumes the majority 
of healthcare resources.  Five percent of the population consistently use 50 percent of the 
healthcare budget and the last week of life is often the most expensive.
115
   One reason 
this select subset takes such a large slice of the ‗healthcare pie‘, is their frequent need of 
clinical laboratory testing.  Thus, both the lack of resources in underdeveloped countries 
and the disparity of resources with the United States are strong motivators for the 
development of cost-effective POC diagnostic and prognostic schemes.   
Although the fundamentals are in place to solve these daunting problems, other 
challenges of science, technology, and engineering linger.  Proper identification of initial 
applications and finding flexible strategies to move the technology from the laboratory to 
the marketplace remain inadequate.
40
  Products reaching commercialization often remain 
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out of the reach of end users or those most in need due to insufficiencies in cost, 
durability, ease of use, their need for support infrastructure, and the resistance of 
pertinacious clinicians and healthcare administrators to emerging technology.  Ultimately 
solving the defects of design will require knowledge integration from diverse 
backgrounds and the utilization of a variety of ideas.  The work below with 
programmable NBC systems works to fulfill some of these deficiencies.   
1.5  MCDEVITT GROUP INTEGRATED APPROACH—THE PROGRAMMABLE NBC 
For over a decade, the McDevitt, Neikirk, Shear, and Anslyn research groups 
have sustained work utilizing microelectromechanical structures (MEMS) for studies of 
the design, fabrication, and testing of microfluidic structures with integrated fluid 
handling and optical detection capabilities.
116
 Inspired by the microelectronics industry 
that has created ever cheaper manufacturing methods for electronic components that scale 
and adjust to the desired application, this team has developed two highly functional NBC 
sensor ensemble approaches.   Created with many of the same microfabrication methods 
popularized by the electronics industry, the first such sensor system can be described as a 
―chemical processing unit‖ and serves for the measurement and collection of soluble 
analytes.  More recently, a second class of miniaturized sensor system, based on a 
membrane capture element that is integrated into a fluidics structure, emerged.
117-119
  
These ―cellular processing units‖ serve as miniaturized analysis systems that mimic flow 
cytometry (FC) instrumentation in their capacity to complete vital cell collection, 
processing, labeling, image and counting applications from complex biofluid samples 
such as whole blood.  In both NBC types, a closed system allows these specific analytes 
to be immobilized from complex matrices and quantitated via a colorimetric or 
fluorescent signal.  In Figure 1.4A, the rudimentary, research-grade NBC system is 
illustrated in profile.  This research-grade system serves to optimize assays and is used in 
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tandem with the benchtop analysis components seen in Figure 1.4B.  The epifluorescent 
microscope and peristaltic pump, both digitally controlled, form the support structure of 
this NBC system.  More elegant condensations of these components will be subsequently 
described in greater detail. 
 
 
Figure 1.4.  Nano-bio-chip Design.  A) The research-grade NBC used these studies 
consists of an aluminum housing with a central processing unit sealed between PMMA 
layers designed to direct fluid flow.  B)  The benchtop support equipment used in 
conjunction with research-grade NBC includes a modified epifluorescent microscope 
with CCD digital camera as well as a peristaltic pump fluid delivery system.  C)  For 
membrane-based NBC experiments, a polycarbonate track-etched membrane is used.  
Pore diameter is determined by analyte size.  D) In bead-based experiments, agarose 
microspheres form the underlying infrastructure.  Any number of chemistries may be 
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Table 1.2.  Assays Demonstrated on NBC Device.  A wide variety of sample and 
analyte types have been incorporated into the McDevitt NBC analysis scheme.  All of 
these assays were performed using a traditional molecular fluorophore or a conventional 
colorimetric assay.  This dissertation seeks to detail analytical improvements available 
via QDs.  (Green inset lists all assays with proof-of-principle on NBC)  
  Sample types amenable to the NBC include, but are not limited to, serum, 
plasma, saliva, whole blood, as well as environmental samples.  These structures have 
been shown to be suitable for the identification and quantitation of C-reactive protein,
127
 
other cardiac risk markers,
128
 pH, and physiologically relevant cations.
129
 More recently 
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work has progressed to develop miniaturized microfluidic systems that service cellular 
analysis applications.
125
 These membrane-based micro-systems have been shown to be 
suitable for the determination of lymphocytes for HIV immune function and total white 
blood cell counts for cardiac risk assessment.
117, 130   
Table 1.2 illustrates with more detail 
the breadth and depth of the NBC approach to measuring biologically important analytes.   
Although this work with NBC systems has been established for well over a 
decade as illustrated in Table 1.2, recently, a new paradigm has evolved from the initial 
LOC-type, ―electronic taste chips‖
129
 to state-of-the-art, integrated NBC systems.
131
 The 
NBC ensemble employs a size-tunable nano-net within agarose microspheres or polymer 
membrane, and a fluorescent transduction signal arising from nanoparticles (nano) to 
isolate and quantify biological analytes (bio) from complex matrices within a closed, 
miniaturized system (chip). The modular NBC used in this work employs two central 
reaction unit types, each tailored to application.   First, a bead-based platform consisting 
of individually addressable agarose beads functionalized with specific chemistry types 
and immobilized within a customizable, etched silicon chip has been employed for the 
quantitation of proteins, including cancer biomarkers (Fig. 1.4D).  Second, membrane-
based experiments (Fig. 1.4C), utilizing a size exclusion device, have been employed to 
sequester and count blood cells.  
These NBCs combine the sample handling abilities and reduced sample 
requirements of microfluidics with the attributes of nanomaterials to quantitate both 
established and emerging biomarkers.  This system analyzes complex samples such as 
blood, plasma, saliva, as well as environmental samples.  An important difference 
between the NBC systems of the previous generation, and the current NBC design is that 
signal output is accomplished via semiconductor nanoparticle quantum dots (QDs). Both 
the bead and membrane-based approaches are part of a much larger effort within the 
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scientific community towards miniaturized and portable biomedical devices that offer 
diagnostic and prognostic information rapidly, cheaply, and robustly. Figure 5 details 
some of the considerations and essential pieces of the analytical machinery needed when 
designing the NBC.   Biomedical devices need have these characteristics to meet the 
demands of clinicians, practitioners, and academicians alike.   
 
 
Figure 1.5.  Essential Elements of the NBC for POC Assays.  The nano-bio-chip 
contains attributes and design contributions from three key areas: biomarkers of disease 
and biological reagents/controls, nanometer size fluorescent tags and the nano-net formed 
within the agarose microspheres, and the microfluidic cartridges that focus fluid flow and 
contain reagents and waste.  All must synchronize to achieve reliable results that meet the 






1.6 SUMMARY AND DISSERTATION OVERVIEW 
 Definitive solutions for all the challenges listed in Section 1.4 is beyond this 
period of study, however this dissertation will explore both membrane and bead-based 
uses of the NBC in tandem with QD nanoparticles for improvements to biological 
determinations and assay development.  Although each chapter will have specific aims, 
the dissertation as a whole seeks answers to the following fundamental questions:     
 Which QDs (size, source, passivation method) offer the most robust signal? 
 What are the best conjugation methods to link QDs to recognition bodies 
while retaining both nanoparticle attributes and bioligand specificity?  
 How can non-specific binding and aggregation of QDs be reduced/eliminated?  
 Which optical components are best suited to the NBC? 
 How do QDs behave relative to traditional, molecular fluorophores in term of 
photostability and signal intensity? 
 How is the QD signal best interpreted? 
 How can QDs improve the multiplexing capabilities of the NBC system? 
 How can very low limits of detection be achieved with the NBC? 
 Which antibodies and bead types are best suited to our assays? 
 What is the best method to capture and detect proteins in small channels? 
Chapter 2 details a membrane-based platform for the analysis of T lymphocytes 
in HIV patients, crucial as the enumeration of such CD3+CD4+ cells is required to 
establish the level to which the immune system has been compromised. After initial 
experiments for optimization of labeling efficiency and flow parameters, cells were 
exposed to primary antibody specific to CD3 and CD4 followed by QD-labeled 
secondary antibodies specific to the primary.  With CD3 coded red and CD4 in green, the 
dually stained T lymphocytes are detected and quantitated using custom automated image 
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analysis algorithms, with QDs allowing for simultaneous excitation of differently colored 
nanoparticles resulting in a reduction in overall analyzer footprint.  This effectively cut 
the optical requirements in half, as molecular fluorophores, such as Alexa Fluor dyes, 
require filters specific to each color channel.  Furthermore, in a side by side comparison, 
cells labeled with Alexa Fluor probes displayed exponential signal decay within minutes, 
unlike their QD counterparts.     
Chapter 3 describes how the NBC system may be used as a bead-based sensor 
for protein biomarker determinations in clinical samples including serum and saliva. For 
this study, three previously identified analytes were chosen:  carcinoembryonic antigen 
(CEA), Her-2/Neu (c-erbB-2), and cancer antigen 125 (CA125), markers which have 
shown correlation to colon, breast, and ovarian cancers, respectively.  The multiplexing 
capabilities of the system were explored from both an intra-bead and inter-bead 
standpoint.  First, beads functionalized to CEA and CA125 capture antibodies were 
compared to beads dually loaded with both.  These dual-type beads have the capability to 
further increase the NBC output by allowing an even greater number of analytes to be 
bound and quantified in our small device area.  Second, in a demonstration of signal 
specificity, beads sensitized to CEA, Her-2/Neu, and CA125 were exposed to each 
antigen individually, followed by a cocktail of detecting antibody; the majority of signal 
comes from the specific interaction with non-authentic output emanating from the 
untargeted beads.  This multiplexing approaches are critical as few cancer biomarkers 
have complete specificity or specificity for their respective disease.   
 30 
 
Figure 1.6.  Motivation and Direction.  A) Current laboratory designs include a bench-
top instrument with fluid handling, electrical, waste, and refrigeration supporting 
instrumentation.  In contrast, POC-type systems work to condense this entire lab 
infrastructure into a small, device with COMMAND QUALS descriptors.  The strong 
trend toward POC systems is illustrated in B.  C) This dissertation will explore the core 
subcomponents of the NBC system with work targeting singularity in a truly integrated 
POC device (D).  (Fig. 1.6B constructed via the number of returns on a search for ―point 
of care‖ in SciFinder Scholar
® 
literature service.)  
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Chapter 4 employs confocal fluorescent microscopy, proteolytic digestion, and 
tunable agarose porosity systems to better understand the distribution of the various 
elements composing the immunoassay throughout the bead.  By reducing both capture 
and detecting fluorescently tagged antibodies from whole IgG molecules to smaller Fab 
and F(ab’)2 fragments control of signal dissemination was explored.  Additional 
experiments varied bead porosity via agarose percentage to optimize efficiency of 
immobilization and the results from such a nano-tailored system reveals the importance 
of size and concentration considerations in designing immunoassays.   
In summary, this dissertation probes the areas of applied nanomaterials, 
biosensors, and clinical indicators of disease, all within the framework of experiments 
designed to analytically improve performance of the NBC and validate it as a diagnostic 
device versus established systems.  Extensive characterization of QD nanoparticles as 
fluorescent probes yielded key information necessary for their inclusion in both cellular 
and protein experiments.  Immunoassay development and microfluidic design as well as 
established analytical techniques including flow cytometry and protein assays were used 
as tools to understand better complex questions about protein and cellular capture and 








Chapter 2:  Integration of Semiconductor Quantum Dots into NBC 
Systems for the Enumeration of CD4+ T Cell Counts  
2.1 CHAPTER OVERVIEW 
Recent humanitarian efforts have led to the widespread release of antiretroviral 
drugs for the treatment of the more than 33 million HIV afflicted people living in 
resource-scarce settings. Here, the enumeration of CD4+ T lymphocytes is required to 
establish the level at which the immune system has been compromised. The gold standard 
method used in developed countries, based on flow cytometry, though widely accepted 
and accurate, is precluded from widespread use in resource-scarce settings due to its high 
expense, high technical requirements, difficulty in operation-maintenance and the lack of 
portability for these sophisticated laboratory-confined systems. As part of continuing 
efforts to develop practical diagnostic instrumentation, the integration of semiconductor 
nanocrystals (quantum dots, QDs) into a portable microfluidic-based lymphocyte capture 
and detection device is completed. This integrated system is capable of isolating and 
counting selected lymphocyte sub-populations (CD3+CD4+) from whole blood samples. 
By combining the unique optical properties of the QDs with the sample handling 
capabilities and cost effectiveness of novel microfluidic systems, a practical, portable 
lymphocyte measurement modality that correlates nicely with flow cytometry (R
2
 = 0.97) 
has been developed. This QD-based system reduces the optical requirements significantly 
relative to molecular fluorophores and the mini-CD4 counting device is projected to be 
suitable for use in both point-of-need and resource-scarce settings. 
 
2.2 INTRODUCTION 
Of the more than 33 million people infected with HIV globally, more than 85% 
live in developing countries with significant resource limitations.
1
 While portable lateral 
immunoassay kits are available and can be used to diagnose patients with HIV, a missing 
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link remains with respect to the treatment and management of HIV patients in these 
developing countries. As HIV infection progresses into active AIDS, clinicians must 
frequently monitor the patient‘s CD4+ T lymphocytes to assess the degree of 
immunological deterioration.
132, 133
 According to Center for Disease Control and 
Prevention guidelines, absolute T-cell counts of 200 cells/μL or 14% CD3+CD4+ are 
reference values at which HIV is considered to become active AIDS.
134, 135
 These cellular 
assessments require a dual staining signaling approach to identify and differentiate 
between the two different CD markers of interest, and are typically obtained on flow 
cytometers (FC), or on double platforms involving FC and hematology analyzers. 
Although such instruments are widely available in the United States and in other 
affluent regions, in resource-scarce settings, access becomes difficult or impossible.  
Frustratingly, these settings may frequently have noblesse oblige stockpiles of anti-
retroviral drugs available, but because T lymphocyte testing remains out of reach, it is not 
until patients begin developing advanced symptoms of AIDS that clinicians become 
aware of whom to dispense the medications.  Figure 2.1 illustrates the distribution of 
HIV positive individuals throughout the world.  Noticeably, the region with the largest 
percentage of positive individuals i.e. sub-Saharan Africa, is also a region without broad 




 Figure 2.1.  Distribution of HIV positive individuals.  The highest rates of HIV 
infection are found in sub-Saharan Africa, a region also known for scarcity of biomedical 
infrastructure.  In these areas, the unmet clinical need is access to diagnostic testing.   
(Reprinted with permission of UNAIDS.  Copyright 2008.) 
To fill this unmet clinical need, a number of more compact FC instruments have 
been developed such as Guava EasyCD4 and the PointCare instrument, however, these 




 Nonflow alternatives have 
also been developed based on impedance, microfluidics, or magnetic beads, yet these 
methods suffer from lower throughput and more labor-intensive manipulations.
138-142
 
These alternatives are also less accurate than FC and have not received endorsement from 
the World Health Organization
138, 141
 
In this area, the development of increasingly smaller bio-analysis devices is 
attractive for several factors including enhanced portability, decreased sample size, and 
reduced turnaround times.
28, 31, 143, 144
 Nano-bio technologies, advanced microfluidics and 
lab-on-a-chip sensor systems offer interesting and exciting new prospects for these 
humanitarian diagnostic challenges. However, despite the remarkable advances in the 
development of miniaturized sensing, and analytical components for use in a variety of 
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biomedical and clinical applications, the ability to assemble and interface individual 
components in order to achieve a high level of integration in complete working systems 
continues to pose daunting challenges for the scientific community as a whole.  For 
example, the optical requirements present in many miniaturized systems frequently 
challenge their development.  Fluorescence, as a common transduction analytical signal, 
presents unique opportunities, as well as demands, in a miniaturized assay platform. A 
robust excitation source, used in conjunction with ideal reagent components, to generate a 
strong target-specific signal and a reduced non-specific background, is crucial for the 
miniaturized system‘s ability to detect the intended target with sensitivity and accuracy. 
Current efforts on these challenges include advanced excitation sources such as lasers and 
powerful light emitting diodes (LEDs), miniaturized charge coupled devices (CCDs), as 
well as next generation fluorophores.   
Here, QDs are an ideal fit.   Their extremely long Stokes shift combined with 
narrow emission profiles and the ability to simultaneously excite a number of different 
size nanoparticles with characteristic emission wavelengths, make QDs ideal 
fluorophores for multiplexed experiments such as CD3+CD4+ dual labeling.  This work 
was also literature-inspired, as QDs have previously been demonstrated to label cells for 
cancer biomarkers and other biologically interesting molecules.
79, 145
  In addition, 
experiments with lymphocytes on microscope slides labeled with QDs have demonstrated 
the feasibility of such labelings.
146
  The clinical chemistry and biomedical engineering 
challenge is the integration of the optical properties of QDs into a useable POC device 
while retaining the previously demonstrated capability of the NBC platform to count 
circulating cellular disease indicators.
118, 147
 
    Working to advance another generation in overall device condensation, we 
describe the integration of nanoparticle QDs into a LOC sensor system for the 
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determination of CD4+ T lymphocytes using unprocessed whole blood samples. These 
efforts synergize developments in the nanomaterials and microfluidics communities to 
simplify the optical requirements and engineering demands of LOC systems, and the 
advances in performance achieved by the NBC bring the release of diagnostic tools to 
resource-poor settings an additional step closer towards realization.  In this chapter, 
efforts are devoted to creating a bridge between QD-based detection methods and the 
integrated membrane-based NBC systems. The efforts strive to relieve the optical 
requirements and reduce the overall engineering demands for both the integrated NBC 
sample processing modality along with the associated fluorescence-based detection 
system. Specifically, the photostability of QDs and the ability to excite and image two 
different colors concurrently with a single epifluorescent arrangement are exploited to 
reduce the optical pathway and thus decrease the overall analyzer size.  These efforts 
strive to bring these evolving diagnostic tools an additional step closer to widespread use 
in resource-scarce settings.   
2.3 MATERIALS AND METHODS 
2.3.1 Reagents and Samples 
Primary mouse antibody specific to CD3 from OEM (Clone 289-13801 (UCH-
T1), Toms River, NJ) and rat antibody to CD4 from Genetex (Clone YNB46.1.8, San 
Antonio, TX) were purchased and centrifuged briefly prior to use. Goat anti-mouse 
secondary antibody conjugated to QD with peak fluorescence intensity at 655 nm (QD 
655), goat anti-rat QD 565, and goat anti-mouse QD 565 were similarly obtained from 
Invitrogen (Carlsbad, CA). Also from Invitrogen were amine-PEG activated QDs, 
streptavidin coated QDs, biotinylated QDs, and carboxy activated QDs.  Alternative 
sources of nanoparticles that were investigated include PlasmaChem (Berlin, Germany), 
and Evident Technology and their distributor eBioscience (San Diego, CA).  For 
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comparison studies goat anti-mouse Alexa Fluor 647, goat anti-mouse Alexa Fluor 488, 
and goat anti-mouse FITC (Invitrogen) were also procured.   
Modified Dulbecco‘s phosphate buffered saline (PBS) at a concentration of 
0.008M sodium phosphate, 0.002M potassium phosphate, 0.14M sodium chloride, 0.01M 
potassium chloride, pH 7.4, from Thermo Scientific (Rockford, IL) was used as diluent 
for all solutions.  To prevent non-specific binding, Fraction V bovine serum albumin 
(BSA) from Sigma Aldrich (St. Louis, MO) was added at 1% by weight.  All buffers 
were filtered by a 0.2 µm Nalgene Supor mach V membrane.  Fluorophore and antibodies 
at immunolabeling concentrations were again filtered immediately before injection into 
NBC with a 4mm 0.2 µm nylon syringe filter (Whatman).   
Fixative and FC reagents were also acquired from Becton Coulter (Fullterton, 
CA).  InSpeck™ calibration beads with a green-channel fluorescence fingerprint similar 
to that of FITC, and reagents for a SMCC and EDC/NHS facilitated conjugation were 
purchased from Invitrogen and Thermo Scientific via Pierce (Rockford, IL), respectively.  
Here, intact IgG molecules were subjected to dithiothreitol (DTT) treatment to cleave 
disulfide bonds.  The SMCC-activated QD particles were then incubated with the reduced 
antibody fragments linking them to the nanoparticles.  The conjugate was purified by size 
exclusion chromatography to remove unbound antibody and concentrated with 50 kD 
cutoff centrifuge tubes to approximately 1 μM.  For Alexa Fluor labeling, monoclonal 
antibodies were labeled via a tetrafluorophenyl activated form of the fluorochrome.  The 
EDC/NHS conjugation was performed as described previously.
76
  For indirect linkages, 
biotin functionalized Protein A from Calbiochem (San Diego, CA), Sulfo-NHS-LC-
Biotin (Pierce), and Zeba
TM
 desalting columns (Pierce) were purchased and used 
according to manufacturer‘s instructions.   Whole blood samples were collected from 
anonymous donors at the University of Texas at Austin in accordance with Institutional 
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Review Board procedures by standard venipuncture technique using dilute EDTA as an 
anticoagulant. Samples were evaluated within 24 hours of collection.   
2.3.2 NBC Construction 
The aluminum housing used in the first generation NBC was machined in house 
as was the polymethyl methacrylate (PMMA) base for second generation NBC.  PMMA 
top and bottom layers for the first generation were also constructed at UT Austin.  
Stainless steel support frits were photofabricated and treated with a non-reflective 
coating.  Vinyl adhesive layers from 3M (Minneapolis, MN) were precision-cut 
according to evolving computer-aided designs via AutoCAD drafting software from 
AutoDesk (San Rafael, CA) and served to focus fluid flow through the nucleopore track-
etched membrane from Whatman/GE Healthcare (Piscataway, NJ). Stainless steel 
conduits were purchased from Small Parts, Inc. (Miramar, FL).  Each unit was typically 
assembled in under five minutes.  The research prototype was used in conjunction with a 
customized optical station.   
2.3.3 Optical Station 
This NBC was secured beneath an infinity corrected 10X objective and analyzed 
with a modified epifluorescent microscope from Olympus (Center Valley, PA) equipped 
with a 12 bit CCD camera from DVC Co. (Austin, TX) and high pressure mercury bulb 
excitation source, which was evaluated with a universal optical power meter from Melles 
Griot (Albuquerque, NM). Sample flow was controlled by a variable speed peristaltic 
pump from FIAlabs (Seattle, WA) with a 500 μL sample loop. The QD 565 images were 
acquired with a filter cube consisting of a 425 nm downfield excitation filter, a 475 nm 
long pass beam splitting dichroic mirror, and a 565 ± 10 nm emission filter. The QD 655 
images were obtained via a 420 ± 20 nm excitation filter, a 475 nm long-pass beam 
splitting dichroic mirror, and a 655 ± 10 nm emission filter.  When these two 
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fluorophores were to be visualized concurrently, a 350 ± 25 nm excitation filter, a 475 
nm long-pass beam splitting dichroic mirror, and a 520 nm long-pass emission filter were 
employed (please see Appendix A).  Alexa Fluor 488 was viewed via a standard FITC 
filter cube: 480 ± 20 nm excitation filter, 505 nm long-pass beam splitting dichroic 
mirror, and a 535 ± 25 nm emission filter.  Alexa Fluor 647 was viewed via a standard 
cytochrome-5 filter cube. Photomicrographs were captured via DVC software with 
adjustable gain, offset, and exposure time, and stored for later analysis.   
2.3.4 Cell Immunolableling 
Aliquots of 50 μL from a thoroughly homogeneous whole blood reservoir were 
briefly treated with 5 μL Cytochex fixative from Streck (Omaha, NE) before dilution to 1 
mL with 1% bovine serum albumin in phosphate buffered saline (PBS/BSA) purchased 
from Sigma Aldrich (St. Louis, MO) and Thermo Scientific (Waltham, MA), 
respectively.  The prepared sample, at 500 µL volume, was injected into the NBC with a 
flow rate sufficient to separate the lymphocytes from the remaining blood components. 
The sample was then subjected to a 500 μL treatment of 10 μg/mL primary antibody at a 
flow rate of ~17 μL/min for 10 minutes. Unbound antibody was subsequently removed 
with PBS rinse at which point 500 μL of 10 nM secondary antibody was introduced, 
incubated, and rinsed similarly to the conditions described above. Alternatively, this 
labeling could be performed in microcentrifuge tubes prior to delivery to the NBC; total 
assay time was under 30 minutes.  For SEM images, the membrane was removed from 
the NBC and fixed with 4% glutaraldehyde followed by ultrapure water washes.  This 
was additionally stabilized with OsO4 and hexamethyldisilazane (HMDS).   
As a reference method, flow cytometry data was collected on a Beckman Coulter 
(Fullerton, CA) Cytomics FC 500 flow cytometers using protocol provided by the 
manufacturer. Aliquots from the same blood reservoir were prepared with Immuno-
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Prep™ lysing reagents (Beckman Coulter) and labeled with CD3-Alexa Fluor 488 and 
CD4-Alexa Fluor 647 (Invitrogen).  Immuno-Trol™ and Cyto-Comp™ standards and 
Flow-Count™ calibration microspheres (Beckman Coulter) as well as mouse IgG 
negative control Alexa Fluor 647 and 488 from Serotec (Raleigh, NC) were used for 
negative control experiments and instrument calibration.  
2.3.5 Image Analysis 
Image analysis was performed with ImageJ analysis software from the National 
Institutes of Health (Bethesda, MD.)
148
  Raw color photomicrographs were split into their 
individual RGB components as 8-bit grey-scale images to identify the different 
lymphocyte subsets. This technique allowed a single image collected with the long-pass 
filter to give information on two different color channels.  Pixels were then thresholded to 
a value 2 standard deviations above the mean of all.  The resulting image contained pixels 
having a value of either 0 or 255. Thresholded areas were then subjected to a ‗watershed‘ 
filter to separate any overlapping lymphocytes and analyzed in terms of size and 
circularity with these regions defined as an area of interest (AOI). These AOIs were 
utilized to glean a variety of characteristics from the cells such as mean and maximum 
intensity, integrated density per pixel, standard deviation, and total count recorded from 
the original image.  In dual staining experiments the geographic location of the red and 
green cells were also recorded.   
To estimate the number of cells on the membrane, the following procedure was 
used. First, the average number of cells per 5 fields of view (FOVs) was calculated. Each 
image captured by the CCD had dimensions of 1292 pixels x 1030 pixels. Via a stage 
micrometer the image area was found to correspond to 860 µm x 690 µm. Total available 
membrane area is 0.74 cm
2
 resulting in approximately 125 available FOVs. This 
correction factor was used to calculate the total number of cells immobilized on 
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membrane.   Please see Appendix B for an example of the Java-based deconvolution 




2.4.1 NBC Device  
For the integrated NBC approach, it is essential that both the optical and 
microfluidic systems operate in a synchronized fashion to provide efficient cell capture, 
as well as imaging.   In Figure 2.2A the optical arrangement of excitation, emission, and 
beam filtering optics inherent to an epifluorescent design is seen.  Optical wavelength 
requirements are determined by the molecular structure, and are specific to each 
fluorophore. In a multi-color analysis, separate filter cubes would be necessary for each 
color regime.  In contrast, the QD-based system utilizes a reduced optical pathway (Fig. 
2.2B) in which a single UV excitation source and a long-pass emission filter replaces the 
unique optical hardware requirements of multiple organic fluorophores.   
     Complementary to the condensed optics, the NBC miniaturized cell capture 
device serves to sequester specific cells of interest from the larger whole blood matrix. 
The NBC used herein was constructed internally and is based on evolution from designs 
described previously, and illustrated in Figure 2.2C.
117, 125
 The stainless steel research 
grade NBC contains reusable parts (except membrane) for conservative materials 
management and is rapidly constructed.  Only a loosening of the top support structure, 
addition of a fresh membrane, followed by sealing is needed to construct a new NBC 
structure.  Because of its speed, this model was used for preliminary experiments in 





 Figure 2.2.  The optical and mechanical requirements of the membrane-based NBC.  
Typical arrangement in an epifluorescent experiment contains excitation and emission 
filters as well as beam splitting optics.  A) With traditional molecular fluorophores, each 
dye has its own requirements, and thus, illuminating different color concurrently 
frequently requires multiple optical sets.  Conversely, with a QD arrangement (B), a 
single UV excitation source, in tandem with a long pass emission filter allows 
simultaneous excitation and visualization of a number of differently colored QDs.  C) 
The first generation ―flow cell‖ NBC assembly was constructed from an aluminum 
housing in which PMMA support mechanisms along with plastic gasket material served 
to immobilize a polycarbonate membrane.  This aluminum model was used for 
preliminary, qualitative experiments.  D) The second-generation NBC was constructed 
entierely of disposable material including vinyl adhesive and precision-cut laminate 
layers designed for fluid flow.    
Later, through evolving microfluidic structure design, this bulky stainless steel 
platform was replaced with a more condensed and elegant NBC ensemble (Fig. 2.2D).  
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Here, a rectangular base houses the complete assembly including the support frit which 
serves to maintain a level surface and provide for membrane integrity, while allowing for 
waste flow through. A polycarbonate track-etched membrane with pore size determined 
by experiment is then positioned upon the support. The clinical data presented in 
Chapter 2 was collected using this second-generation, disposable NBC. 
 
 
Figure 2.3.  Cells immobilized and isolated by NBC.  A)  SEM image of whole blood 
sample after NBC processing indicates that the vast majority of erythrocytes and platelets 
are relegated to waste while leukocytes are preserved on top of membrane.  B) Cartoon 
cross section of membrane illustrates the ability of the NBC to concurrently isolate a 
cellular fraction and label it by subtype.   
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For this lymphocyte-specific application, 3 μm diameter holes within the 
membrane serve a dual role of both retaining structures larger than that of the pores while 
allowing the sample matrix to pass through. Thus, the more rigid and structured 
lymphocytes are immobilized, while the remaining blood components including the more 
supple erythrocytes and platelets, as well as plasma, are allowed to pass, effectively 
isolating the cells of interest while allowing the remaining blood components and 
unbound antibody to be relegated to waste without lysis or additional preparatory steps 
(Fig. 2.3). After support frit and membrane are inserted, a precision-cut layer of double-
sided vinyl adhesive is affixed to the top of the device effectively immobilizing the 
separation mechanism.  The adhesive vinyl layer seals the membrane securely around the 
surface of the underlying support, and also fastens a cover slip to top the system. The 
NBC is serviced by inlet and outlet channels fitted with stainless steel tubing facilitating 
fluid flow including sample introduction and waste removal.   
 
2.4.2 QD Evaluation 
For initial attempts to explore QD-labeled lymphocytes, survey studies were 
completed using reactions in microcentrifuge tubes whereby direct conjugation schemes 
were employed including EDC (Fig. 2.4) and SMCC-facilitated (Fig. 2.5) coupling of 
antibody to nanoparticle surface.  This involved a 5 min incubation of 50 µL whole blood 
with 5 µL of QD-antibody adduct, subsequent dilution to 1 mL total volume with buffer, 
and injection of 500 µL of the sample into the NBC. After a 3 min wash to ensure 
separation of blood components, images were captured with both a 1 and 3 sec exposure.  







Figure 2.4.  EDC Conjugation.  A-B) The EDC cross linker was examined both in the 
presence and absence of the S-NHS stabilizer to link carboxy-coated QDs to IgG 
antibodies.  This technique gave poor results as it non-specifically cross links amines to 
carboxy groups.  C) The method to determination signal (S), noise (N), and background 
(B) is reminiscent of traditional methods in spectroscopy and are created by drawing line 
profiles through the fluorescently labeled cells (D).  For the lymphocyte counting 
application in the NBC, signal to background ratio (SBR) was a particularly important 
descriptor as it defined an authentic cellular event.  White line in D indicates line profile 






Figure 2.5. SMCC Conjugation.  A)  SMCC coats the surface of amine funtionalized 
QDs with an active maleimide group.  B)  DTT reduces disulfide bonds effectively 
cleaving whole IgG into smaller fragments with a free sulfhydryl.  C) This sulfhydryl can 
then reduce into the maleimide ring structure linking fragment to QD. 
The resulting photomicrographs were then analyzed for particles via digital image 
processing in terms of size (70-500 pixels), circularity (0.6-1.0 and defined as 
4π(area/perimeter2)) and intensity (2ζ above mean of image).  We found the 2ζ 
discrimination point to be sufficient to identify 95% of fluorescent bodies on the 
membrane. The pixel size range was determined empirically and evolved from 
experiments with InSpeck™ 6 µm fluorescent polystyrene beads serving as a model for 
the lymphocytes.  This range was sufficiently broad to identify particles immobilized in 
slightly different focal planes as well as those partially overlapping.   
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The cells could be further characterized by comparing the signal intensity present 
in the AOI to the signal of membrane surrounding the area, i.e. the background signal.  
Variation (RMS) in this background membrane signal was defined as noise.  Signal to 
background (SBR) ratios could then be determined by subtracting background from 
signal, with the resulting value divided by background (see Fig. 2.4C, D).  Signal to noise 
(SNR) ratios were calculated by taking the background corrected signal over noise.  In 
this application, SBR served as the more relevant figure-of-merit as it was the basis for 
identification of the AOI as a cell; particles with an SBR above a value of 1 were 
considered to be an authentic event.     
With these techniques, photomicrographic results of different QD-antibody 
conjugation methods could be qualitatively and quantitatively evaluated for labeling 
performance.  With the SMCC conjugation, in addition to particles matching the 
lymphocyte qualification descriptors, additional fluorescent artifacts with irregular 
patterns, very large size, and extremely high intensity were seen.  Especially important 
were the blank experiments in which only QD-antibody conjugate, in the absence of 
blood, was introduced into the NBC.  Here, total mean membrane auto-fluorescence 
without blood was actually higher than in the presence of sample, 8.08 and 5.11 a.u., 
respectively.  This problem persisted despite filtration, sonication, and further 
purification.   Although it is possible that some of the particles in the sample-positive 
experiment were authentic lymphocytes, discriminating between artifacts and labeled 
cells using only morphological characteristics is impossible with the current software 
protocols.  Aggregates could be misconstrued to be lymphocytes, thus contributing to the 






Figure 2.6 Secondary Antibody QD Linkage Conjugation.  A)  SMCC coats the 
surface of amine funtionalized QDs with an active maleimide group.  B)  Proteolytic 
digestion DTT reduces disulfide bonds specifcally cleaving whole IgG into F(ab‘)2 
fragments including a free sulfhydryl.  C) This sulfhydryl can then reduce into the 
maleimide ring structure linking fragment to QD.  This conjugate was purchased in the 
form of panel C from Invitrogen.   
 
 
The EDC technique, though less problematic in terms of precipitation (negative 
control mean membrane fluorescence 3.66 a.u.), gave vague and dim labeling.  This 
conjugate behaved well for labeling stabilized, FC blood-type products, but results were 
unacceptable with traditional venipuncture samples.  Mean SBR ratios were near unity, 
and although some lymphocyte identification was possible, further optimization was not 
performed. This poor performance of established conjugation methods may be 
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attributable to the specific structure of the antibodies employed and reinforces the 
necessity to separately consider each application in terms of conjugation scheme.  
Effective in eliminating the obtrusive precipitate and increasing signal, were 
commercially available QDs, thiol-linked to secondary antibodies (Fig. 2.6) Here, 
unlabeled primary antibodies specific to CD markers were applied first, followed by a 2 
minute on-membrane wash; secondary QD-labeled antibody specific to primary was then 
applied. Clone specificity of the secondary antibodies to their respective primaries was 
exploited to allow simultaneous staining of two different lymphocyte populations.  To 
find experimental conditions optimized for highest cell intensity with low membrane 
staining and low non-specific signal, a series of titrations were performed using varying 
concentrations of secondary antibody versus a constant primary and vice versa (see 
Appendix B); 10 μg/mL primary antibody and 10 nM secondary QD conjugate were 
used for the remainder of the experiments. This was repeated in the absence of any blood 
components and a nearly complete lack of precipitate was observed.  Negative and 
positive control mean membrane fluorescence was 2.80 and 5.28 a.u, respectively for QD 
655 and 15.01 and 19.56 a.u for QD 565.  SBR ratios were well above 4 for QD 565 and 







Figure 2.7. Performance Features of Three QD Linkage Strategies.  A)  SMCC 
technique non-selectively links fragmented IgG onto QD surface.  This strategy 
consistently gave unacceptable fluorescent precipitate both in the presence and absence 
of blood sample.  B)  Although the EDC technique was more reliable at giving low 
backgrounds, its lack of a defined orientation and high fluorophore to antibody ratios 
resulted in cells with low SBR.  C) The secondary antibody scheme specifically labeled 
cells with high specificity and little background.   
2.4.3 Expanded Pathway Assessment  
Later, to confirm the identified secondary antibody based system was indeed the 
ideal choice, a more extensive evaluation of the QD performance metrics was done.  QDs 
have yet to completely replace molecular fluorophores partly because they are inherently 
hydrophobic and thus tend to flocculate out of aqueous solution.  Due to their size and 
surface chemistry, fewer established protocols for bioligand labeling exist.  Nevertheless, 
a number of different pathways use either novel reagents or build upon previously 
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demonstrated linking strategies.  Table 2.1 shows some of the most common routes and 
their performance in the membrane-based cellular processing unit.  Here, a more in depth 
characterization of the different pathways was undertaken as determined by a number of 
descriptors.  First, the length of the linkage from target to QD surface was calculated 
from crystallographic data.
150-152
  Additional performance descriptors include antibody to 
fluorophore ratio, quantum yield (Φ), molar extinction coefficient (ε) at 350 nm, 
aggregation coefficient (Ă), non-specific signal (NS), and signal to background ratio 






 were determined 
similar to previous reports; however the Ă, NS, and SBR (vide supra) values offer fresh 
insight into how to characterize QDs as labeling tools in NBC-type devices.  Briefly, Φ 
was determined by Equation 2.1.  
 
Where ΦR is the quantum yield of a reference material, m is the slope of an absorbance 
versus integrated density linear plot across five different concentrations of samples and 
reference, and η is the refractive index of the medium in which the fluorophore is 
dissolved.  For these experiments quinine in 0.1 N sulfuric acid was used as the reference 
material.  Values for ε were determined by Equation 2.2 in which a linear relationship 
between absorbance and concentration is determined in a 1 cm path length cell. 
 
 
The antibody to fluorophore ratios were calculated by determining moles of antibody or 
fluorophore per volume, either through a protein assay or a spectroscopic absorbance 
(A280) measurement.   
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Table 2.1. Extended Evaluation of QD Conjugation Schemes.  SMCC (A), EDC (B), 
and secondary (C) techniques were subjected to an extended evaluation in addition to an 
avidin/biotin linkage (D) and protein A facilitated pathway (E).  Some avidin/biotin 
labeled cells were subjected to additional biotin amplification (Bt. Amp.) and those 
values separated by dashed line.  These were characterized in terms of path length (as 
determined by crystal structure and literature reports), antibody to fluorophore ratio, 
quantum yield, molar extinction coefficient, background, non-specific signal, and signal 
to background ratio.  The superior performance of the secondary antibody scheme 
remains apparent by its high SBR and low non-specific signal.  Note ΔΦ is change in 
quantum yield upon linkage to antibody and ε is measured at 350 nm.  Other descriptors 
are explained further in the text of Section 2.3.3. 
SBR was determined and evaluated as above while Ă was calculated by passing antibody 
labeled QDs over the membrane (in the absence of any blood sample) and observing 
aggregates.  The percentage of the membrane that was covered by this aggregate was 
recorded and defined as Ă; acceptable values are well below 1%.  This method is a 
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straightforward way to determine passivation layer defect and addresses a critical need 
addressed in Nann‘s recent Nature Methods paper.
158
  Finally, NS signal was determined 
by incubating raw QDs with blood and then analyzing with the NBC.  Raw QDs only 
were then analyzed with NBC (Ă).  The difference in number of counts between the two 
experiments results in an increased number of particles present with blood which is due 
to the non-specific interaction of QDs with cells and is reported as the value NS.    This 
method effectively eliminates any of the biological components and is a straightforward 
method to determine non-specific binding.   Not surprisingly, QD particles with a high 
negative charge, i.e. carboxy QDs, have a higher coefficient of non-specific binding.
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Conjugation pathways have been discussed in detail in a number of quality 
reviews.
59, 66, 160
  The values for Ă, NS, and SBR reinforce what has been previously 
demonstrated—for our lymphocyte application, a secondary approach is the best fit.  The 
proper conjugation pathway will have not only low Ă and low NS, but also high SBR.  
The secondary labeling approach remains the ideal choice for lymphocyte labeling.   
All of the data in Table 2.1 was collected with source QDs from Invitrogen.  To 
evaluate differences between vendors, a study with CdSe/ZnS particles from Invitrogen 
and Evident were compared, in addition to CdTe particles from PlasmaChem.  Table 2.2 
illustrates that the CdTe particles are substantially dimmer; a 50X concentration increase 
needs to be performed before signal can be observed.  They do however, demonstrate less 
non-specific binding and yielded fewer problems with aggregates.  The high signal 
intensity of the Invitrogen particles, as evidenced by their higher Φ ultimately influenced 
the decision towards their use.  Interestingly, their greater than 50% reduction in Φ upon 
antibody linkage is consistent with the literature and may be due to non-radiative decay 
of excited states as influenced by singlet oxygen.
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Table 2.2.  Performance Features of QDs From Various Vendors.   QDs were used in 
conjunction with the EDC method to label CD3+ lymphocytes in the NBC.  Invitrogen 
(A, E) and EvidentTech (B) QDs are carboxy coated and consist of CdSe core and ZnS 
coat.  PlasmaChem (C, D) QDs have a CdTe core which resulted in a much dimmer 
signal; however, these QDs also had much less problems in terms of aggregation and 
non-specificity.  An additional parameter included here not in Table 2.1 is macroscopic 
precipitation (macro ppt) a term used to evaluate how much of the antibody-QD 
conjugate is in solid form at the end of conjugation.   
2.4.4 Optimization and Validation 
To validate further the secondary antibody QD-based labeling scheme, whole 
blood samples were labeled with Alexa Fluor 488 bound directly to CD4-specific 
antibody from mouse.  The sample was then counterstained with QD 655 secondary 
antibody specific to the mouse IgG.  This sample was analyzed with the NBC and imaged 
through filters specific to the two fluorophores with >99% spectral overlap (data not 
shown) of the red and green signal seen, verifying this secondary antibody QD 
visualization methodology.  Unlabeled primary antibodies were henceforth used.  When 
secondary antibodies were incubated with blood samples devoid of primary antibody, and 
subsequently injected into the NBC, fluorescence signal was reduced by 86.5% relative to 
the positive controls, as the unbound fluorescent antibody is passed on to waste. This 
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background signal is attributable to membrane staining and stray, conspicuous 
aggregate—both easily identified and removed via image processing.   
      
 
Figure 2.8. Cross Reactivity in Secondary Antibody Labeling Pathway.  Panel A  and 
B are the same sample subjected to CD4 primary antibody raised in rat and then 
subjected to secondary staining by both goat anti-rat (QD565) and goat anti-mouse 
(QD655) antibodies.  The sample was then imaged with optical settings specific to either 
green (A) or red (B) QDs.  Only the specific rat-rat interaction elicits a signal.  
Conversely, panels C and D employed a CD3 specific primary antibody raised in mouse 
and an identical secondary cocktail as employed above.  Again, specific signal comes 
from the iso-species interaction.  Images captured at three seconds exposure.   
As clone specificity between the primary and secondary antibodies is of utmost 
importance in this dual color staining approach, any non-specific binding within the 
system was also investigated. Whole blood samples were first incubated with CD4 
primary antibody raised in rat; washed, blocked, and incubated with QD 655 labeled 
secondary antibody specific to both mouse and QD 565 goat anti-rat (Fig. 2.8A, B). Non-
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specific signal was 9.1% in such a trans-species experiment. CD3 mouse primary/QD 565 
goat anti-rat and QD 655 goat anti-mouse secondary experiment was performed 
analogously to that described above with similar results (Fig. 2.8C, D).   
 
 
Figure 2.9. Lymphocyte subset profiling via QDs. Representative photomicrographs of 
whole blood labeled with CD specific antibody and QD fluorescently tagged secondary 
antibody taken with a 10X objective and 3 seconds of exposure time. The QD 565 labels 
CD4+ cells including monocytes and T lymphocytes in the green  channel (A) while QD 
655 stains CD3+ lymphocytes red (B), as observed through separate filter cubes specific 
to each fluorophore. A digital overlap of the red and green images (C) shows monocytes 
(CD3+CD4+, green), T lymphocytes (CD3+CD4+, yellow) resulting from signal both in 
red and green channels, and remaining NK and CD8+CD3+ T-killer lymphocytes 
(CD3+CD4+, red). An alternative approach (D) utilizes a long-pass emission filter cube 
(520 nm and longer) allowing a single capture event to produce a similar image to that 
generated by separate photomicrographs. Insets illustrate highlighted areas with 2X 
digital zoom; images captured with three seconds of exposure.     
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Thus, for the remainder of the experiments, CD4+ lymphocytes appear green 
(Fig. 2.9A) and CD3+ cells red (Fig. 2.9B). Upon digital overlay of these two images, the 
dually stained cells of interest emerge yellow (Fig. 2.9C). Dim green cells in the image 
are monocytes, as they express the CD4 surface receptor to a much lesser degree than 
lymphocytes.  Cells remaining solely red represent CD8+ killer T lymphocytes.  Images 
were also obtained with a long pass emission filter (Fig. 2.9D) similarly to those acquired 
with individual filters.   Monocytes were found to have a fluorescent intensity 
approximately 6 times less than lymphocytes.  This is consistent with their decreased 
expression of the CD4 epitope relative to the T cells.   
2.4.5 Monocyte Discrimination 
Monocytes, like CD4+ T lymphocytes, possess the CD4 surface marker and, as 
such, are a critical consideration in the membrane-based NBC analysis. The presence of 
monocytes can lead to artificially high CD4 counts. Figure 2.10 details both the spatial 
and intensity gating strategies employed to diminish any artificial monocyte contribution 
to desired cell count. First, the CD4+ cells are divided into two categories, dim and 
bright, with only the bright cells subjected to further processing (Fig. 2.10A). Second, the 
presence of the CD3 marker is required to confirm the cell‘s authenticity as a T 
lymphocyte (Fig. 2.10B) Only cells positive for both markers are then counted (Fig. 
2.10C). Monocytes and lymphocytes are clearly separated by the membrane-based NBC 
into two distinct populations with a bimodal distribution as seen in the histogram in 
Figure 2.10D. The distribution gives baseline separation between the two populations of 
CD4+ cells. Flow cytometry produces a similar distribution, but also contains a low level 
population of non-specifically stained cells (Fig.2.10E). Monocytes in the membrane-
based NBC were found to have a fluorescent intensity approximately 4 times less than 
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lymphocytes. This is consistent with their decreased expression of the CD4 epitope 
relative to the T cells.
162
             
 
Figure 2.10. NBC Gating.  Graphical depiction of cells and the spatial and intensity 
gating procedures used for selected lymphocyte and monocyte populations. A)  The 
CD4+ cells fall into two distinct populations: CD4+ bright, lymphocytes, and CD4+ dim, 
monocytes as shown in the schematic. The intensity of this CD4-specific signal is an 
initial descriptor to remove monocytes from analysis. B) The CD3+ cells include T and 
NK lymphocytes. C) Overlap of the two images results in red, green, and yellow cells. 
Cells doubly positive for red and green, and thus yellow, are the CD4+ T lymphocytes of 
interest.  Cells remaining green are the interfering monocytes. D) A green color channel 
8-bit intensity histogram is shown for the CD4+ cells as analyzed by the membrane-based 
NBC. The cells are labeled with QD 565. E) A similar 10-bit histogram is shown for the 
populations as determined by FC.  (FC histogram truncated from 1024 to ~550 to 
maximize plot area.) 
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2.4.6 Absolute Determinations 
Having validated that the fluorescent particles seen on the membrane were indeed 
authentic lymphocytes of identifiable subsets, the ability of the membrane-based NBC 
system to count QD-labeled cells was next explored. Critical to this success, was a NBC 
design in which a near uniform distribution of sample is achieved across the entire 
membrane area. To evaluate whether this was indeed the case, photomicrographs in five 
different FOVs across the membrane were captured, with one in the center of the 
membrane and 4 additional locations arranged orthogonally from each other and 
surrounding the center image.  This consistent method of defining FOVs across the 
membrane involves analysis areas both in the center and near the edges of the membrane 
and creates a broad sampling of surface area.  Additional investigations have used 
different membrane sizes, pore sizes, and flow rates and found that with the parameters 
used herein, low CVs were routinely obtained, consistent with previous work.
130
  Cell 
counting and profiling studies were done to show that a small fraction of the membrane 
could be used to accurately represent the total count within the entire volume.  Standard 
deviation and mean when 5 FOVs were used result in a %CV value that was typically 5-
10% (vide infra). These measurements serve to establish that the cell distribution is 
optimized across the membrane structure.  No further decrease in variance was seen upon 
the inclusion of more than 5 FOVs. 
Also critical were consistent background autofluorescence of the membrane as 
this served to define the SBR ratio.  Autofluorescence is reduced in the red, QD 655, 
channel relative to the green, QD 565, channel.  Fortunately, this was negated by the high 
QD signal to still measure high SBRs. An alternative method used image capture before 
introduction of sample and a resulting background subtraction.   
Converting digital images into meaningful cell counts utilizes digital image 
processing and custom-built deconvolution coding macros.  To initially optimize the 
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software to correctly interpret our photomicrographs, fluorescent beads with physical 
dimensions near lymphocytes were first used.  Next, through an iterative process, such 
descriptors as size, circularity, and signal to background ratio were trained on nearly 1 
million individual cellular events to result in cell counts that were statistically identical to 
those provided by flow cytometry.  The difference between each FOV is less than 10% 
and indicates that the arrangement of cells on the membrane is random and generally free 
of bias.  Importantly, with appreciably different blood volumes (< 10 µL or > 75 µL) the 
distribution moves away from random distribution.  The variance between repeated 
analyses of the same sample within the NBC is 5-8% compared to values nearing 25% 
for flow cytometry.   This cell counting approach has been validated down to 50 cells/µL 
and up to 600 cells/µL which includes both the region where increased testing is 
recommended (200-600 cells/µL) as well as the area considered active AIDS (< 200 
cells/µL).  Cellular crowding on the membrane leads in inaccurate counting and may 
hamper cell counts above 600 cells/µL as lymphocyte overlap leads to exclusion from 
macro analysis.  Photomicrographs containing more than 20% of active pixels generally 
had a large number of overlapping lymphocytes.  To circumvent this shortcoming, an 
alternative method of analysis—total membrane fluorescence—was demonstrated to 
extend the linear dynamic range in a spore counting applications by three orders of 
magnitude.  This system achieved detection limits of ~500 Bacillus globigii (a commonly 
used simulant for Bacillus anthracis) spores, a value highly competitive with similar 
technology, but with analysis times of approximately 5 minutes.
163
   
To demonstrate the ability of the membrane-based NBC ensemble to count across 
a wide linear dynamic range of cells, increasing volumes of whole blood ranging from 5 
to 100 μL were stained for CD4 cells and injected into the mini cell capture system. The 
resulting cell count values were plotted versus volume and yielded a linear response over 
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this sample volume range (R
2
 = 0.98, Fig. 2.11A). The linearity of this dose response 
curve provides strong evidence for the analytical capabilities of the approach and 
suggests that the fluorescent nanoparticles and automated digital counting methodologies 
here defined may be used to measure lymphocyte populations under these conditions. As 
might be expected, at either very high or very low blood volumes, the %CV of the 
measurements increases.  This behavior is due to overlap and clumping at the high end, 
and lack dissemination (reduced sample viscosity) across the entire membrane at low 
volumes. For the remainder of the experiments 50 µL of sample was used.  Fig. 2.11A 
also demonstrates the importance of the threshold parameter in CD3 counting.  For the 
blue ―set‖ approach, a S = 17 was designated as the discriminator between background 
and cell surface while for the ―auto‖ approach a floating cut-off of 2δ above the mean of 
all pixels.  The simplicity of this data analysis approach allows digital changes to the 
macro to produce the most accurate results output.   
To simulate the ability to perform cell counts over the range of values typically 
encountered in both healthy and immunocompromised individuals, a dilution study was 
performed in which blood volumes of 5-50 μL were diluted with 1% PBS/BSA to a total 
volume to 50 μL.  Cells were stained for both CD3 and CD4 and doubly positive cells 
(yellow) from 5 FOVs were counted. This was again extrapolated via entire analysis area 
to give a total cell count which was divided by the 50 μL sample volume resulting in a 
measurement of counts per µL.  Good linearity was observed across the 350 to 500 
cells/µL region where increased monitoring is recommended.
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 Lymphocyte counts 
below 200 cells/µL were measured with acceptable accuracy indicating the diagnostic 
criterion for the separation barrier between HIV and AIDS, in addition to measurement of 
healthy cell count values, can be achieved with this approach (R
2




Figure 2.11.  Cell Counting and NBC Validation for HIV Studies.  Whole blood of 
varying volume was subjected to the staining process and membrane-based NBC 
analysis. A) Undiluted blood was stained for CD4+ lymphocytes and counts per field of 
view translated into total number of cells distributed across the entire membrane. This 
was interpreted by either a constant (set) or dynamic (auto) threshold value.  B) To 
simulate immunocompromised samples, blood volumes were subjected to PBS/BSA 
dilution to a total volume of 50 μL and stained for CD3+CD4+ lymphocytes with total 
membrane area and dilution correction factors utilized to estimate cells per μL in the 
original 50 μL sample.  C) Small pilot study comparison of the membrane-based NBC 
method to flow cytometry for %CD4 determinations correlates at R
2
 = 0.97. 
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2.4.7 Flow Cytometry Correlation  
To compare the membrane-based NBC to the gold standard of cellular 
determinations, flow cytometry, parallel experiments were executed to measure values of  
%CD4 (i.e. CD3+CD4+ cells per total CD3+ cells). Similar measurements have been 
completed previously using a combination of red encoded CD3, CD19 and CD56 cell 
surface markers to secure the entire population of  lymphocytes.
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 For the purpose of 
these experiments, whole blood samples were collected from 6 different healthy donors 
by venipuncture, divided into 2 aliquots, and analyzed the same day as collection on both 
the FC and membrane-based NBC systems. Through the image analysis protocol 
described above, the number of cells displaying both the CD3 and CD4 receptors can be 
determined and compared to CD3 counts. In the membrane-based NBC, this corresponds 
to the total number of dually-positive yellow cells divided by total red cell counts. In FC, 
lymphocytes were first identified from monocytes and granulocytes via their unique side 
and forward scatter signature. These cells were further characterized by the number of 
CD4 and CD3 surface receptors present, as determined by red and green fluorescence 
intensity, respectively. Separation between dually positive and CD3+CD4- cells was seen 
and cell counts per µL derived via calibrator bead standards.  The values of %CD4 could 
then be determined by number of cells CD3+CD4+ divided by total CD3+.  Regression 
analysis shows correlation between the methods using a single long pass emission filter 
(R
2
 = 0.84) or separate filter cubes (R
2 
= 0.97, Fig. 2.11C).  Differences between the two 
optical approaches include higher background, and thus less contrast between the 
membrane and cells, resulting in fewer events detected during image analysis of 
photomicrographs obtained with the long pass filter. This optical interference could 
possibly be eliminated with a dual band pass emission filter or simply a more discerning 
long-pass filter.  Nevertheless, this degree of agreement in a small pilot study is an 
encouraging example of the utility of nanoparticle QDs employed in a biochip sensor.   
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To assess the precision of both approaches one sample was repeatedly assayed 6 
different times with both flow cytometry and the NBC. Although the NBC system 
showed higher standard deviation, the CD4% values for individual filters, 53.28% ± 
5.13%, and long pass filter 46.96% ± 8.83%, were within the statistical range of that 
given by flow cytometry, 51.11% ± 0.35%. Differences here may be attributed to 
variation in NBC construction, pipeted volume, or sample decay.  Typical trial to trail 
variance values for flow cytometry is in the range of 5 to 8%.
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  The FC procedure takes 
> 60 minutes from startup to results as its‘ elaborate optical and fluid handling design 
require daily maintenance.  The NBC system produced results in < 30 minutes.   
 
2.4.8 Comparison to Molecular Fluorophores 
 
For evaluation of QDs relative to organic fluorophores, 50 μL whole blood was 
labeled with mouse CD3 primary antibody and then fluorescently tagged with equimolar 
quantities of goat anti-mouse secondary antibody conjugated to QD 655, QD 565, Alexa 
Fluor 647, Alexa Fluor 488, or fluorescein isothiocyanate (FITC).  A sequence of images 
was acquired with photomicrographs taken every 20s for 15 minutes.  The AOIs, specific 
to each experiment, were created from the initial and most intense image, and then 
applied to subsequent photomicrographs recording the mean intensity of each AOI 
collection.  This value was plotted vs. time for three of the fluorophores resulting in 
Figure 2.12. The attributes of the fluorescent nanoparticles becomes clear as the intensity 
ratio advantage versus their molecular counterparts (with the exception of Alexa Fluor 
488) after only one minute was 1.4 and 3 for the red and green fluorophores, respectively. 
At fifteen minutes these ratios increase to 2.2 and 6.  Power meter interrogation of the 
two systems, indicates an excitation intensity advantage factor in the QD system of 1.3 
versus Alexa Fluor optics.  The Alexa Fluor dyes used in these comparisons are provided 
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with a fluorophore to antibody ratio of ~ 7:1. Conversely, due to the large size of the 
quantum particles relative to the molecular dyes, this ratio drops to ~ 0.3:1.         
     This stability is particularly advantageous to our NBC system as multiple 
FOVs are captured and in which any loss of fluorescence would directly translate into a 
reduced number of lymphocytes imaged.  Furthermore, additional reagents targeting 
other intra, or extra, cellular moieties of interest could be added after this initial analysis 
gleaning supplementary information from the sample while retaining the stable QD 
signal. The powerful Alexa Fluor 488 signal is likely due to its very large excitation 




 Figure 2.12.  QD Photostability. CD3+ cells were processed with equimolar 
concentrations of both primary and secondary-antibody-fluorophore conjugate, which 
was normalized to fluorophore.  This was injected into the NBC, and images captured 
every 20 sec for 15 min.  Intensities from each fluorophore were plotted relative to their 
individual maximum, initial intensity. Conventional fluorophores exhibit exponential 
decay versus QD photostability that is critical for capturing a number of FOVs in the 
NBC system. This stability may also be exploited to add additional reagents for further 
cell analysis. Images captured at one second exposure.   
 67 
 
 Figure 2.13.  QD Filter Optical Properties.  Signal to noise and signal to background 
ratios for individual filter cubes versus a single long pass filter for staining CD3+ cells. 
Individual cell intensities were evaluated relative to immediate environment in terms of 
membrane auto-fluorescence and variation in background signal. For this application, 
SBR proved critical in identifying authentic events. 
 
2.4.9 Optical Pathway Evaluation 
    
     To evaluate the performance characteristics between individual filter cubes for 
red and green QDs versus a single long pass filter, images were captured under both 
conditions.  Photomicrographs were split into their RGB components, AOIs determined 
as described above, and average pixel intensity in the gated regions recorded.  The SNR 
and SBR values were calculated, the results of which may be seen in Figure 2.13.  
Amplification of SBR by 13.7% is observed with the long-pass filter for QD 565, 6.2% 
for QD 655.  SBR values for the green channel QDs are 61.4% lower than red channel 
QDs.  This is attributable not to decreased intensity, but rather to increased 
autofluorescence of the membrane.  Capturing an image before sample introduction with 
resulting background subtraction negates this effect.  The system was capable of 
adequately identifying cells even at SBR values approaching unity.  The similarity 
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between the individual filter cubes and a single condensed method demonstrates the 
ability to develop QD-based NBC systems utilizing only a single optical pathway for 
reduced overall analyzer footprint.   
2.5 DISCUSSION 
2.5.1 Role in HIV 
     Despite the availability of antiretroviral therapy (ART) as treatment for 
declining immunity, use of ART as a tool to decrease morbidity among the more than 33 
million people infected with HIV has not become widespread in resource-scarce settings. 
Lack of CD4 HIV immune function testing has been described as the ―missing link‖ in 
the management of HIV+ patients in resource-scarce settings.
1
 Problems with CD4 
measurements here can be attributed to the above highlighted infrastructure requirements 
including a lack of skilled operators, high cost, constant power supplies, the need for 
refrigerated reagents, and lengthy sample preparation. Identifying those individuals most 
at need for ART as determined by the immunological profile remains the ultimate goal of 
these efforts.  In order to meet that goal and push for further reductions in overall 
analyzer size, this chapter demonstrates the feasibility of incorporating next generation, 
nanometer-sized fluorophores into a microfluidic device to monitor the progression of 
HIV and other immunologically relevant diseases.  Existing techniques, including flow 
cytometry and nonflow alternatives, have the drawbacks of low throughput, extensive 
sample preparation, and limited portability.  The self-contained NBC apparatus is 
completely disposable reducing risk of biological contamination and allows fingerprick-
sized samples to be analyzed in under an hour, with CD4 percentages obtained to a 
degree similar (R
2
 = 0.97) to traditional flow cytometry without the need for erythrocyte 
lysis, manual counting, or internal bead standardization.   
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2.5.2 NBC Advantages  
     The analytical behavior observed by the NBC is an effective proof-of-principle 
demonstration of the miniaturized system with several advantages versus flow cytometry.  
First, the use of reagents is greatly simplified; no lysis reagents are required to remove 
erythrocytes and no calibration beads are required as in single platform FC.  Fixation and 
dilution are the only a single sample preparation steps required in the NBC system.  
Second, the optical and fluidic standardization protocols required of FC for maintenance 
and calibration are largely eliminated with the NBC.  In contrast to the complex and 
relatively delicate optics of benchtop cytometers, our NBC system needs only a single set 
of excitation/emission optics when operated in tandem with QD probes; a reduction in 
moveable subcomponents is an attribute to LOC-type devices. Third, size is drastically 
reduced from a FC apparatus requiring an entire benchtop to a potential hand-held device.  
Finally, the amount of sample required is less than half of that required for flow 
cytometry.  Although the difference between 50 µL and 100 µL is not especially 
substantial, this decreased volume moves the sample size into a range highly compatible 
with finger-prick sized samples, a less invasive collection method.  Additional studies are 
needed to further determine the validity of finger-prick as a venipuncture replacement.   
     The NBC served to effectively isolate components of interest from the greater 
sample matrix.  Critical to our success was NBC design with optical considerations in 
mind.  A flat and monodisperse membrane prevented uneven illumination and allowed 
nearly all cells in one field of view to be in focus concurrently. Cell overlap on the 
separation mechanism, although minimized by small sample volumes and injection flow 
rate, was sometimes unavoidable. However, digital imaging functions were capable of 
separating these AOIs based on size and location.   The mean diameter of cells present in 
the photomicrographs when imaged with a 10X objective is 14 pixels or 8 µm.  This 
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2.5.3 Fluorophore Considerations  
     Low membrane auto-fluorescence and resistance to non-specific staining from 
the quantum particles increased SBR and facilitated accurate cell identification.  Red 
emitting nanoparticles had a greater propensity to stain the membrane than their green 
counterparts which is likely attributable to their larger size and increased attraction to the 
membrane. Although initial experiments using covalent coupling between cell specific 
antibody and QDs resulted in vague labeling and disappointing aggregation, these 
challenges were remedied with a secondary antibody-QD approach.  Table 2.3 further 
elucidates the shortcomings and attributes of the three covalent linking strategies.  
Although not the most direct route between biological target and fluorescent label, this 
method proved to be a specific and effective transduction pathway.  This labeling scheme 
utilizing secondary antibodies provides the advantage of increasing the number of 
fluorophores immobilized on a single lymphocyte.  With organic fluorophores, upwards 
of 7 molecules of dye per antibody may be achieved, but due to their larger size, this 
becomes impossible with QDs (5-20 nm).  Allowing multiple secondary antibodies to 
bind to a single primary further amplifies the signal output.   
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Table 2.3.  Performance Features of Covalent QD Linking Techniques.  A 
summation of the shortcomings and highlights of the EDC, SMCC, and secondary 
antibody conjugation methods reveals that, for this application, secondary antibodies are 
best suited due their lack of aggregation and intense, specific signal.   
 
2.5.4 Quantum Dot Performance  
 A definitive explanation for the failure of established direct conjugation protocols 
in this application may be impossible; however, it may be attributable to the specific 
types of antibody used in the application or the generation of QD probes obtained from 
the vendor.  As the EDC technique links non-specifically through free amines, a variety 
of antibody orientations is possible.  This method yields high antibody to QD ratio which 
could potentially induce steric hindrance of active sites.  Further, this EDC can 
potentially induce cross-linking of non-targeted amines. The SMCC method employs 
DTT, a strong reducing agent. While DTT may cleave the disulfide linkages along the 
IgG backbone, it may also break other S-S bonds, damaging tertiary structure and thus 
antigen specificity.  This damage may go so far as to denature the protein and perhaps 
explains the aggregates seen. It should be noted, however, that this phenomenon is likely 
specific to individual antibody structure as Chapter 3 details the use of the SMCC 
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method with excellent results in other non-cellular applications. Poor performance with 
directly bound QDs is not uncommon, and the secondary antibody method thus employed 
proved to be a specific and effective transduction pathway.
76, 85
 In addition, more than 
one secondary antibody may be bound to each primary, further increasing the number of 
fluorophores per lymphocyte and thus signal output. QD-avidin produces a large number 
of aggregates perhaps due to the size of avidin relevant to QD.  The high NS from the 
Protein A experiment signal indicates that the protein is not specifically targeting the 
primary antibody and may be binding to irrelevant cell surface markers.   
An accurate comparison of the performance features between biologically active 
QDs and molecular dyes is admittedly difficult.
158
  Although information describing the 
attributes of QDs in their native state abounds in the literature,
166-168
 the spectroscopic 
data characteristic of the particles upon synthesis including molar extinction coefficient, 
quantum yield, FWHM, emission maximum, and average radius can radically change 
after passivation and further functionalization with biological ligands. Evaluation versus 
organic fluorophores adds the additional challenge of uncertain antibody to fluorophore 
ratio and differences in excitation intensity. Nevertheless, we observed photostability in 
the QDs superior to their molecular counterparts.  In the time dependant study, in which 
relative intensities were calculated via each fluorophores initial intensity, Alexa Fluor 
488 diminished to an intensity one half maximum in 280 s with Alexa Fluor 647 and 
FITC achieving this value in less than 80s (Fig. 2.12). Neither QD 565 nor QD 655 
displayed significant intensity loss during this period. 
2.5.5 Optical Gating     
 Analogous to the gates placed on data by flow cytometrists with parameters such 
as scatter and intensity, our microfluidic NBC and subsequent image processing allows 
individual components of a complex sample to be identified and quantified.  In lieu of 
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lysing to isolate the fraction of interest, our system utilizes a size gate, i.e. membrane, to 
isolate white blood cells from the greater sample matrix. Both the size gate described 
above as well as a fluorescent intensity discriminator replace the scatter gate, typically 
related to cell morphology in FC.  The intensity gate has two important applications.  
First is the SBR ratio, used to discriminate between authentic and non-authentic events.  
Secondly, the intensity gate addresses monocytes, an important consideration in these 
types of cell assays as the presence of such cells in samples could artificially contribute to 
the total CD4 count.   Thus, low-level CD4 expressing monocytes are effectively ignored 
in the digital image leaving only green channel positive lymphocytes.  Literature 
reference values of approximately 48,000 copies of the CD4 antigen on lymphocytes, 
with 3,000 – 9,000 copies on monocytes,
162
  corresponds nicely to the factor of 6 
intensity difference between monocytes and lymphocytes in the NBC.  Intensity 
histograms for all CD4 positive cells show baseline resolution between lymphocytes and 
monocytes.  From these histograms, the ratio of monocytes to lymphocytes could be 
determined for each image and compared to the ratio determined by flow cytometry.  The 
difference between the two methods was less than 6%.   Finally, cell location on the 
membrane serves as a spatial gate to identify doubly positive CD3+CD4+ T lymphocytes 
of interest and a circularity gate in the ImageJ software rejects any debris that may be 
present on membrane surface.           
     
 
2.5.6 Limitations and Comparison to Other Miniaturized Techniques  
     Although many reports have been published in which QDs are used for cellular 
imaging,
30, 31
 to the extent of the author‘s cognizance, this is the first report in which QDs 
are used for cellular quantitation in an enclosed, disposable device. Other methods using 
interference or impedance are frequently incompatible with peripheral blood samples as 
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they are overwhelmed by the presence of erythrocytes.
139, 142
 Manual counting methods 
involving magnetic beads
140
 often fail to correlate to established methods above R
2
<0.90, 
perhaps due to residual monocyte contamination.  Other alternatives to FC using QDs are 
not self-contained,
77
 an important consideration when dealing with HIV-positive samples. 
Literature reports using QDs quantitatively is limited to protein disease markers.
169
  The 
membrane-based NBC correlates to FC at levels similar to non-labeling methods, based 
on cell affinity immobilization,
138, 141
 but also has the built-in capability for further 
analysis including ratios and percentages along with the capacity to exclude monocyte 
contamination in a rigorous way. Indeed, the membrane-based NBC can be extended to 
measurements of CD4/CD8 ratios, rare cell event detection,
170, 171
 panel evaluations 
similar to complete blood counts
172, 173
 and other advanced FC experiments.
174, 175
  As 
such, the membrane-based NBC serves as an interesting new approach that can service 
the requirements for a ―personal flow cytometer‖ for use in both resource-scarce 
environments as well as in numerous research settings where the cost and complex nature 
of FC limits its current utility.  Although only 6 samples were available for analysis with 
the QD-based approach (Fig. 2.11C), the correlation of results to FC suggests a study of 
greater scope be performed as well as experiments including immunocompromised 
individuals.  To be certain, additional large-scale clinical trials including 
immunocompromised individuals needs to be performed before further claims may be 
made.  Other limitations of this approach include the lack of FDA-approval and no 
integrated online filtration system for QD bioconjugate as the QD-secondary antibody 
conjugate required filtration by hand before labeling.  Nevertheless, these results intimate 
another generation of analyzer size reduction may be realized.   
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2.5.7 Bridging Gaps—Towards a Condensed Analyzer  
Thus, a number of different size regimes have been crossed through this use of the 
NBC system, Figure 2.14.  On the cell surface, immunoreagents and QD particles with 
nanometer size characteristics are assembled to create a specific, intense signaling 
method (2.14A).  Cells (microns, 2.14B) then decorate a single FOV (millimeter, 2.14C) 
within the NBC (centimeter, 2.14D).  The NBC shown in 2.14 is an additional generation 
forward-looking assay platform to be used in tandem with a similarly condensed analyzer 
(2.14E).  Additional details on this unique analyzer type will be discussed in later.  
Regardless of whether signal is read with a benchtop microscope, or compact analyzer, 






 Figure 2.14. Size Regimes Involved in NBC.   The NBC uses elements from many 
different size scales including nano (A), micro (B, C), and macro (D, E).  The integration 









2.6 SUMMARY AND CONCLUSIONS 
These experiments demonstrate the viability of incorporating a quantum dot 
detection scheme into a microfluidic analysis device for lymphocyte enumeration as a 
tool for monitoring HIV progression.  Cell counts are obtained through interpretation of 
the fluorescent images with automated software and require no manual counting.  The 
device‘s strong (R2 = 0.97) correlation to gold standard flow cytometry is superior to 
bead-based systems and some other chip-based approaches.  Proof-of-principle CD4% 
determinations, verified by traditional FC could be extended to absolute CD4 counts and 
CD4/CD8 ratios and other cellular analyses. Although additional trials are needed to fully 
assess the comparability of this cellular processing unit within the NBC system to 
traditional cell analysis methods, preliminary data shows strong correlation among 
healthy individuals.  This synergy of advances in nanotechnology, materials chemistry, 
and microfluidics, promises to yield a final product with relaxed optical requirements, 
which yields diagnostic information rapidly, robustly, and reliably.  Such a device would 
serve as a transformative tool in joining currently available anti-retroviral therapies with 














Chapter 3:  Utilization of QD Bioconjugates in Nano-Bio-Chip 
Assemblages for Multiplexed Detection of Oncologic Biomarkers  
3.1 CHAPTER OVERVIEW 
The integration of semiconductor nanoparticle quantum dots (QDs) into a 
modular, microfluidic biosensor for the multiplexed quantitation of three important 
cancer markers, carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), and Her-
2/Neu (C-erbB-2) was completed.   The functionality of the integrated sample processing, 
analyte capture and detection modalities was demonstrated using both serum and whole 
saliva specimens.  Here, nano-bio-chips that employed a fluorescence transduction signal 
with QD-labeled detecting antibody were used in combination with antigen capture 
within a microporous agarose bead array supported within a microfluidics ensemble so as 
to complete the sandwich-type immunoassay.  The utilization of QD probes in this 
miniaturized biosensor format resulted in signal amplification 30 times relative to that of 
standard molecular fluorophores, affording a reduction in observed limits of detection by 
nearly 2 orders of magnitude (0.021 ng/mL CEA; 0.11 pM CEA) relative to enzyme-
linked immunosorbent assay (ELISA).  Assay validation studies were also completed and 
demonstrated that measurements achieved by the nano-bio-chip system correlate to 
standard methods at R
2
 = 0.94 and R
2
 = 0.95 for saliva and serum, respectively.  This 
integrated nano-bio-chip assay system, in tandem with next-generation fluorophores, 




Despite advances in treatment strategies, as well as molecular diagnostics, cancer 
remains a disease of grave lethality with more than 1.44 million new cases and 
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approximately 567,000 deaths estimated in 2008 in the United States.
176
  Fundamental to 
the progression of healthy cells to cancerous ones is an alteration in the genomic and 
proteomic makeup of tissue; early detection of these changes remains key to decreasing 
morbidity.  Protein biomarkers show promise in the treatment of cancer early in its 
development through screening as well as staging, metastasis evaluation, and determining 
response to pharmacologic intervention.
177, 178
  Occult blood tests, PAP smears, and 
prostate specific antigen (PSA) are established screening tools for cancer detection in 
asymptomatic individuals.
179
  Breast cancer companion diagnostic tests based on Her-
2/Neu and prognostic assays utilizing alpha-fetoprotein in testicular cancers have also 
been developed.
3, 180
  Additional progress has been made using protein biomarkers to 
monitor colon cancer response to treatment via carcinoembryonic antigen (CEA) or 
ovarian cancer via cancer antigen 125 (CA125).
181
  In spite of these advances, 
widespread use of protein biomarkers remains elusive due to methodological and 
technological obstacles.   
Most biomarkers provide evidence for a generalized disruption of homeostasis, 
rather than indicate the presence of a specific disease as illustrated in Figure 3.1.  
Therefore, values outside the physiological normal range demand interpretation in 
conjunction with other assay results and clinical symptoms.
182, 183
  Early stage detection 
of cancer frequently requires the use of four or more biomarkers analyzed simultaneously 
to identify at-risk individuals with adequate confidence and currently used methods, 
based on ELISA, are not easily multiplexed.
184
  Furthermore, in order to diagnose a 
cancer in its nascency, physicians recommend regular and frequent screening events—an 
arrangement incompatible with the high cost, lengthy turnaround times, and intrusive 
sampling procedures of current assay designs.  In addition, most of the currently used 
screening methods have limits of detection (LODs) near the diagnostic decision values 
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that provide optimal separation between clinical categories, creating difficulties in 
accurately evaluating patients in early stages of neoplastic disease, when biomarker 
concentrations are only slightly altered.
185
  Thus, the lack of cost effective, convenient 
and minimally invasive testing instrumentation, for use without sacrificing analytical and 
clinical accuracy, may translate into inferior clinical performance and hence poor patient 
outcomes.   
 
 
Figure 3.1.  Ratios of Individuals Testing Above CEA Disease Threshold.  Cancer 
and other disease biomarkers are rarely the proverbial ―smoking gun‖ sought by 
diagnosticians.  Rather, they indicate a generalized disturbance in normal body function 
and may present in both benign, malignant, and even asymptomatic individuals.  For 
CEA, any number of conditions may cause an increase in serum levels.  Note too, that no 
one condition is represented by uniform upregulation of serum CEA.  (Data reproduced 
from Bayer Diagnostics/Siemens white paper.) 
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To satisfy this unmet clinical need, advanced integrated systems have become an 
increasingly attractive alternative to the centralized laboratory paradigm.  These 
approaches combine a microfluidic architecture for sample and reagent handling with a 
biological receptor to identify the analyte followed by a reporter scheme and signal 
transduction and readout. These POC systems allow clinicians to have access to a wide 
array of diagnostic test results, information that is conventionally only available at large 
oncology-focused hospitals or via lengthy and expensive reference laboratories.  From 
the perspective of cancer prevention and treatment, in which early diagnosis is key to 
long term survival, POC analysis devices are particularly advantageous. Their ability to 
offer early, routine, and frequent diagnostic events increases the ability of clinicians to 
identify neoplastic abnormalities. To supplement further the potential for facile screening 
events, an increasing number of POC methods have begun using saliva as a diagnostic 
medium.  As dentists are the most frequent medical contact among asymptomatic 
individuals, the integration of oral fluids as a diagnostic medium into compact 
bioanalytical instruments allows a new generation of affordable, broadly accessible 
cancer screening.
186
   
Indeed, there is growing evidence that saliva serves as a ―mirror of the body‖ and 
contains biomarkers that offer important information on both oral and systemic 
disease.
187, 188
  Important studies completed by Wong, Oppenheim, Malamud, Streckfus 
and others have resulted in critical information related to the genomic and proteomic 
profiles that are present in various oral secretions.
189, 190
  These profiles are critical to 
development of new diagnostic devices utilizing glandular secretions as well as 
components of the serum proteome present in these samples.
191, 192
 Whole saliva is simple 
to collect, store and is obtained easily in sufficient quantities for testing. For patients, the 
non-invasive collection method of oral fluid sampling reduces anxiety and discomfort, 
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thereby ameliorating testing antipathy and promoting more frequent screening events. In 
addition, as a constantly regenerated fluid, saliva offers a physiological snapshot with 
temporal resolution; work by Wong, Singh and others has made important initial 
contributions toward the use of saliva for POC analyses.
193, 194
  
Despite the obvious advantages offered by saliva, there are also distinct 
challenges associated with its use for analytical diagnostic testing. The saliva sample 
matrix is more variable and heterogeneous than serum, and contains high levels of 
mucins as well as proteolytic enzymes.
195
 In addition, the concentrations of disease-
relevant biomarkers in saliva are different from those found in serum specimens.  
Membrane proteins especially, may be expressed at concentrations several orders of 
magnitude lower than in serum, although they still reflect nicely the expression profiles 
of biomarkers found in blood that are of diagnostic significance.
196
  Thus, because of the 
low levels of salivary biomarkers, it sometimes becomes difficult to distinguish between 
background and target-specific signal in these low concentration samples.   
Here, the use of advanced detection methodologies, such as QDs, promises to 
help overcome some of the challenges inherent to using saliva in POC devices for cancer 
diagnostics.  For the applications discussed in Chapter 3 the high intensity and capacity 
for simultaneous emission are the most important attributes of QDs.  In this study, the 
incorporation of QDs as detection elements in the NBC system is detailed for the 
measurement of three well-characterized cancer biomarkers: carcinoembryonic antigen 
(CEA), cancer antigen 125 (CA125), and Her-2/Neu (C-erbB-2). These NBC assay 
systems are explored in their capacity to serve as sensitive and specific cancer diagnostic 
tools for use with both serum and saliva samples.  Here, the advantages of QDs relative to 
gold standard molecular fluorophores, are explored in an integrated, POC-compatible 
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device using a completely integrated system including all optics, mechanical and 
microfluidic elements in tandem with clinical samples.   
3.3 MATERIALS AND METHODS 
3.3.1 Immunoreagents    
Phosphate buffered saline (PBS) at pH 7.4, used as a wash buffer as well as a 
diluent of the protein standards for the NBC assays, was prepared fresh daily and filtered 
with 0.2 μm membrane filter from Thermo Scientific (Waltham, MA).  To maintain 
protein stability and reduce non-specific binding, bovine serum albumin (BSA) was 
added at 1% by weight from Sigma Aldrich (St. Louis, MO) to PBS.  CEA antibody 
clone 057-10009 (capture) and M111147 (detecting) and CA125 M8072321 (capture) 
and M8072320 (detecting), were purchased from Fitzgerald (Concord, MA); Her-2/Neu-
specific antibodies (AF1129-capture and MAB1129-detecting) were acquired from R&D 
Biosystems (Minneapolis, MN).  An isotype (same species) control antibody was 
procured from Fitzgerald.  Recombinant CEA, CA125, and Her-2/Neu antigen were 
obtained from Biodesign (Saco, MA), Fitzgerald, and R&D Biosystems, respectively.  
These were used without further purification and diluted in PBS/BSA to appropriate 
concentration.  QDs with emission maximum at 565 nm (QD 565) and 655 nm (QD 655) 
were purchased from Invitrogen (Eugene, OR) as were reagents for a succinimidyl 4-(N-
maleimidomethyl) cyclohexanecarboxylate (SMCC) facilitated antibody conjugation.  
Alexa Fluor 488 and reagents for immunolabeling were purchased from Invitrogen along 
with purification supplies. 
3.3.2 Preparation of Beads 
Agarose bead preparation was adapted from Gustavvson‘s method and tailored by 
Wong.
197-200
   Briefly, agarose from Sigma Aldrich (St. Louis, MO) was added to 50 mL 
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water to the desired percentage and heated to 85
o
C in a water bath.  A suspending 
solution of 10 mL Span85 also from Sigma Aldrich in 100 mL n-heptane was heated to 
61
o
C.  The agarose mixture was then introduced into the suspending solution and stirred 
for 1 min.  As temperature dropped with vigorous stirring, the agarose gel beaded out of 
solution and precipitated to the bottom of the flask.  Beads were then washed with a 
50/50 ethanol/water mixture for hydration and size sorted by a sieve.  Beads were stored 
at 4
o
C until future use.  For linkage of antibodies and antibody fragments to the beads, the 
well established sodium cyanoborohydride technique described in Goodey and Lavigne‘s 
initial papers was used.
116, 120, 201
   
3.3.3 IgG-Fluorophore Labeling 
 Passivated CdSe/ZnS QDs were linked to antibody by established techniques.
85
 
Briefly, intact IgG molecules were subjected to dithiothreitol (DTT) treatment to cleave 
disulfide bonds.  SMCC-activated QD particles were then incubated with the reduced 
antibody fragments linking them to the nanoparticles.  The conjugate was purified by size 
exclusion chromatography to remove unbound antibody and concentrated with 50 kD 
cutoff centrifuge tubes to approximately 1 μM.  Monoclonal detection antibodies were 
labeled with Alexa Fluor 488 via a tetrafluorophenyl activated form of the dye.    
3.3.4 Clinical Sample Acquisition and Preparation  
 University of Texas Institutional Review Board approval was obtained to 
minimize patient risk for collection of both saliva and blood samples.  Saliva was 
collected from 6 volunteers after stimulation of salivary glands by chewing an 
unflavored, sugar-free gum base for 5 minutes while expectorating into a collection tube 
with flow rates determined gravimetrically.  The sample was protected from enzymatic 
digestion by addition of 1 μL 1 mM DTT and 1 mM sodium orthovandadate from MP 
Biomedicals (Solon, OH) per mL of sample and kept at 4 
o
C until analysis the same day.   
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Blood samples were collected via standard venipuncture at The University of 
Texas Health Sciences Center at San Antonio (UTHSCSA), centrifuged after clotting to 
remove cellular components, and stored at -20 
o
C until analysis.  Serum analyzed with 
NBC at UT were drawn from a sample bank at UTHSCSA with the 24 samples selected 
across a range of CEA concentrations with 7 samples < 2.5 ng/mL, 10 between 2.5 and 
7.5 ng/mL, and 7 > 7.5 ng/mL.  In addition, 1 sample with a very high concentration (> 
100 ng/mL) was used for linearity studies.  Saliva samples were analyzed at dilutions of 
1:20 and serum samples were analyzed undiluted unless sample volume available was 
less than 1 mL, in which case a 1:2 dilution was performed.                        
3.3.5 NBC System and Assay Conditions 
As described previously, 280 μm agarose beads were prepared and covalently 
coupled with capture antibody via reductive amination, as were anisotropically etched 
silicon wafers which served to sequester the beads into unique, individually addressable 
wells.
116, 120
 Chip arrays with a 3x4 configuration were used for single analyte 
determinations allowing measurements of 9 analyte beads and 3 isotype control beads; 
4x5 chip arrays were used for multiplexed analyses.  The chip was immobilized between 
precision-cut adhesive layers designed for optimized microfluidic flow and affixed onto a 
polymethylmethacrylate (PMMA) base.  Assays were performed at room temperature 
under continuous flow conditions: an initial 5 min 1% BSA/PBS blocking step to reduce 
non-specific binding (1.1 mL/min), antigen incubation with sample recirculation for 15 
min effectively exposing sample to beads 3 times (0.2 mL/min), 2 min wash (1.1 
mL/min), 5 min detecting antibody exposure (0.1 ml/min), followed by stringent 
washings and image acquisition.   
The NBC was secured firmly beneath an infinity-corrected 4X objective and 
analyzed with a modified epifluorescent microscope from Olympus (Center Valley, PA) 
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equipped with a 12 bit CCD camera from DVC Co. (Austin, TX) and high pressure 
mercury bulb excitation source, which was evaluated with a universal optical power 
meter by Melles Griot (Albuquerque, NM).  Sample flow was controlled by a variable 
speed peristaltic pump purchased from FIAlabs (Seattle, WA).  QD 565 images were 
acquired with a filter cube consisting of a 425 nm downfield excitation filter, a 475 nm 
long pass beam splitting dichroic mirror, and a 565 ± 10 nm emission filter.  QD 655 
images were obtained via a 420 ± 20 nm excitation filter, a 475 nm long pass beam 
splitting dichroic mirror, and a 655 ± 10 nm emission filter.  Alexa Fluor 488 was viewed 
via a standard FITC filter cube: 480 ± 20 nm excitation filter, 505 nm long pass beam 
splitting dichroic mirror, and a 535 ± 25 nm emission filter.
202
  Photomicrographs were 
captured via DVC software with adjustable gain, offset, and exposure time.                             
3.3.6 LOD and Assay Range 
The LOD for the NBC assays were established as follows.  First, assay dilution 
buffer in the absence of antigen was processed to establish the mean signal intensity on 
the analyte-specific beads for the zero-analyte condition. The standard deviation of the 
zero-analyte signal from bead to bead was recorded. The assay was then repeated with 
increasing concentrations of protein standard added in each experiment. The LOD was 
defined as the lowest concentration of antigen yielding an average bead signal three 
standard deviations above the mean value recorded for the zero analyte.  
The linear dynamic range of the assay was defined by its LOD at the low end of 
the protein standard concentrations, and by limit of linearity, or the concentration 
producing a near saturation signal in the CCD camera, at the high end.  The mean signal 
intensities of the analyte-specific beads from each run were then plotted against the 
analyte concentration to establish the dose-response curve for the given assay. The linear 
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portion of the dose-response curve established the quantitation range (also known as 
useful range) of the assay. 
3.3.7 System Precision 
Both intra-assay and inter-assay precision of our bead-based studies were 
determined.  Intra-assay precision, in the context of system parameters, was derived from 
the degree of agreement in the signals obtained from at least three redundant beads within 
the array used in an assay run.  Inter-assay precision was determined after evaluating the 
agreement between repeated measurements of an unknown sample. Repeatability of each 
assay was evaluated with a standard curve, testing the sample six times and then 
interpolating the value of the unknown from the standard curve for each assay run. 
Results from each run were compared and precision was reported as percent coefficient 
of variation (%CV).  
3.3.8 System Linearity 
A series of assays using one high volume, high concentration sample gave critical 
information on the ability of the NBC system to determine accurately sample 
concentration over several dilution factors, as well as the linearity of system response 
across a range of analyte intensities. This high concentration sample was diluted with 
increasing amounts of buffer, with a fixed total volume, until the signal produced by the 
diluted sample approached that of buffer only.  Signal could then be plotted versus 
dilution factor and concentration determined for each dilution via calibration curve.   
3.3.9 Immunodepletion  
A depletion experiment, resulting in sample consisting of the remaining saliva 
matrix, verified the specificity of the CEA signal in saliva.  To remove specifically CEA 
from saliva samples, agarose beads coated with three different types of monoclonal 
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antibody specific to CEA were mixed and incubated with the sample for one hour with 
moderate shaking as appropriate for a viscous solution. The sample centrifugation 
removed beads with the resulting supernatant decanted for analysis.   
3.3.10 Method Comparison Studies 
Saliva samples were analyzed for CEA both with NBC and with ELISA from 
BioQuant (San Diego, CA).  CEA antigen standards used in the NBC were analyzed on 
the ELISA plate in addition to the manufacturer‘s provided standards, at identical 
concentrations for comparison purposes.  ELISA was performed according to 
manufacturer‘s instructions on the same day as NBC saliva determinations and 
spectrophotometric color change was determined with a Molecular Devices SpectraMax 
Plus spectrophotometer (Sunnyvale, CA).  
Method comparison studies for the serum tests were conducted in collaboration 
with UTHSCSA and the University Hospital, the primary in-patient facility for the 
University Health System of Bexar County, Texas. The Clinical Chemistry Laboratory 
retained serum samples submitted for routine testing that would normally be discarded 
after testing was completed. Marker values from these samples had been determined 
using conventional clinical laboratory FDA-approved technology, a Siemens Centaur 
(Deerfield, IL).  
The patient identifiers were removed from the sample tubes and new 
identification numbers were assigned. Each sample was split into two aliquots and frozen 
at -20
O
C for future testing. One aliquot from each sample was shipped on dry ice to UT 
and the second aliquot was kept in the University Hospital Clinical Chemistry 
Laboratory.  Testing by both methods was performed on the same day to minimize bias 
resulting from storage age differences between the specimens at the time of testing and to 
eliminate potential difference due to stability problems. Therefore, the serum marker 
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values using gold-standard testing could be compared with values obtained using the 
NBC system 
3.3.11 Data Interpretation 
Photomicrographs were saved as 12-bit colorized TIFF files and analyzed via 
ImageJ software from the National Institutes of Health (NIH, Bethesda, MD) with bead 
fluorescence signal intensity correlating to the concentration of analyte in the sample.  
Deconvolution macros were written using JAVA that converted the image to a grayscale 
8-bit image with areas of interest (AOIs) drawn corresponding to individual beads.  These 
AOIS serve as a rough boundary in which the bead resides.  Four different methods were 
then be used to describe the information contained within the AOI.  The line profile (LP) 
method scanned the AOI one row of pixels at a time—the highest pixel value from each 
successive line profile was then averaged to calculate a mean signal.  The circular AOI 
(CAOI) method begins analysis in the geographic center of the region and expands 
outwards until it finds a circular region of pixels having the highest intensity.  All pixels 
inside this circle are then averaged to give a measurement of intensity.  The integrated 
density (D) technique takes the same circular region of pixels having the highest intensity 
uncovered in the CAOI method, and expands the analysis region 2 or more pixels on 
either side of the maxima.  All pixels in this region are then averaged to yield an intensity 
measurement.  Finally, the circular profile (CP) scheme simply averages the circular 
region identified in the CAOI and takes the mean pixel values.  All four of these 
parameters may then be reported with their respective standard deviations and 
coefficients of variation.    
3.4 RESULTS AND DISCUSSION 
In previous work, the NBC assay platform was successfully employed in a 
number of analytical applications targeting detection of analytes in complex fluids, such 
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as serum and saliva.
128, 203, 204
 These assays utilized molecular fluorophores conjugated to 
analyte-specific antibodies as detection elements for the LOC sensors. The advanced 
performance characteristics of the LOC were attributed to the inherent properties of the 
porous structure and three-dimensional nature of the agarose bead sensor as well as the 
stringent washes associated with the microfluidic LOC design.  The main objective of 
this study was to characterize the analytical improvements of cancer antigen NBC assays 
employing QDs as a detection moiety.   
The QD-based platform includes all fundamental components of sandwich 
immunoassay, with the inclusion of agarose beads as solid phase support. Different 
clones of monoclonal antibody, specific to the protein of interest, serve as capture and 
detection bodies. Figure 3.2 more clearly illustrates the differences between the NBC 
(Fig. 3.2B) systems and conventional ELISA (Fig. 3.2A) and its additional requirements 
of enzyme and conjugate.  The other fundamental distinction between the two designs is 
the 3-dimensional design of the bead arrays versus ELISA‘s 2-D, planar plastic substrate.  
The sponge-like capacity of the NBC to sequester large amounts of analyte from samples 
is exploited—a sample pre-concentration method similar to dynamic headspace 
sampling.
205
 Also in contrast here are differences between QD-based and Alexa Fluor 
labeled detecting antibody.  Due to size differences, the QD nanoparticle (Fig. 3.2C) can 
be linked to larger number of antibodies relative to its molecular counterpart.  The effect 




Figure 3.2. Formats of Sandwich Immunoassay. The fundamental components of 
sandwich immunoassay are retained across all three types of assay designs including 
underlying assay support (i), capture antibody (ii), antigen or biomarker (iii), and 
detecting antibody (iv).  A) ELISA designs expand further this transduction pathway and 
include an enzyme (v) and substrate (vi) to affect a color change for a later absorbance 
measurement.  B)  The NBC system changes planar substrate in A, for the sponge-like 
agarose solid-phase support.  The transduction pathway is also truncated to fluorophore 
tagged detecting antibody.  C) The QD-based NBC design is typified by a larger 
fluorochrome and thus a detecting antibody to fluorophore ratio that inverts relative to B.      
 
Each bead is individually addressable by location of well within the silicon chip 
and bead specificity determined by type of antibody covalently bound to the agarose 
support (Fig. 3.3A). The agarose bead supports are layered within the NBC between 
precision-cut layers of laminate adhesive designed for reagent delivery (Fig. 1.4A). These 
fluids are delivered through the top inlet of the flow cell apparatus, allowed to pass 
through and around the sensitized beads with nonreactive components passed on to waste 
through the lower port. Fluorophore conjugated detection antibody completes the 
immunocomplex and yields signal output digitally recorded by CCD camera.  The 
intensity of fluorescence signal, embedded in a digital photomicrograph, relates directly 
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the amount of detecting antibody immobilized on the bead completing the sandwich 
immunoassay and thus, amount of antigen originally present in the sample (Fig. 3.3B).     
 
 
Figure 3.3. Bead-based NBC. A) SEM photomicrograph of beads in anisotropically 
etched silicon chip.  B)  Fluorescent image of beads after immunoassay including 
negative controls with DVC camera settings of ‗gain‘ 10, ‗offset‘ 0, and 1 sec. exposure. 
3.4.1 QD Integration into NBC 
Several steps are required to make optimal use of QDs in POC cancer diagnostic 
systems.  For life science applications, stabilized nanoparticles are linked to a recognition 
element, i.e. antibody, through a variety of covalent and non-covalent strategies with all 
techniques emphasizing the importance of retaining QD optical properties and 
hydrophilicity as well as recognition moiety specificity.
85
  The first challenge was 
identification of the optimal source of the QD labels for bead-based assays.  Using a 
microtiter plate and spectrofluorimeter with λex = 400  nm, a 1 nM solution of Invitrogen 
(Life Technologies) nanoparticles (λem = 655 nm) yielded fluorescence signal of 691.1 
a.u., and a 1 nM solution of Evident Technologies nanoparticles (λex = 625 nm) signaled 
at 7.8 a.u., an amplification of nearly two orders of magnitude for the former.  Thus, the 
remainder of these experiments utilized Invitrogen QDs.   
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Characterization of QDs in the transduction pathway of the bead-based sensors 
employed such figures of merit as background, signal, and non-specific signal (noise). 
Importantly, the definition of S, B, and N changes from that used in Chapter 2.   Beads 
were analyzed with the line profiling method described in Section 3.3.10, which presents 
four possible methods to interpret the images.  To determine which method delivered the 
most efficacious signal, Figure 3.4 was constructed indicating that the LP method gives 
the steepest dose response curves and the most sensitive signal.  In typical 3 x 4 
arrangements, 9 bead replicates with a concentration of 3.0 mg/mL capture antibody 
reported specific signal and 3 beads with an isotype antibody served as controls (Fig. 
3.3B).  With a 4X objective, the macro resulted in the averaging of 104 successive line 
scans across each 280 µm bead or a resolution of 2.69 µm/pixel.  The mean of the 9 
beads was defined as signal (S), with the non-specific signal emanating from 3 isotype 
beads termed noise (N); background (B) was defined as output from biomarker-specific 
beads in the absence of antigen (zero calibrator).   
 
Figure 3.4. Analysis Methods Used in the Bead-based NBC. A graphic representation 
of the analysis methods described in Section 3.3.10: (A) Line profile (LP), (B) circular 
profile (CP), (C) integrated density or doughnut (D), (D) circular area of interest (CAOI).  
E) Dose response curves of the three different methods of analysis indicates that the LP 
approaches consistently yields the highest signal and most sensitive response.   
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With the proper source of nanoparticles indentified, naked QDs (unbound to 
antibodies), were examined for non-specific binding without any antigen present and 
yielded a S/N ratio of 1.05.  When 100 ng/mL of CEA antigen was included and 
experiment repeated with bare QD particles, S/N was 0.70.  These ratios, in addition to 
low signal output (S < 2), for these two experiments indicates that the minimal 
background and noise later observed should be attributed to non-specific biological 
interactions between antibody moieties, and not to aberrant binding of nanoparticle to 
immobilized antigen or bead scaffold.  Next, this investigation explored the most 
appropriate method to prepare QD-antibody bioconjugates for quantitative biological 
analyses.   
In Chapter 2, excellent labeling was achieved in the NBC via a secondary 
antibody strategy in which QD was thiol bound to secondary F(ab‘)2 which was then 
linked to primary antibody on the cell surface (Fig. 2.6).
131
  This scheme was found to be 
incompatible with the bead-based assays, as the secondary antibody binds to the capture 
as well as detecting molecules.  Other groups report using the avidin/biotin pathway for 
labeling biological analytes with QDs.
81, 87
  Although a pathway using biotinylated 
detecting antibody and avidin coated QDs successfully reported mid-level antigen values 
at S values above 60, it unfortunately resulted in non-specific noise and yielded S/N 
values of 0.82.  This use of avidin/biotin is compounded by the sponge-like agarose solid 
phase support and its net of nano-scale tubules.  The poor response observed for this 
application is due to inadequate passivation of the QD surface, electrostatic attraction of 
avidin to agarose, and the inability to remove the relatively large unbound QD-avidin-
biotin-antibody immunocomplex from the bead‘s (2% agarose by weight) nano-net pores.  
For the CEA assay, this structure consists of QD (~15 nm) bound to avidin (12nm),
151
 
biotinylated detecting antibody (10nm),
150
 as well as antigen (27 nm),
206
 and capture 
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antibody (10nm), for a total immunocomplex length of 74 nm and molecular weight 550 
kD.  This size is on the order of the 100 to 300 nm pore diameters typical of 2% agarose 
gels making these conditions consistent with the clogging of bead apertures or QD probe 
trapped non-specifically in substrate interior. 
207
   
To engineer probes more compatible with the agarose environment, the protein 
capture elements were tailored to a size roughly half the QD diameter, or 7.5 nm. This 
decreased steric crowding within the bead, while retaining the analyte recognition portion 
of the antibody, by reduction of whole antibody via DTT, effectively cleaving the 
disulfide IgG backbone and exposing free sulfhydryls (Fig. 2.5). Preparation of the QD 
component of the bioconjugate proceeded via SMCC activation of PEG-carboxy coated 
nanoparticles.
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 The active groups on cleaved IgGs then reduced onto activated QDs 
yielding an intense, specific transduction bioconjugate that was stable up to six months 
from preparation.   
To verify specificity of the QD-antibody bioconjugate and determine B, an 
antigen free sample, consisting only of PBS buffer, was introduced followed by detecting 
antibody conjugate.  After washing steps, B and N values below 1 resulted (Fig. 3.5A).  
Upon inclusion of CEA antigen in buffer, exposure of sample to CEA sensitized beads, 
followed by QD-CEA detecting antibody bioconjugate, a signal on the CEA sensitized 
beads developed proportional to amount of antigen introduced (Fig. 3.5B, 3.5C).  For 
example, at 10 ng/mL, S = 65.23 and S/N = 17.17.  Importantly, S values drop by 97.4% 
when a Her-2/Neu detecting antibody replaces the QD-CEA bioconjugate, demonstrating 
specificity of reporter probe. Values for N were 3.1% of S at mid level antigen 
concentrations, further authenticating the specificity of the immunoassay and remains 
consistently low across the range of antigen concentrations used in these experiments. 
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Results of background and isotype-controlled experiments for Her-2/Neu and CA125 
antigen were similar to those of CEA with N less than 10% of S, and B values below 2.    
 
 
Figure 3.5.   Photomicrographs Show Intensity Differences Between Samples.  A) 
Zero-calibrator, negative control, consisting of buffer only gives little signal, while 50 
ng/mL (B) and 100 ng/mL (C) show increasing fluorescent output.  Fluorescent signal 
intensity advantage with QDs (C) versus molecular Alexa Fluor dye (D)  is greater than 
30 fold at identical antigen concentration.   An additional row of negative control beads 
with similarly negative output on the photomicrograph right side was digitally cropped.   
All images procured at DVC camera settings ‗gain‘ 10, ‗offset‘ 0, with one sec. exposure.   
3.4.2 The QD Advantages Relative to Molecular Fluorochromes  
Having defined optimal modes for protein detection within the NBC system and 
having demonstrated a proof-of-principle application of QDs as the detection modality 
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for the NBC assays, the next objective was to compare their performance to traditional 
fluorophores. Such comparisons have challenges including the maintenance of similar 
excitation energies and antibody/fluorophore ratios.
158
 For comparison purposes, 
isomolar concentrations of recombinant CEA (100 ng/mL) were analyzed under identical 
experimental conditions except for fluorophore on the detecting antibody. Through 
titration studies similar to Appendix B, 3.7 nM of the QD element of the detection body 
(0.47 μg/mL of antibody) was determined to be optimal for labeling efficiency while 
keeping background signal to a minimum. As inherently hydrophobic materials, the 
tendency of QDs to aggregate at high concentration can be a challenge for use.  Detecting 
antibody bioconjugates at 3.7 nM in PBS/BSA, in tandem with 0.2 μm nylon filtration of 
antibody-QD conjugate immediately prior to introduction into the NBC eliminated 
flocculation.  These conditions were used for the below described comparisons. 
Before exploring the capabilities of QDs relative to standard organic dyes, an 
initial study examined the attributes of three established fluorophores:  fluorescein 
isothiocyanate (FITC), Alexa Fluor 488, and Alexa Fluor 647.  The stability and intensity 
of isomolar concentrations of these three dyes were examined under constant excitation at 
λex of 490 nm for FITC and Alexa Fluor 488 and 650 nm for Alexa Fluor 647.  Signal 
intensity decreased to one half of initial maximum within 80 seconds for FITC and Alexa 
Fluor 650 and 280 seconds for Alexa Fluor 488.  Furthermore, the initial values of S/N 
before significant photobleaching were recorded at 21.8, 8.0, and 4.2 for Alexa Fluor 
488, Alexa Fluor 647, and FITC, respectively. These observations of Alexa Fluor 488 
robustness are confirmed secondarily.
208
 Thus, to make the most stringent evaluation 
between nano-based and molecular systems, Alexa Fluor 488 was chosen for further 
direct comparisons.   
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To characterize the exact amount of both antibody and fluorophore in the AF488 
and QD bioconjugate stock, quantitative absorption spectroscopy was employed.  First, 
calibration curves using the monoclonal detecting antibody were constructed via a 
Bradford assay.  These curves, in tandem with values for the fluorophore labeled 
bioconjugate, gave amount of IgG in the two detecting antibody preparations.  
Specifically, 5.9 x 10-6 M IgG was present in the AF488 conjugate and 7.6 x 10-7 M 
antibody was found for the QD case.  To calculate amount of fluorophore, absorbance 
measurements were used with the extinction coefficients provided by fluorophore 
manufacturers; concentrations of 3.7 x 10-7 M QD and 2.5 x 10-5 M AF were measured.  
Since both bioconjugates were extensively purified with size exclusion chromatography, 
the fluorophore and IgG concentrations determined here reflected the amount of labeled 
detecting antibody.   
To complete the studies exploring the intrinsic signaling capabilities of the QDs, a 
series of conditions were explored as follows.  First, isomolar concentrations of 
fluorophore in the bioconjugate were prepared (3.7 nM) and used to label 100 ng/mL of 
CEA antigen, and images for both QD (Fig. 3.5C) and Alexa Fluor 488( Fig. 3.5D) 
recorded. Due to the larger size of the quantum dot (~15 nm with passivation layer) 
relative to the molecular Alexa Fluor dye, a greater number of antibodies may be bound 
to its surface (Immunoschematics in Fig. 3.2B and 3.2C).  This specific batch of QD-
antibody conjugate had an antibody to fluorophore ratio of 2:1. Conversely, more than 
one Alexa Fluor labeling molecule may be bound to each antibody and this ratio becomes 
inverted; approximately four Alexa Fluor elements attach to each whole IgG antibody. 
This necessitated an additional assay at isomolar concentration (0.47 µg/mL) of antibody 
in the Alexa Fluor 488 bioconjugate.   
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Comparison of S values for the three photomicrographs (1 QD-based and 2 Alexa 
Fluor-based) indicates a values 33.5 times higher for QD versus Alexa Fluor 488 at 
isomolar fluorophore concentration and 6.5 for the isomolar antibody experiment. Similar 
to QD, Alexa Fluor 488 yielded N values less than 10% of S.  Interrogation of the 
excitation optics with power meter at 400 and 480 nm, corresponding to the QD and 
Alexa Fluor optics, respectively, indicated a QD illumination strength advantage of 1.3.  
Thus, even when the relative concentrations of the labels are tracked carefully alongside 
the excitation powers, there is a significant enhancement of QDs relative to Alexa Fluor 
488, one of the most robust commercially available fluorochromes.  In addition to whole 
IgG for Alexa Fluor 488 labeling, Alexa Fluor 488 bioconjugates consisting of Fab and 
F(ab‘)2 antibody fragments were also explored.  These values were lower by a factor of 
1.5 relative to whole IgG.   An extended treatment of these results will be reported in 
Chapter 4.  Regardless, the QD system was an order of magnitude more intense than 
Alexa Fluor 488—this substantial signal increase aids in detection of ultra-low 
concentrations of analyte as described below. 
3.4.3 Analytical Performance of NBC Assays  
After validating the QD immunoassays, the next objective was further 
characterization of their utility by determining the assay analytical performance, 
especially versus ELISA systems, the gold standard protein detection method since 
1971.
209
  The first descriptor explored was assay time, which minimized four separate 
assay events: sample introduction, sample wash, detection bioconjugate incubation, and 
bioconjugate wash. On the NBC system, sample and bioconjugate incubation times were 
empirically determined by systemically reducing them from 30 minutes until the 5.0 
ng/mL calibrator dropped below S/N of 10. Times of 5 minutes for sample flow and 15 
minutes for bioconjugate were optimal and further reductions resulted in unacceptable 
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reductions in LOD. For washing, 1 minute of 1.1 mL/min PBS/BSA rinse eliminates the 
vast majority of unbound immunocomplex.  For very low backgrounds, however, a two-
stage final washing scheme was critical, which used the stringent 1.1 mL/min flush, 
followed by a 5 minute, 0.2 mL/min, gentle cleanse cycle.  This slower rate allowed both 
diffusion and convection to remove unbound bioconjugate deep within bead 
infrastructure.  The assay outline detailed above results in a total analysis time of 27 
minutes, versus the 4 – 24 hours needed for conventional ELISA.
209
  Assays based on 
ELISA require the NBC steps described above, and also include substrate and color 
change (stop) steps.  Furthermore, ELISA methods require a lab-based infrastructure 
including spectrophotometer, incubator, as well as manual liquid handling steps.  
Additional analytical parameters, such as assay range, linearity, precision, limit of 
detection were determined as follows.  
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Figure 3.6.  CEA Dose Response Curves. Curves were constructed by adding 
recombinant antigen to buffer followed by analysis with the NBC.  A) Logarithmic figure 
spanning six orders of magnitude concentration of CEA with sharpest response 
overlapping physiologically relevant range from 0.1 to 100 ng/mL. Signal is relative to 
the maximum intensity produced by highest concentration calibration point and expressed 
as relative fluorescence units (RFU).  B)  Linear and sensitive dose response over region 
of typical sample concentration.   
Calibration curves for all three analytes were constructed across a range of 
concentrations using recombinant antigen in buffer as well as a negative control, zero 
calibrator point.  To determine the linear dynamic range, increasing concentrations of 
analyte across six orders of magnitude—from the limit of detection to the saturation point 
of the assay—give differing intensities as detailed in Figure 3.6A for CEA. Here, it was 
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critical that the linear dynamic range of the NBC assay overlap with the physiologically 
relevant range of analyte in biological samples.  Commonly accepted disease diagnostic 
decision thresholds for the three analytes in serum are 2.5 ng/mL for CEA (5 ng/mL for 
smokers), 15 ng/mL Her-2/Neu, and 35 U/mL CA125.
210, 211
 The three analytes on the 
NBC system gave linear dose responses across the range of 0 – 100 ng/mL CEA, 0 – 60 
ng/mL Her-2/Neu, and 0 – 400 U/mL CA125.  Although all had acceptable performance, 
CEA was the focus for the remainder of the quantitative studies and later optimized to 
give the very sensitive dose curve seen in Figure 3.6B. Calibration data above 25 ng/mL 
was unnecessary for routine analysis, especially upon sample dilution.  Importantly, the 
sensitivity of the NBC for any of the analytes attenuate easily in order to have a wider 
linear dynamic range by decreasing either capture or detection antibody concentrations 
(vide infra).  Best-fit line regression analysis for the two methods gives S = 5.144 [CEA] 
+ 11.86 (R
2
 = 0.99) with the NBC approach, and S = 0.0562 [CEA] + 0.2071 (R
2
 = 0.98) 
for ELISA at 0 – 50 ng/mL, where S, signal, is QD fluorescent intensity as described 
above in the NBC or absorbance at 450 nm (substrate λmax) in ELISA.  When S is 
standardized relative to the highest calibrator, and NBC and ELISA data plotted on the 
same axis, sensitivity, as determined by the slope of a best-fit line, is 1.9 times larger with 





Figure 3.7.  Limits of Detection via CEA Dose Response Curves. Both ELISA and 
NBC methods allow calculation of a LOD and are compared here by maximizing their 
12.5 ng/mL signal intensity to unity and scaling the others relative to the most intense 
point.  A) ELISA data is indicated by the red points while 3ζ above the background (zero 
calibrator) is indicated by the green circle.  The point is then graphically translated via the 
best fit line, to a point on the ordinate for LOD determination.  B)  This is repeated with 
NBC data to give the results in C that indicates the enhanced performance of the NBC 
relative to conventional enzyme-based assays.    
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As mentioned above, low LODs are critical when analyzing saliva for biomarkers 
as analytes may be in lower concentrations than serum. The NBC system obtained 
excellent LOD values by having both a powerful transduction signal, as well as low 
background.  Increasing the amount of fluorophore can increase the intensity of signal 
output, but may also increase background and non-specific signal.  The use of QDs 
allows for a high signal output at relatively low concentrations of detection element to 
maintain the low background signals critical for excellent LOD measurements. The LOD 
for CEA, defined at 3ζ above background, was 0.021 ng/mL in the NBC, 2.61 ng/mL 
when Alexa Fluor 488 signaling method replaced the QD-based system, and 1.20 ng/mL 
in ELISA; see Figure 3.7. The limit of linearity as calculated as 10 standard deviations 
above the signal of the background was 0.10 ng/mL CEA.  This value was the LOD 
observed for more typical calibration curves as well.  Similarly, low LODs were seen 
with Her-2/Neu with results of 0.27, 3.70, and 1.50 ng/mL for NBC, NBC-Alexa Fluor 
488, and ELISA, respectively.  For CEA, a glycosolated protein with a molecular weight 
of 180 kD, the LOD corresponds to 0.11 pM.
212
 Although improved performance with 
molecular Alexa Fluor
 
fluorophores results after that system‘s optimization, these 
experiments were performed at the concentrations optimized for the QD platform 
allowing for a direct comparison between the two methods. Importantly, this order of 
magnitude improvement in LODs via QD detection compensates for the order of 
magnitude decrease in concentration of some biomarkers in saliva and also demonstrates 
the efficacy of the NBC for detecting trace amounts of biomarkers in diluted samples.
213
 
Thus, the enhanced signaling capabilities afforded with the QDs in the NBC system allow 
for salivary diagnostics to be completed more readily using the QD detection modality.  
Reproducibility of the system was evaluated both from an intra-assay and inter-
assay approach.  As each analysis contains nine analyte beads, every assay results in a 
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mean concentration with standard deviation.  The RSD values are <10%, with lower 
values found at decreasing concentrations of analyte.  Even illumination within the 
excitation path, uniformity of NBC optical layers, and monodispersity of the reagent flow 
fields across beads within the silicon chip affects this value.  Bead to bead variations are 
partly due to fluid dynamics for the setup used in these experiments, but do not appear to 
be due to inherent differences in bead composition or disparity in amount of capture 
antibody present on the beads. Computational fluid dynamic experiments, to homogenize 
the flow conditions across all bead local environments, are ongoing.     
To evaluate precision between assays, one serum sample (mean value 8.60 
ng/mL) was examined 6 times—these analyses had a %CV of 6.5; variances for ELISA 
approach 40% depending upon analyte concentration.
214
  An additional study of linearity 
and precision utilized a single high volume, high concentration serum sample analyzed 
unadulterated and at five dilutions down to 1:32. Background corrected intensities were 
converted to concentration by calibration curve, and multiplied by dilution factors 
resulting in the corrected concentration.  Fluorescence signal as a function of dilution 
factor was also linear at R
2
 = 0.99. 
3.4.4 Analytical Performance of NBC for Clinical Samples 
The NBC analytical performance was evaluated in the context of CEA 
determinations for both saliva and serum samples. The NBC approach was compared to 
standard methods in the context of correlation studies. For the initial stages of these 
clinical proof-of-principle studies, signal generated by saliva was compared to 
recombinant CEA antigen. Figure 3.8A displays rows of beads from larger 
photomicrographs of recombinant CEA antigen (Fig. 3.8Ai, 50 ng/mL), 1:4 dilutions of 
saliva (Fig. 3.8Aii), saliva (1:4, Fig. 3.8Aiii) spiked with recombinant antigen (to 50 
ng/mL), and saliva (1:4, Fig. 3.8Aiv) depleted of CEA by immunoaffinity 
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chromatography. The presence of signal in saliva, increase upon spiking with antigen, but 
most importantly, 94.84% (Fig. 3.8B) reduction in signal when CEA was exclusively 
removed from the sample, gives strong credence to the validity of this saliva-based assay 
on the NBC and the authenticity of CEA-specific signal. Indeed, saliva signal changes 
from near saturation of 8-bit camera (S values approaching 255) with the authentic 
sample, to values near PBS buffer blank for depleted samples.   
 
 
Figure 3.8.  Validation of authentic CEA signal in saliva.  A) Assay results of i) 
recombinant antigen at one half calibration curve maximum (50 ng/mL), ii) saliva at 1:4 
dilution, iii) saliva sample spiked with recombinant antigen, iv) CEA depleted saliva.  
One row from each image was digitally sliced to create montage above.  B) Results after 
digital image processing indicates the specific nature of CEA signal. (All images have 





Figure 3.9.  Analytical Validation of NBC System via Clinical Samples.  Saliva (n = 
6) (A) and serum (n = 24) (B) samples correlate well with measurements achieved on 
reference methods.  Saliva samples were validated versus ELISA; serum samples via a 
Siemens Centaur clinical chemistry analyzer.  In addition to best fit line (solid), the 95% 
confidence interval (short dash) and 95% prediction interval (long dash) are presented.   
For a correlation study, stimulated whole saliva was collected from apparently 
healthy subjects and these specimens analyzed with the NBC and concurrently with 
ELISA.  Shown in Figure 3.9A is the correlation graph between the two methods.  Here 
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a strong correlation is noted with R
2
 value of 0.94. The relatively high concentration (> 
50 ng/mL) of analyte present in saliva is consistent with previous reports and is 
reasonable, as CEA is a known epithelial protein.
215, 216
  In serum, the NBC platform 
correlates nicely also with an automated clinical analyzer (Siemens Centaur) and yields 
R
2
 value of 0.95 for 24 samples (Fig. 3.9B).  Although the serum results correlated, they 
did not agree.  This may be due to differences in standards as the NBC reports results 
approximately double that of Siemens Centaur.  Unfortunately, it was not possible to 
analyze the onboard standards used in the Siemens instrument on the NBC.  To ascertain 
whether matrix interferences were responsible for this discrepancy, standard additions 
allowed concentration calculations in addition to the calibration curve method for a single 
sample.  The standard additions experiment resulted in an approximately 2-fold higher 
concentration value than the single point calibration curve determination, which 
corresponds to the twice-high concentrations found by the Siemens instrument.   These 
systematic differences may also be due to variations in the values for standards and/or 
changes in the specimen concentrations that resulted from the differences in sample 
handling at the two sites. Nevertheless, these proof-of-principle pilot studies yielded 
strong correlation results for both serum and saliva analysis using the new NBC relative 
to established laboratory-based methods. 
3.4.5 Multiplexing Capabilities 
As stated above, the use of numerous cancer biomarkers increases both the 
sensitivity and specificity of cancer assays; the capacity of the NBC for use in 
multiplexed tests is demonstrated.
184
  First, dose response curves for Her-2/Neu, and 
CA125 were prepared and tailored to match the physiologically relevant range of 
concentrations.  The analytical response of these assays and LOD calculations are 
presented in Figure 3.10.  
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Figure 3.10.  Expansion of NBC to Additional Analytes.  Dose response curves for 
CA125 (A) and Her-2/Neu (B) show linear response across the physiologically relevant 
range.  C) Her-2/Neu detection limits calculated for three differement detection methods.  
The NBC-QD approaches yields values five times lower than ELISA methodology, and 
nearly 14 times lower than NBC-Alexa Fluor 488.  This order of magnitude is similar to 
the intensity advantage seen in Section 3.4.2.   
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Next, beads in redundancies of three and sensitized to either CEA, Her-2/Neu, 
and CA125, were arranged in a 4 x 5 chip along with isotype control beads. One-row 
portions of the resulting photomicrographs appear in Figure 3.11A. All beads produced 
signal upon introduction of all three antigens, in buffer, at concentrations near the dose 
curve maximum, as well as a 9.2 nM cocktail of all detecting antibodies (). When only 
Her-2/Neu antigen and the detecting antibody cocktail was introduced, signal from the 
specific interaction between immobilized Her-2/Neu antigen and Her-2/Neu detection 
bioconjugate was 20.2 with a small amount of signal cross talk emanating from the CEA 
(S = 0.03) and CA125 non-specific beads (S = 0.97) (Fig. 3.11Aii).  This assay was 
repeated for CA125 (Fig. 3.11Aiii) and CEA (Fig. 3.11Aiv) analytes and the strong, 
specific signal normalized to a value of unity (Fig. 3.11B).  Signal from non-specific 
beads was less than 5% of the most intense, specific signal for all three experiments.  
Importantly, no signal increase occurred when using the detection cocktail, versus 
individual detecting antibodies.   
In addition, an analogous series of assays in which all three antigens at values 
near the dose curve maximum, i.e. 25 ng/mL for CEA were introduced concurrently, 
followed by sequential interrogation by a single detection antibody (3.7 nM) resulted in 
non-specific interactions that were less than 5% of the specific signal. This data 
demonstrates the utility of the NBC sensor as a highly specific, multiplexed tool for 






Figure 3.11.  The NBC Multiplexes via the Spatial Arrangement of Beads.  A) In 
these experiments, cross-reactivity was evaluated.  (i)  All three antigens, at 
concentrations near calibration curve maximum, were incubated concurrently followed 
by a cocktail of all three detecting antibodies.  (ii)  Beads were exposed to only Her-
2/Neu antigen, and again, the detecting antibody cocktail.  Similarly, assays specific to 
CA125 (iii) and CEA (iv) were performed, as well as a zero antigen, negative control (v).   
B) Non-authentic output emanating from untargeted beads plotted as a percentage of 
specific signal intensity shows strong specificity across all three analytes. Non-specific 
signal (noise) was less than five percent of the intense, specific signal.  (All images have 
been background corrected and use one second of exposure.)  
To demonstrate the capacity of the NBC system to perform a multiplexed assay 
within a single bead, beads functionalized with 1.0 mg/mL CEA or 1.0 mg/mL CA125 
specific capture antibodies (or both antibodies at 1.0 mg/mL) were arrayed on a single 
chip along with beads conjugated to isotype control antibody. Both antigens and a 
cocktail of relevant fluorescently labeled detection antibodies at (1:100 dilution or 3.7 
nM) were introduced into the NBC.  Here, detecting antibody specific to CEA and bound 
to QD 565 fluoresces green, and CA125 antibody labeled with QD 655, emits red shifted 
signal.  These experiments revealed the specificity of bead-based reactions on beads 
loaded with single-type antibodies, as well as the capacity of the dual function beads 
(loaded with both types of antibody) to capture and detect both antigens.  
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Figure 3.12.  Intra-bead Multiplexing.  A) Multi-analyte capabilities of the NBC 
include intra-bead duplexing in which dually functionalized beads measure two analytes 
concurrently.  Beads sensitized to CEA, CA125, and both biomarkers are used 
simultaneously on a single chip and demonstrate independent assay behavior.  B) Across 
the physiologically relevant range of concentrations, no statistical difference is seen in 
fluorescent signal output between sole CEA and dual CEA/CA125 beads.  (All images 
have been background corrected and use one second of exposure.)  
As expected, the CA125 sensitized beads fluoresced red, while the CEA 
sensitized beads fluoresced green (Fig. 3.12A). The dual-function beads, which 
fluoresced orange after this assay, demonstrate efficient detection of both captured 
analytes and later, their respective detecting antibody. For assays at concentrations near 
the dose curve maximum (25 ng/mL CEA and 300 U/mL CA125), the S/N values for the 
dual function and singly selective CA 125 beads are not significantly different at 1.59 ± 
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0.25 and 1.79 ± 0.30, respectively.  Similarly, S/N values for single and doubly selective 
CEA beads are 130 ± 12 and 104 ± 22. Differences between the two assays systems are 
due to non-specific binding of detecting antibody.   
This bead type increases NBC throughput by quantifying a larger number of 
analytes in the same small device footprint. Furthermore, the CEA-specific signal 
response achieved by both CEA-sensitized and dual-function beads are statistically 
identical across the physiologically interesting region (Fig. 3.12B). Here, little to no 
reduction of signal is seen in the dual-function beads versus their singly selective 
counterparts either at higher (100 ng/mL) analyte or lower concentrations (1 ng/mL), 
again demonstrating that these bead types may be efficiently used in this system to 
increase throughput.  When CA125 antigen dose response is performed (0 - 400 U/mL), 
dual function beads and single function beads behave identically regardless of CEA 
antigen presence, similar to Fig. 3.12B (data not shown). This is the first demonstration 
of multianalyte detection on a single bead with this NBC system type. The additional 
element of multiplexed capacity demonstrated here via multiple colors on individual 
beads, allow an increased number of independent assay systems to achieve robust 
measurements in the same miniaturized space.  In addition, as UV light easily excites 
different color QDs (corresponding to unique analytes), this novel multiplexing scheme, 
in tandem with a dual bandpass emission filter and color CCD detector, would not 
increase analyzer optical requirements, a design critical for POC systems.   
Table 3.1 expounds further the performance descriptors of the NBC versus 
ELISA as well as other clinical chemistry analyzers for the CEA assay.  Modern 
pathology laboratory analyzers yield utilize a chemiluminescent pathway with results in 
approximately an hour.  An  important feature not detailed in Table 3.1 is analyzer size.  




Table 3.1.  Performance features of CEA analysis methods.  Comparisons between the 
NBC, ELISA , and bench-top hospital laboratory analyzers reveals superiority of NBC.  
Detailed here are coefficient of variation (CV) both within a single experimental run and 
between assays.  The LOD listed here was defined previously while limited of linearity 
(LOL) is defined classically as the concentration at which a best-fit curve deviates at 





The construction and validation of a microfluidic biosensor incorporating the 
intensity and fluorescence attributes of semiconductor nanoparticle QDs is completed. 
Although some reports have recently demonstrated quantitative immunoassay of cancer 
biomarkers such as CEA with QDs via both avidin and SMCC facilitated bond formation, 
very few studies have utilized QDs to measure human specimens versus gold standard 
methods.
81
  These prior studies rely on QDs in tandem with a chaperon structure such as 
a latex bead.
169
  To the extent of the author‘s cognizance, this is the first report in which 
QDs provide quantitative cancer biomarker information using blood and/or salivary 
clinical samples.  
The NBC system has several advantages over conventional approaches.  First, the 
QD-facilitated transduction signal yields output values >30 times that of conventional 
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fluorophores without enzymes or any secondary signaling amplification reagents. This 
feature allows the device to produce sensitive, linear response curves across the 
physiological relevant range of CEA, Her-2/Neu, and CA125.  Second, this high signal 
output, combined with effective QD conjugation methods and efficient analyte 
processing within bead-populated MEMS structures, affords very low LOD values for 
these essential cancer antigens.  In this study, we achieve LOD values of 0.02 ng/mL (or 
0.11 pM) for CEA, values competitive with the most sensitive CEA assays reported to 
date.
219
 The LOD for Her-2/Neu, 0.27 ng/mL, is lower than commercially available 
ELISA kits (2.5 ng/mL) and benchtop analyzers (0.5 ng/mL).  These values translate into 
low-level detection of the analyte in saliva for minimally invasive screening procedures. 
Third, turnaround time (<30 min) is substantially shorter than methods based upon 
ELISA technology and is quite amenable to analyses at the POC. Finally, preliminary 
studies combining all three biomarkers onto a single chip reveal low cross-talk and high 
analyte specificity using real biological samples. The NBC also demonstrates the capacity 
to increase throughput via multianalyte beads.  Such multiplexing capacity is critical in 
designing cancer sensors that are both selective and specific. As mentioned by QD 
pioneer Shuming Nie in a recent review, the potential for ―nanotyping‖, or multiplexed 
profiling of disease fingerprints via QDs, is an exciting application of this class of 
fluorophores that is closer to realization upon completion of this study.
85
 Flexible, 
modular, and multiplexed analysis platforms are essential tools in better understanding 
the relationship between a dynamic proteome and clinical symptoms and disease 
outcomes.   
The NBC system was validated as a tool for the detection of CEA in both saliva 
and serum clinical samples and correlated to reference methods, R
2
 = 0.94 and R
2
 = 0.95, 
respectively.  The inclusion of saliva and other glandular secretions opens the possibility 
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for a new testing prototype to emerge.  This area was previously relatively unexplored 
due to the low levels of analyte present, but due to the efficient capture of agarose beads 
and high signaling capabilities of QDs, new advances in saliva-based diagnostics may 
now be envisioned.  The demonstration of the NBC‘s ability to obtain low LODs, in 
conjugation with its verified compatibility with oral fluids, suggests that it would be an 
ideal tool for use in screening individuals for cancer by detecting biomarkers in saliva.  
This work is consistent with other literature reports describing methods to quantify tumor 
markers in saliva as screening cancer tools,
194, 220
 but is among the first to validate QDs as 
quantitative and sensitive reporters in the context of clinical sample analysis.
221
 The 
integrated, disposable NBC described herein is highly compatible with the prototype 
analyzer described previously that combines optics, battery power, optics, and image 
analysis into a compact tool.
131
  Such an arrangement is among the most integrated use of 
applied nanomaterials reported to date and expands further the utility of our compact 
NBC analyzer.
221






Figure 3.13.  Molecular Level Programming of NBC Assay components.  The 
integrated NBC cartridge (B) is read with a compact, self-contained analyzer (A).  This 
labcard still contains the fundamental agarose bead micro-reactors (C) as the research 
grade NBC (Fig. 1.4A) only in tandem with more elegant microfluidic condensations.  It 
is this agarose core (D) that contains the nano-net serving as support for 
immunocomplexes. E) Close-up of a single sandwich immunocomplex within the bead 





In addition to hosting ultra-sensitive assays, the miniaturized NBC assay platform, 
offers a multi-analyte testing capacity, whereby results for multiple targets come from 
single experimental runs.  Future work will incorporate additional biomarkers onto the 
platform as well as arrays designed to meet specific diagnostic needs as in a ‗well-
woman‘ themed chip similar to the cardiac chips previously reported. 
223
  Such a system 
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would have markers indicative of female-specific cancers integrated onto a single wafer 
used in tandem with current well-woman type exams, again at the POC.  A further 
application for these ultra-low detection limits includes screening patients for reoccurring 
cancers post-surgical tumor removal.
224
  For example, PSA levels in patients post- 
prostatectomy do not drop to zero, rather they decrease 2-4 orders of magnitude lower 
than patients who enjoy a healthy prostate—values in the femtomolar regime are 
reported.
224, 225
   The PSA analyte also shows promise in detecting breast cancer in 
women.
226
  Conventional ELISA cannot screen these patients with ultra-low amount of 
circulating PSA for the subtle changes in levels that may indicate a resurgence or 
presence of cancer.  This work with NBC systems is potentially appropriate in this area.   
In addition, other applications including oligonucleotide quantitation, gene expression 
work, and biomarker discovery could all potentially benefit from these advances in NBC 
performance.
227, 228
  Future work toward decreased fluid handling techniques and next 
generation optics that behave in a cohesive fashion with the QD signaling moieties, will 
continue to reduce overall analyzer size leading to even more elegant and functional POC 









Chapter 4: Molecular Level Programming of NBC Sensor Components 
for a Universal Approach to Assay Building 
4.1  CHAPTER OVERVIEW AND GOALS 
The work presented in Chapter 4 draws more analytical comparisons between the 
NBC and typical ELISA measurements that those presented in Chapter 3.  The three 
elements identical in both systems: capture antibody, antigen, and detecting antibody are 
examined and their impact on immunocomplex and assay development is elucidated.  
The unique features of the bead‘s three-dimensional reaction coordinates are not fully 
understood relative to the extensive characterization of the ELISA system.
209, 229
 Here, 
another generation of study on the 3D bead matrix and internal reagent transport, 
including location of all three immunocomplex contributors, helps to solidify insight into 
those factors that contribute to the high performance assay characteristics typical of the 
NBC. Figure 4.1 illustrates that diffusion, convection, and kinetics are all important 
contributors to reagent transport in the NBC and experiments in this chapter strive to gain 
both a mechanistic understanding of these phenomenon as well as to exploit this 
knowledge in context of exploring enhanced immunoassay performance characteristics.  
Improved molecular-level perspectives on the space-filling geometries typical of the 
agarose bead will hopefully lead to a superior appreciation for the variables necessary to 
consider upon construction of a new assay system or optimization/attenuation/variation of 
a current analysis format.      
As detailed in Figure 3.2C and Figure 4.1D-F, at the core of the bead-based 
NBC is an immunoassay sandwich attached to the NBC scaffolding infrastructure 
(agarose strands).  In this chapter, the concentration and size of fundamental 
experimental building blocks within the NBC will be tailored to optimize assay 
performance: capture antibody, detecting antibody, and agarose filament.  Previous 
studies using the NBC take the general format of addressing a unique challenge.  Assay 
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conditions are usually manipulated to solve a specific problem, that is, to optimize an 
assay or series of assays for an individual application.  The studies in Chapter 4 work to 
develop a universal approach to assay building.  
 
Figure 4.1. Contributors to assay performance in NBC.  In A the location of an 
agarose microsphere in the MEMS structure is considered from the xz optical plane.  
Reagent transport into the bead structure is affected by active transport (flow) of material 
(B), diffusion of reactants into the sponge-like bead center (C), and the kinetic rate 
constants of interaction between non-covalently linked antigen and antibody (Kon and 
Koff, D).  In this chapter, work is performed to move beyond a 2D conception (E), to an 
improved 3D appreciation of the agarose bead environment (F).  Red line in A indicates 
the plane used for fluorescent confocal imaging studies.   
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4.2  INTRODUCTION 
Two dimensional surface areas as the underlying support structures for 
immunoassays have been the norm for many decades now.
230
 Microtiter plates in a 
variety of formats and from many different material types are common with the 96-well 
―ELISA plate‖ from poly-vinylchloride (PVC) being one of the most common.  Coating 
techniques have remained relatively unchanged since the 1970s and still suffer from 
many of the same challenges that exists during that era.  First, in both commercially 
available ELISA kits as well as in laboratory-prepared systems, the capture antibody 
elements is non-covalently linked to the plate surfaces via passive absorption.  This 
coating process takes advantage of the hydrophobic interactions between nonpolar 
protein structures and the plastic microtiter plate matrix.
209
  As interactions between 
polymer and protein are dependent on size, charge, and polarity of the two systems, each 
antibody has a unique affinity for substrate as well as binding constants.  To allow 
contact between the hypdrophobic protein core and well plate, and thus encourage more 
robust interactions between antibody and plastic, mild denaturation of antibody via pH is 
common.  Alternatively, many researchers use the avidin/biotin pathway to link capture 
antibody to ELISA surfaces—this technique also may interfere with recognition kinetics 
of antigen and antibody.  Second, systemic control of antibody orientation is largely 
absent in the ELISA design.  Figure 4.2 illustrates a few of the myriad scenarios possible 
with this non-specific approach to assay building in ELISA.  Not only may the reactive 
site be directed away from reaction area, but layering or steric overcrowding can prevent 
antigen from linking to antibody due to an inordinately high concentration of antibody 
during the coating step.
231
  Third, due to the non-covalent method of ligand attachment, 
antibody may leach off during wash steps.  Finally, the extent of antibody coating is 
highly dependent upon the diffusion coefficient of bioligand, the ratio of surface area 
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being coated to the volume of reagent solution, as well as the time and temperature of the 
coating step.
209
    
 
Figure 4.2. Inconsistent ELISA Capture Antibody Design.  A) In optimal coating 
environments, capture antibody is evenly distributed across the surface of a microtiter 
plate.  However, any number of alternative schemes can result in less than ideal antigen 
capture including IgG linkage through active site (B), orthogonal antibody orientation 
(C), insufficient antibody coating (D), antibody stacking (E), and antibody layering (F).  
In addition, non-covalently linked antibody may disassociate from plate surface upon 
washing, effectively rinsing away analyte and later decreasing signal (G).   
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Thus, due the above listed reasons, ELISA systems are rarely capable of ultra-low 
detection limits, even when used in conjunction with enzyme-amplification steps.  
Because of these failures in monolayer assembly, some studies estimate that the percent 
of capture antibodies that remain active and capable of binding antigen is below 10%.
232
  
This poor performance is in contrast to superior detection capabilities of the NBC both 
with molecular fluorophores and with QD probes (recall Fig. 3.10 and Table 3.1).  There 
are many reasons for the strength of the NBC assays, notably the highly effective 
washing  that results from chip design, the high signal of the QD reporter,  but also 
important here is the avidity with which the capture antibodies bind there target.  For the 
purposes of this discussion, avidity is defined as a highly effective, multivalent mode of 
analyte capture and immobilization.  The agarose beads, and their ―nano-network‖ of 
fibrous, reactive strands, epitomize an analyte capture modality with high avidity.   The 
reader is referred to Figure 3.13E for a deeper appreciation of the nanoscale lattice of 
immbolization elements, typical of the agarose bead.  Methods to improve this capture 
efficiency and control reagent distribution is an important goal of this chapter.   
 First, some previous studies quickly bear mention. Former McDevitt Group 
member, Marc Rodriguez found that using the overnight capture antibody immobilization 
protocol, this reagent completely penetrated the agarose microsphere.
233
  However, for 
investigations using the C-reactive protein (CRP) analyte, neither the antigen, nor the 
detecting antibody made significant penetration into the bead core.  Rather, these reagents 
remained on the periphery to a depth of ~20 µm for the homogenous agarose and was 
attributed to the size of the entire 460 kD immunocomplex.  Jorge Wong, also in the 
McDevitt group, studied similar bead types, but with a labeled antigen in lieu of 
traditional fluorescence detecting antibody.
199
  In this work, sample recirculation over 
beads resulted in a slow, radial penetration of antigen into the core of the capture 
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antibody coated beads over a 45-minute time course.  From this progression, rates of 
diffusion were calculated and this work demonstrated how increased penetration could be 
achieved via active transport.     
Both Wong and Rodriguez used confocal microscopy to optically cross section 
the beads, which allows a much more detailed description of the agarose substrate versus 
epifluorescent images.  From these studies, an absence of fluorescence implied a lack of 
reaction participant.  That is, if no green signal is present on the bead interior, then no 
green fluorescence labeled protein was present on the interior of the bead.  Other work in 
the field, however, cast doubt over the exact phenomenon surrounding this ring-like 
effect.   Yan and Lee suggested that self-quenching of signal was possible, especially at 
higher concentrations of fluorophore, effectively causing signal emitted by dyes near the 
center of the bead to be reabsorbed by fluorophores closer to the periphery.
234
  As this 
energy transfer is proportional to the Forester distance according to 1/r
6
, a small increase 
in concentration has the potential to dramatically impact fluorescence emission 
reabsorption.  Other work by Kress and Bradley suggested that the lack of signal on bead 
interior is a result of poor illumination, that is, the incident radiation necessary to excite 
fluorophores on the bead interior is unable to penetrate the center either due to 
concentration effects or bead composition.
235, 236
 Although this other work was 
sometimes done using bead types other than agarose, its repercussions on NBC research 
was important to consider.  This work implies that the dearth of signal on bead interior 
may not be the result of a lack of labeled probe, and hence reagent. 
Fortunately, Mehnaaz Ali‘s dissertation offered important clarification in this 
area.
237
  Here, beads were coated with molecular beacons using biotin/avidin affinity; this 
reagent was demonstrated to penetrate completely into the center of the bead.  Incubation 
of these beads with the molecular beacon target sequence gave fluorescence near the 
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periphery with both epifluorescent and confocal imaging techniques.   Next, the beads 
were microtomed and imaged epifluorescently—fluorescent signal remained on the outer 
bead area confirming that a physical absence of analyte was responsible for signal 
decrease, not internal optical effects and interferences. 
 
Figure 4.3.  Size Considerations of Bead-based NBC Recognition Elements.  Both the 
capture and detection bodies in sandwich immunoassay are typically whole IgG 
fragments (A).
150, 238
  A variety of proteolytic digestion schemes can be used to render 
this whole antibody into smaller F(ab‘)2 (B) or Fab (C) fragments.  Alternatively, scFV 
(single chain variable fragment, D) chains, using recombinant pathways, consist of only 
the heavy and light antibody target recognition chains.  (E)  Comparison of the molecular 
weight, maximum distance, radius of gyration (all left axis), as well as total number of 
amino acids in the protein (right axis) for different size recognition bodies as well as the 
CEA antigen.
206
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With this validation of confocal microscopy as an analysis tool in mind, Chapter 
4 works to understand better the fundamental components of the bead-based NBC.  An 
initial parameter optimized in this system was the size of the capture and detection 
antibody via fragmentation.  The use of Fab and F(ab‘)2 antibody fragments has 
established attributes including the elimination of Fc based nonspecific binding, reduced 
steric hindrance with retention of active sites, decreased immunogenicity with potential 
for reduced immunoreactivity.
238-241
  Figure 4.3 offers a comparison of the size and 
structural differences between these various fragments.  Currently, scFv fragments are the 
subject of intense investigation and reduced IgGs have been used in therapeutics delivery, 
blots, immunohistochemistry, and well as for NMR/crystal structure determinations in 
lieu of the larger whole fragment.
242, 243
  In an application similar to the NBC, Song and 
Fan demonstrated that the use of F(ab‘)2 fragments as capture elements gave lower limits 
of detection and better correlation to reference method in a planar, sandwich 
immunoassay for cancer biomarkers than did whole IgG.
244
 This prior work, in addition 
to the capability and even necessity for antibody fragments demonstrated in Chapters 2 
and 3 is the impetus for this work with reduced recognition elements.  This hypothesis, 
that smaller antibody fragments will allow for higher densities of antibody and thus 
increase analyte sequestration will be detailed in Section 4.4.1.   
An additional focus of Chapter 4 is an examination of the influence antigen size 
has on distribution of signal in sandwich immunoassay via the agarose beads in NBCs.  
Nearly any multiplexed assay with a sizeable number of analytes will contain antigens of 
various molecular weights, radius of gyrations (Rg), and thus maximum diameter.  
Previous work has considered all antigens to behave identically in the NBC.  Work 
detailed in Section 4.4.3 will illustrate the inaccuracy of this presumption and offer 
guidelines for designing effective assays that consider the analytes‘ size and shape.  
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Finally, this chapter will examine the effects of agarose bead porosity has on 
immunoassay performance, and reagent penetration will be used to estimate bead pore 
sizes.  Previous work using either atomic force microscopy (AFM) or advanced 
absorbance measurements  have given a wide range of estimates for pore size in planar 
agarose and are highly dependent upon the method of preparation and cooling.
207, 245
  
Despite this, some general trends may be discerned.  Mainly, pore size decreases as 
agarose porosity increases and pore size is on the order of 100s of nanometers.  Although 
excellent SEM images are detailed in Section 4.3.3, it is imprudent to use only this 
invasive sample preparation and analysis method exclusively to glean quantitative 
information about pore size.   
Thus, Chapter 4 will work to answer the following fundamental questions about 
the bead-based NBC:      
•   How do Fab and (Fab‘)2 fragments behave relative to whole IgG? 
•   How does capture antibody size affect signal intensity and location? 
•   How does detecting antibody size affect signal intensity and location? 
•   How does antigen size affect signal intensity and location? 
•   How does bead porosity affect reagent transport? 
•   What more may be learned about our bead behavior in terms of diffusion, 
sterics, and distribution of fundamental assay building blocks?  
The results will offer refined understanding of methods to develop immunoassays for 
ultra-low limits of detection as well as other valuable performance characteristics.  Most 
sandwich systems explored previously have been done on a planar surface.  Little 
information is known about protein capture and reagent distribution within 3D, pressure 
driven, microfluidic flow chambers.  This study will allow for a more comprehsive 
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comparison between standard commercial ELISA assay kits and the NBC scheme under 
development here.   
4.3 MATERIALS AND METHODS 
4.3.1 Preparation of Components for CEA Assay 
Similar to the work in Chapter 3, detecting and capture antibody pairs specific to 
CEA were purchased from Fitzgerald (Concord, MA) as was recombinant CEA antigen.  
Detecting antibody was labeled with Alexa Fluor 488, capture antibody with Alexa Fluor 
647 and antigen was tagged with Alexa Fluor 546.  Labeling was performed by adding a 
500 µL of protein at ~1 mg/mL to powdered fluorophore followed by incubation with 
stirring for 1 hour.  All dye molecules have a tetrafluorophenyl moiety bound which 
forms an excellent leaving group allowing for linkage of dye to free amine on protein.  
Unbound fluorophore was separated from labeled protein using size exclusion 
chromatography.   
4.3.2 Ficin Fragmentation of Whole IgG1 Molecules  
All antibodies used for this digestion were mouse IgG1 molecules.  Both labeled 
and unlabeled capture antibodies were subjected to proteolytic digestion while, due to the 
necessity of signal, only Alexa Fluor 488 bound detecting antibody was subjected to this 
further processing step.  Both Fab and F(ab‘)2 fragments were prepared via ficin, a well 
characterized digestion agent.
240, 246
  Reagents needed for this cleavage were purchased 
from Pierce (Rockford, IL) and included:  immobilized ficin on 6% agarose beads in 
storage buffer (>1.8 mg ficin/mL resin), cysteine hydrochloride, pH 6 digestion buffer 
(10x), pH 8 Protein A binding buffer with EDTA, pH 6 elution buffer, and AffinityPak
TM
 
Protein A columns with Protein A immobilized onto 6% crosslinked agarose of 2.5 mL 
volume with a binding capacity of 6-8 mg of mouse IgG.   
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A detailed protocol for digestion of IgG1 molecules is available via Pierce product 
#44880.  Briefly, working digestion buffer was prepared from the 10x concentrate and 
cysteine HCl added to a final concentration of 0.011 M for F(ab‘)2 digestion and 0.11 M 
for Fab preparations.  Ficin columns were equilibrated with working digestion buffer and 
then sample (500 µL, ~ 1mg/mL) containing IgG1 was introduced and allowed to enter 
column bed.  Upon sample permeation of gel, the column was sealed and stored at 37
o
C 
for 4 hours for Fab experiments and overnight for F(ab‘)2.  The sample was eluted by 
addition of 4 mL portion of Protein A binding buffer and column washed and regenerated 
for additional use.  The sample containing aliquot was then loaded onto a Protein A 
column, allowed to enter gel, followed by addition binding buffer.  Fractions of 1 mL 
were collected and saved for later characterization by protein assays using A280 or 
Bradford‘s method (A595).
154, 247
  Alternatively, A494 or A650 could be used on the Alexa 
Fluor labeled fragments.  Aliquots identified as containing fragments of interest were 
then pooled and purified using a 10,000 MW cutoff concentration microcentrifuge tube 
from Sartorius (Aubagne, France.)   The IgG binding buffer was then used to wash the 
Protein A column followed by elution buffer, pH 3 0.1 M citric acid, and 10 mL water.   
Both the Protein A and ficin columns were stored at 4
o
C for later use.    
4.3.3 Preparation of Beads 
Agarose bead preparation was adapted from Gustavvson‘s method and tailored by 
Wong.
197-200
   Briefly, agarose from Sigma Aldrich (St. Louis, MO) was added to 50 mL 
water to the desired percentage and heated to 85
o
C in a water bath.  A suspending 
solution of 10 mL Span85 also from Sigma Aldrich in 100 mL n-heptane was heated to 
61
o
C.  After introduction of the agarose mixture into the suspending solution stirring 
proceeded for 1 min.  As temperature dropped with vigorous stirring, the agarose gel 
beaded out of solution and precipitated to the bottom of the flask.  Beads used for the 
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antibody fragment studies were subjected to a cross linking procedure, while those of 
tuned porosities remained uncross-linked.  Beads could then be washed with a 50/50 
ethanol/water mixture for hydration and size sorted by a sieve.  Beads were stored at 4
o
C 
until future use.  For linkage of antibodies and antibody fragments to the beads the 
sodium cyanoborohydride technique described in Chapter 3 was again used—all 
reactions were allowed to proceed overnight with precocious agitation.
201
   
4.3.4 Microscopy Design 
Beads were loaded into a silicon chip using dissection tweezers and sealed into 
the NBC.  For preliminary experiments, the same epifluorescent microscopy design was 
employed as in Chapter 3 and detailed in Section 3.3.5.    Using the adjustable gain, 
offset, and exposure time of the CCD camera, settings were found to image beads with 
little or no saturation of pixel intensity.  These images were saved as 12-bit TIFF files.  
Upon completion of the immunoassay sequence in the research-grade NBC, in tandem 
with the epifluorescent design, the NBC housing could be detached from peristaltic 
tubing and transported to an advanced imaging facility.  Here, the NBC was positioned 
upside down and immobilized on two plastic supports to facilitate the inverted design of 
the confocal microscope.   
Confocal images were taken with a Leica CTR microscope with a TCS SP2 
acousto-optical beam splitter (AOBS) with a 10x objective of 0.3 numerical aperture.  
Optimal settings for gain and offset on the Leica instrument were determined by using a 
quantitative look up table and pixel saturation values.  Bead medial sections were 
determined by scanning in the z direction until width of slice is maximized, indicating the 
bead‘s medial plane was in focal plane.  Initial settings used simultaneous scanning of all 
color channels to determine rapidly both the best physical location and optical settings.  
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For data collection, channels were collected sequentially to minimize cross talk and eight 
images were averaged into a single scan to increase resolution and decrease pixelation.   
4.3.5 Image Analysis 
Photomicrographs were saved as 12-bit colorized TIFF files and analyzed via 
ImageJ software from the NIH (Bethesda, MD) with bead fluorescence signal intensity 
correlating to the concentration of analyte in the sample.  Deconvolution macros, written 
using Java, converted the image to a grayscale 8-bit image with areas of interest (AOIs) 
drawn corresponding to individual beads.  These AOIS serve as a rough boundary in 
which the bead resides.  Four different methods described the information contained 
within the AOI.  The line profile (LP) method scanned the AOI one row of pixels at a 
time—the highest pixel value from each successive line profile was then averaged to 
calculate a mean signal.  The circular AOI (CAOI) method begins analysis in the 
geographic center of the region and expands outwards until it finds a circular region of 
pixels having the highest intensity.  All pixels inside this circle are then averaged to give 
a measurement of intensity.  The integrated density (D) technique takes the same circular 
region of pixels having the highest intensity uncovered in the CAOI method, and expands 
the analysis region 2 or more pixels on either side of the maxima.  All pixels in this 
region are then averaged to yield an intensity measurement.  Finally, the circular profile 
(CP) scheme simply averages the circular region identified in the CAOI and takes the 
mean pixel values.  All four of these parameters may then be reported with their 
respective standard deviations and coefficients of variation.   Additional data analysis of 
colocalization was performed using ImageJ supplemental code JACoP available at the 
ImageJ website.
248
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4.4 RESULTS AND DISCUSSION 
4.4.1 Effect of Antibody Size on Assay Performance 
Although a number of novel recognition elements have recently been proposed 
including aptamers, peptides, and surface-imprinted or molecular imprinted polymers, 
monoclonal antibodies have been the gold-standard for protein antigen immobilization 
for over 40 years.
249
  While the variety of antibodies has increased dramatically, the 
fundamental techniques for their production in hybridoma has largely remained the 
same.
238
  Thus, the antibodies used for these experiments were mouse IgG1 bioligands.  
Unlike IgG (human IgG), mouse IgG1 is resistant to digestion by pepsin (for F(ab‘)2 
production) and papain (to create Fab fragments).  This inactivity is attributed to the lack 
of N-linked glycosylation and absence of a leucine-234 residue in mouse IgG1, a highly 
conserved feature of human IgG and the active pepsin cleavage site.
240, 250
  This feature, 
as well as the resulting secondary, tertiary, and quaternary effects on protein structure in 
the mouse IgG1 gamma chain, results in a restricted hinge region and resistance to pepsin 
cleavage.  Furthermore, pepsin digestion requires a proton rich pH, an environment that 
can induce non-specific bond destruction or otherwise denature sensitive antibodies.
238
  
A number of alternatives exist to pepsin and papain, for mouse IgG1, the digestase 
ficin is an interesting option.  Ficin, a thiol protease, can facilitate a diverse range of 
reactions that involve the interconversion of carboxylic acids, esters or amides.
246
 It is 
obtained from Ficus carica and purified from fig latex.  The final product has a molecular 
weight of 25,000 with an extinction coefficient of 21 units at 280 nm for a 1% (wt./wt.) 
solution.
251, 252
 It is activated by week reducing agents including cysteine, sulfide, sulfite 
and cyanide; EDTA, N-bromosuccinimide, acridine dyes and cysteine are enhancers of 
ficin. Inhibitors include sulfhydryl blocking agents such as N-ethyl maleimide and 
iodoacetamide, heavy metal ions, mercuric chloride and carbonyls.
253
 To determine the 
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optimal digestion pathway, a study of five mouse IgG1 monoclonal antibodies with 
pepsin, bromelain, ficin and elastase determined which generated the high yields of 
stable, active F(ab')2 fragments. Results indicated that ficin digestion produced high yields 
of F(ab')2 fragments.  In addition the antigen-binding activity, immunoreactivity, affinity 
constants of ficin-generated F(ab')2 fragments remained similar to unadulterated IgG1 as 
determined by cell binding experiments using radiolabeled fragemnts.
240
   For the 
characterization of assay performance described below, the CEA assay outlined in 
Chapter 3 is elucidated in greater detail.   
4.4.1.1 Characterization of Immobilization Elements   
Ficin digests of CEA antibody 057-10009 (capture) and M111147 (detecting) 
were prepared.  A fraction of the capture elements were visualized fluorescently using 
Alexa Fluor 647, while all detecting moieties were tagged with Alexa Fluor 488.  
Experiments with unlabeled capture elements were also done to determine the effect of 
labeling on antibody efficiency; both labeled and unlabeled whole mouse IgG1 were 
subjected to Fab or F(ab‘)2 digestion procedures described in Section 4.3.2.  The 
resulting 1 mL aliquots from Protein A column eluate were characterized by three well-
known methods as shown in Figure 4.4.  Fractions 2-6 consistently contained the 
fragments on interest.   
This is seen most clearly in Figure 4.4A in which the Alexa Fluor-tagged F(ab‘)2 
fragments elute early in the chromatograph, followed by a subsequent change in pH and 
ionic strength allowing for release of the Fc and undigested molecules retained on the 
Protein A column.  Measurements observed with A280 absorption (Fig. 4.4B) were not as 
clearly resolved as A650.  These experiments measure UV absorption by aromatic 
structures within the protein and as the starting concentration was 1 mg/mL, the 
concentration individual fractions was <0.1 mg/mL, a value near the low end of the 
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performance range of A280 and the available spectrophotometer. Bradford assays with 
Coomassie reagent (Fig. 4.4C) indicates presence of fragmented protein in the initial 
eluate fractions, while later fractions show signal undistinguishable from background.  
The relatively poor performance of A280 and Bradford assay in this range is attributed to 
not only low levels of protein in the samples, but also the changing solvent environment 
inherent to gradient elution and the presence of non-specific and background signal.   
Some absorption at 280 nm can also occur due to components in the proprietary 
buffer, in addition to phenylalanine, tyrosine, and tryptophan residues in the protein.  
Furthermore, Bradford experiments are somewhat non-specific in detecting the presence 
or absence of arginine, lysine, or histidine in the protein—the presence of other amine 
compounds can increase signal.  An additional inherent challenge comes from the 
gradient elution method used here.  The background of the intial pH 8.25 binding buffer 
is A595 = 0.30 in the Bradford assay, a value that changes to A595 = 0.37 in the pH 6.02 
elution buffer.  Fortunately, the labeled capture and detecting antibody fragments were 
discerned visually; only the unlabled capture antibody control experiments absolutely 
demanded the use of these spectrosocopic methods.  These experiments were not 
concerned with producing detailed reports of the Fc and undigested fractions. Regardless 
of the characterization method, fractions 2-6 for each digestion were identified as 
containing product and thus pooled, and later concentrated, to prepare the antibody digest 
required for later conjugation to bead (capture element).   
Dose response curves using the A280 method for protein and A650 for Alexa 647 
were used to calculate concentrations in the final pooled and concentrated retentate 
(Table 4.1).  The distribution in final concentrations may be due to a number of factors 
including the efficiency with which 10K molecular weight centrifugal concentration 
tubes retain protein and interference of dye molecules with protein absorbance.   
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Figure 4.4.  Characterization of Antibody Fragments.  These figures arise from the 
Fab fragment preparation from Alexa Fluor 647-coated IgG capture antibody.  After 
proteolytic fragmentation, antibody digests were purified using a Protein A affinity 
chromatography column with agarose solid phase support, in tandem with gradient 
elution.  Yellow highlighted sections indicate pH 8.25 binding buffer, sections in green 
employ pH 6.02 elution buffer, and pink areas are pH 3.00 0.1 citric acid.  A)  
Absorbance values at 647 nm indicate that the antibody fragments elute in basic buffer 
while Fc regions are not released from Protein A beads until change to acidic liquid 
phase.  B) Absorbance at 280 nm shows similar signal increases from Fab fragments and 
poorly defined increase for Fc pieces.  C) Similarly, the Coomassie reagent and 595 nm 
absorption indicates the presence of Fab fragments and vague presence of Fc.  
Fortunately, only the first six aliquots from each elution were needed for further 
processing.   
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 Table 4.1.  CEA Capture Antibody and Antibody Fragment Characterization.  
Absorption at 650 nm and 280 nm was used to calculate the amount of protein and Alexa 
Fluor 647 fluorophore in various fractions of digested immobilization elements.  The 
‗647‘ indicates fluorophore labeled product while ‗Un‖ implies unlabeled antibody.         
(¥ - concentration provided by manufacturer)   
More importantly, it was necessary to use whole IgG to create the standard curve as 
prepared standards of Fab or F(ab‘)2 fragments of this clone were not commercially 
available.  Differences in amount of fluorophore may be attributed to differences in 
binding efficiency. Nevertheless, this method of characterizing the prepared fragments 
gives adequate accuracy.   
4.4.1.2 Preparation of Bead Micro-reactors   
As described in Section 4.3.3, agarose beads were linked to capture antibody.  
Here, it was critical to coat the bead surface and interior with an equimolar amount across 
all different recognition types.  Upon analyzing the data Table 4.1, it was decided to react 
beads with 0.042 mg/mL of antibody.  This concentration was necessitated by the low 
volume and low concentration of the F(ab‘)2 bioconjugate.  Although this is lower than 
the amounts used in other experiments and described in Chapter 3, this amount proved 
to be sufficient for these purposes and post-binding studies suggested that approximately 
70% of this protein covalently linked to bead.  Unfortunately, as illustrated in Figure 4.5, 
isomolar amounts of protein did not correspond to identical fluorescent signaling.  Here, 
the IgG/647 beads were brighter than their Fab and F(ab‘)2 by more than two orders of 
magnitude because they retained the dye containing Fc region in addition to the analyte 
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recognition epitope .  At exposure times short enough to prevent IgG pixel saturation, the 
Fab and F(ab‘)2 beads were not visible.  Furthermore, when these beads were observed 
with a green channel filter cube (even at 0.5 s of exposure), strong, green-channel signal 
bleed (S = 23.5) was seen from the intense IgG/647 beads.  When assays were performed 
with these beads, it was difficult to discriminate between aberrant signal from red channel 
cross talk, from authentic signal from detecting antibody.  To construct a more 
comparable system, new batches of agarose beads were prepared with isomolar amounts 
of fluorophore, specifically 7.0 x 10
-7
 M Alexa Fluor 647.   Thus, two sets of beads were 
prepared, one with isomolar fluorophore concentration and an additional set with 
isomolar amount of capture antibody.   
For the remainder of fragmentation work, beads with 7.0 x 10
-7
 M Alexa Fluor 
647 were used regardless of IgG, Fab, or F(ab‘) fragment status.  These beads yielded 
statistically identical fluorescent output and have antibody concentration of 0.0066 
mg/mL, 0.075 mg/mL, and 0.042 mg/mL respectively.  To achieve equivalent fluorescent 
signal for Fab and F(ab‘)2 systems, a 1.8 decrease in Fab concentration to 0.024 mg/mL 
of capture antibody was needed.  This corresponds closely to the 2X size difference 
between the two systems.  Similarly, the IgG scheme needs a factor 6.4 reduction to give 
beads with 0.0067 mg/mL of capture antibody, again compensating for the larger volume 





Figure 4.5. Intensity Differences by Capture Element Type and Concentration.  A) 
Photomicrograph of six different bead types reveals intensity differences.  B) Bar graph 
of signal intensity for five bead types.  Beads functionalized to F(ab‘)2 are represented 
only once—the isomolar antibody and fluorophore values were calculated relative to 
these  beads. This data reveals that the isomolar antibody has much larger signal intensity 
due to the additional numbers of dye that may be bound to Fc region.  Photomicrograph 
in B created with DVC camera settings of gain 10, offset 0, and 25 ms of exposure time.  
Note that IgG/647 isomolar antibody beads are saturated at a pixel depth of 255.  
Exposure times below IgG saturation were insufficient to record signal from fragment 
beads.   
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4.4.1.3 Fragment-Based Immunoassays—Signal Intensity 
With comparable beads containing a CEA-specific, fluorochrome-labeled 
detecting antibody prepared, a quantitative comparison of immunoassay performance was 
the next goal.  In addition to the three bead subsets described above, additional controls 
were needed.  First, as the presence of the Alexa Fluor transduction method has 
interference potential, especially with antibody specificity, similarly digested, but 
unlabeled antibody fragments were also linked to beads at a concentration of 0.042 
mg/mL.  Second, beads with 0.042 mg/mL of a CA125 isotype control antibody were 
prepared.  A 5 x 7 silicon chip to assay the following 7 beads types was required: 
Fab/647, IgG1/647, F(ab‘)2/647, CA125 isotype control, Fab/Unlabeled, IgG1/Unlabeled, 
and F(ab‘)2/Unlabeled.   
Third, all seven bead types were assayed both in the presence (100 ng/mL) and 
absence of antigen (negative control) with assay conditions similar to those described 
previously.  Completing the immunoassay, were three different detecting antibody types, 
again, Fab, IgG1, and F(ab‘)2.  It was necessary to design experiments that exposed the 
beads to identical detection conditions, yet all three detecting bodies had different 
concentrations, and ratio of fluorophore to antibody, similar to the conundrum described 
for the capturing antibody.  A 1:1000 dilution factor for Alexa Fluor 488 labeled IgG1 
detecting antibody was determined empirically to deliver S/N > 20 in the 3 mg/mL beads 
used for assays in Chapter 3 at 100 ng/mL antigen.  The 1 cm path length absorbance 
values at 494 nm for Fab, IgG, and F(ab‘)2 portions were 0.2274, 1.504, and 0.3388; 
proportional calculations determined that dilutions of 6.61:1000 and and 4.44:1000 were 
needed for Fab and F(ab‘)2, respectively.  The results of these six experiments are 





Figure 4.6. Signal Intensity Generation in Different Capture Element Types.  Radar 
plots of CEA assays with beads containing isomolar amounts of capture antibody bound 
to Alexa Fluor 647 as well as unlabled capture antibody were performed and evaluated 
via the four different analysis methods (LP, CP, CAOI, D).  A-C details the results of 
these assays for three different detection schemes, again at isomolar capture ligand 
concentrations, including IgG (A), F(ab‘)2 (B), and Fab (C).  D-F displays the same data 
as A-C, but with axis redrawn to the same scale.  The most intense signal output comes 
from the IgG-IgG interaction.   
The data acquisition displayed in Figure 4.5 was created by collecting images 
both before and after detecting antibody incubation, which provided for processing into a 
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background-corrected digital photomicrograph.  Such an image could be prepared for 
both the positive (100 ng/mL) and negative (0 ng/mL) experiments—it is this difference 
that is displayed graphically in Figure 4.6 through the four different methods of signal 
interpretation described in Section 4.3.5.  Panels A-C scale relative to the most intense 
signal in each experiment.  Here, some observations on signaling trends are apparent.   
First, the LP analysis scheme typically yields the highest pixel depth, a trend observed 
previously in Chapter 3.  Specifically, the LP method produces signal enhancement by 
factors of 1.8, 1.5, and 1.4 versus the CAOI, D, and CP analysis methods, respectively.  
Second, Alexa Fluor 647 tagged beads yield less signal relative to their unlabeled 
controls (with the exception of Fab), for IgG1 beads, signal reduction happened by a 
factor of 1.7 to 2.8.  As labeled capture antibody may have fluorophore in the binding 
pocket, this decreases analyte capture efficiency—the binding of fluorescent molecules to 
active sites on the antibody, reducing its ability to bind antigen, explains this 
phenomenon.  Third, capture antibody fragments decrease signal relative to their whole 
IgG counterparts.  Fourth, signal intensity of the different detecting antibodies is quite 
different and increases in strength according to size, i.e. IgG1 signal is most intense 
followed by F(ab‘)2 (62% reduction) and Fab (77% reduction).  These results suggest 
that using a whole IgG1 recognition element for both capture and detecting antibody 
yields the highest signal intensity 
The underperformance of antibody fragments to capture analyte and higher 
intensity of whole IgG1 as a reporter group may be explained by a deeper examination of 
these proteins‘ structure.  The four amino acids containing a terminal amine—arginine, 
lysine, glutamine, and asparagine—are the basis for both dye immobilization and linkage 
 142 
 
Table 4.2.  Terminal-amine Containing Amino Acids in Recognition Elements.  The 
major amino acids through which both fluorophore conjugation and immobilization onto 
agarose substrate are completed include lysine (Lys), arginine (Arg), glutamine (Glu), 
and asparagine (Asp).  As recognition element size decreases, the percentage of amine-
containing amino acids tasked with facilitating a bond increases.   
to agarose substrate in the NBC system.  To demonstrate the effect decreasing size has on 
these residues, protein database sequence details are listed in Table 4.2.
150, 254, 255
  These 
values explain in a more quantitative fashion the results seen in Figure 4.6.  As the size 
of capture body decreases, so does the number of amino acids capable of performing 
secondary chemistry.  In the third case on page 138, a reference to Table 4.2 is helpful to 
understand why capture antibody fragments underperforms whole IgG.  Both fragments 
and whole IgG link to the agarose substrate through the roughly four amine-containing 
amino acids. For larger bodies, IgG1, this is only 1.3% of the total available, but for 
F(ab‘)2 and Fab this number increases to 2.4% and 4.2%, respectively.  Thus, there is a 
greater chance that fragments are linked through an active site amino acid than for the 
larger IgG1.  For the fourth case explored on page 138, the decreased signal by fragments 
as detecting antibody, it may be seen that Fab and F(ab‘)2 bodies have 31% and 61% as 
many amine amino acids as does the whole IgG.  Therefore, upon fragmentation, the Fc 
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region and its wealth of labeled amino acids is lost while retaining the same analyte 
recognition moiety.   
4.4.1.4 Characterization of Immunoassay Signal Distribution 
 Although the results above make clear that smaller signaling probes cannot give 
more intense signal, the following work is designed to characterize whether smaller 
antibody fragments may be useful at detecting antigen immobilized on the bead‘s 
interior, and thus change signal distribution.  Figure 4.7 contains panels of 
photomicrographs reduced from the larger 5 x 7 array and highlighting beads with 
unlabeled, equimolar concentrations of Fab, F(ab‘)2, and whole IgG1 CEA capture 
antibody, as well as isotype control.  From these studies, it is clear that, the most 
important variable determining location of green fluorescent detection signal is not 
detecting antibody, but rather capture antibody and its spatial arrangement inside the 
porous bead.  While detecting antibody fragment affects output signal intensity (as 
illustrated above and confirmed below), it does not affect location.  Panel 4.7Aii 
illustrates succinctly the spatial affects of detecting antibody size.  When 125 pixels long 
line profiles cross each bead, the most intense pixel indicates location of highest signal.  
For Fab, this occurs at pixel 48, or approximately 15 pixels away from center.  For 
F(ab‘)2, peak intensity is at pixel 87 (25 pixels from center) and IgG1 maximum is at 
pixel 14, or 49 pixels from center.  This reproducible result indicates that detecting 
antibody penetrates deeper into the center of the bead when the capture antibody is 
reduced in size.  Indeed, the F(ab‘)2 and IgG1 beads show the ring-like signal pattern 
typical of data seen in Chapter 3.  It was curious that reductions in size of detecting 
antibody did not promote further increases in penetration depth.  Again, this only served 
to decrease signal.  This data provides evidence that little antigen is immobilized in the 
center of the bead without later detection output.  Smaller detection antibodies would be 
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able to penetrate deeper and report signal, but as no such change occurred upon reduction 




Figure 4.7.  Signal Distribution Generation in Different Capture Element Types.  
Three different detection schemes (A, IgG1; B, Fab; C, F(ab‘)2) yield three different 
patterns in beads. The top row of photomicrographs show beads with IgG1, Fab, and 
F(ab‘)2 capture antibody as well as an isotype control.  The middle collection of surface 
plots reveal that IgG1 and F(ab‘)2 beads relegate most of their signal to periphery of the 
bead; Fab beads have signal more evenly distributed.  This pattern remains the same 
regardless of detection antibody type.  That is, capture element type determines location 
of antigen, and hence, location of detection antibody.  The lower panel offers an 
alternative view of bead intensity.   
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4.4.1.5 Further Systemic Characterization  
Having studied signal intensity and distribution, the next goal was further 
optimization as well as interpretation of the non-specific signal (noise) and background 
present in the immunoassay platform.  Background (B) and noise (N) were determined 
similarly to the methods described previously in Section 3.4.1.  Briefly, B arises from the 
zero antigen calibration point and is caused by non-specific biological and chemical 
interactions between agarose support and detecting antibody.  Noise, defined as signal 
from isotype control beads, is an additional descriptor of detecting antibody misbehavior.  
In Figure 4.8A, the results of both B and N are detailed.  Importantly, these values 
increase relative to those values of Chapter 3, explained as follows.   
Due to the lower concentration (0.042 mg/mL) of capture antibody necessary for 
this fragmentation work versus work in Chapter 3 (up to 6.0 mg/mL) overall signal 
values are lower.  This requires the use of longer exposure times even up to 3 seconds.  
Even though background-corrected images were used, i.e. subtraction of image before 
detecting antibody from image after incubation and wash, B values increase.  More 
importantly though, is the change from a QD-based system in Chapter 3 to this work 
focusing on smaller molecular fluorophores.  Interactions between Fab capture and Fab 
detecting bodies gives the lowest values for B (B = 2.6); this interaction also gives the 
lowest values of S (vide infra). Noise in Figure 4.8A is indicated by the column marked 
‗Ctrl.‘ abbreviating the isotype control beads.  The lowest value of N comes from F(ab‘)2 
detecting antibody (N = 3.0).  Characterization of the changes the occur in immunoassay 
upon the inclusion of antibody fragments as detecting and capture elements is the focus 




Figure 4.8.  Ideal Antibody Combinations and Analysis Methods to Improve Signal 
and Reduce Background.  A)  Background and noise for three different approaches 
reveals that signal generated with zero antigen (background, B) is consistently low for 
F(ab‘)2 beads.  The lowest B values come from the Fab-Fab interactions, which also 
gives the lowest signal values.  Also, the isotype control beads (Ctrl.) reveals that the 
lowest values of N comes also from F(ab‘)2 beads, followed by IgG, and Fab.  B) IgG 
beads are used with three different detection methods and interpreted with the four 
analysis techniques described in Section 4.2.5.  For highest signal, IgG beads and a line-
profile analysis approach is the best technique.   
In Figure 4.8B the results of assays using three different unlabeled capture 
antibody bead types followed by 100 ng/mL CEA antigen, and whole IgG1 detecting 
antibody indicates differences between the four methods of deconvoluation as well as 
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inherent differences in capture efficiency.  First, IgG1 beads consistently generate the 
most intense signal, regardless of analysis approach.  Versus F(ab‘)2 beads, IgG1 signal is 
greater by a factor of 1.54, 1.50, 1.46, and 1.52 for the LP, CAOI, D, and CP analysis 
method detailed in Section 4.3.5.  When this identical comparison is relative to Fab 
beads, the amplification ratios rise to 4.00, 2.96, 3.80, and 3.92.  The increased values of 
F(ab‘)2 beads relative to Fab is approximately 2.5 for LP, D, and CP methods and 2.0 for 
CAOI, values appropriate considering the F(ab‘)2 fragment‘s 2X increase in size versus 
Fab.   
Comparison of the results for the different analysis methods again indicates that 
the LP method yields the most intense signal, followed by CP, D, and CAOI.  The LP 
analysis technique produces output values nearly twice as high as CAOI.  This 
observation is attributed the LP method‘s selection of only the most intense pixels across 
successive line profiles; the CAOI approach averages both the dim and bright pixels into 
a single value.  For a 280 µm bead, the LP method takes 104 successive line scans (156 
pixels wide) and effectively identifies the 104 most intense pixels out of the entire bead.  
The average of these 104 pixels is reported as S for the bead.  Conversely, the CAOI 
approach takes those same 104 pixels and dilutes them with the other 76301 pixels in the 
entire AOI, drastically dampening their contribution to signal transduction. The D and CP 
approach, although analyzing fewer pixels than CAOI, are still influenced by the 
averaging effect of dim pixels.   
Having identified the most appropriate capture and detection bioligands as well as 
analysis approach, a final comparison and representation of data is presented in Figure 
4.9.  Here, 50 ng/mL CEA antigen and 11 µM detecting antibody were used.  These 
experiments again demonstrate that the IgG-IgG analyte capture and detection pathways 
results in the highest signal, nearly double the next nearest neighbor, F(ab‘)2 capture, IgG 
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detection.  Although Fab-Fab has low background (vide supra), this advantage is 
tempered by the poor signal output seen below.   
 
 
Figure 4.9.  Signal Optimization.  A)  One row cropped sections of photomicrographs 
analyzed with three different detecting antibodies.  Again, the most intense signal came 
from the IgG-IgG interactions.  B) LP intensity values from the photomicrographs in A 
were scaled in relevance to the most intense signal.  Whole IgG antibodies were used for 
the remainder of the studies.  (All images have been background corrected and use one 
second of exposure.)  
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4.3.1.6 Effect of Capture Antibody Size on Antigen Location.   
To understand better the molecular level location of all immunoassay 
components, fluorescently labeled CEA antigen was next integrated into the NBC.  
Initially, Alexa Fluor 350 labeled this protein, but after extensive efforts to increase the 
loading level on CEA it was found incompatible due to its low fluorescent intensity and 
low quantum yield.  This blue fluorophore would have been preferable as its spectral 
signature is substantially different from the Alexa Fluor 488 on detecting antibody and 
Alexa Fluor 647 on capture antibody (see Section 4.4.2).  While the fluorophore 
appeared in epifluorescent microscope images, it was invisible in the confocal 
arrangement and the inherent thin optical slices.  To remedy this, Alexa Fluor 546, a 
more robust, orange fluorochrome was employed.   
Figure 4.10 illustrates the differences in antigen distribution between the three 
different bead types: Fab, IgG, and F(ab‘)2.  In Figure 4.10A, a grayscale look up table 
was used in tandem with the Alexa Fluor 546 dye system and confocal microscope.  
Initial observations on signal intensity correlate well with the epifluorescent 
arrangements seen above.  The S/N ratios of 11.7, 16.9, and 20.1 result from the Fab, 
F(ab‘)2, and IgG beads, respectively; amplification factors are similar to those seen 
above.  More interestingly, is the different behavior in bead penetration.  Note the narrow 
distribution of antigen in the IgG bead—the almost near uniform arrangement of signal 
on the periphery.  This is in contrast to the less monodisperse signal dissemination of 
signal in the smaller fragment beads.  To characterize quantitiatively these observations, 
136 pixel (393 µm) line profiles were drawn across each bead (Fig. 4.10B).  Penetration 
depth could then be calculated using the half-max approach as follows: The highest 
intensity value was identified by spatial pixel location.  This intensity value was then 
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divided by two and the spatial pixel value that corresponded to that intensity was 
identified.  The pixel difference between maximum and half maximum was calculated 
and converted into values of micrometers and listed in Figure 4.10C.  Antigen penetrates 
1.5 times deeper into the bead interior via Fab beads relative to whole IgG, an 
observation attributed to decreased pore occlusion, explored further in Section 4.4.3. 
 
Figure 4.10. Antigen Location in Bead.  A) Confocal image of antigen location in beads 
with either Fab, IgG, or F(ab‘)2 as the capture moiety.  B) Line profiles from the three 
different bead types reveal differences in both intensity and distribution.  As the capture 
antibody becomes larger (IgG) beads sequester more of their target on the exterior.  
Smaller capture elements (Fab) allow penetration of analyte deeper into the exterior.  
Data compendium in C was determined as penetration at one-half of maximum signal.  
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4.4.2 Multiple Color Channel Colocalization  
Figure 4.10 introduces labeled antigen as a third fluorescence body into this 
analysis and several challenges arise in attempting any type of colocalization, much less 
three-color experiments.  Colocalization implies the presence of two or more reporter 
molecules in the same location in three-dimensional space.  Key to understanding these 
experiments is a realization of the limitations of optical microscopy and the wavelength-
dependant resolving power.  Fortunately, these bead-based confocal images do not 
demand the kinds of cellular level resolution typical of colocalization experiments.
256
  
Also, the location specificity of the signal is due to specificity of the conjugated 
biological moiety.  Non-specific binding of a labeled antigen or antibody could imply 
untrue colocalization.  Further, the various fragments may not have an even distribution 
of dye.  For example, whole IgG has one third fewer amine sites for fluorochrome 
binding than does F(ab‘)2, but both have nearly identical analyte recognition epitope.  
Additional challenges inherent to the microscopy arrangement include retaining 
excitation strengths across all three labels and minimizing chromatic aberration.   
Imaging considerations also arise from the use of the fluorescent probes.  First, all 
dyes have different quantum yields as well as characteristic excitation and emission 
profiles.  Second, and more importantly, these dyes are not spectrally resolved either 
from an emission or excitation standpoint.  This leads to the possibility of the signaling 
scheme experiencing fluorescence resonance energy transfer (FRET) decreases whereby 
emission from one dye may be reabsorped by another molecule, effectively reducing 
signal out.  Furthermore, the dye emission profiles experience overlap.  For example, 
both Alexa Fluor 488 and Alexa Fluor 546 emit light at 575 nm and determining which 
molecule type (and thus corresponding bioligand) is responsible for the signal is only 
possible with careful controls.  Third, the Bayer filters of color CCD cameras are prone to 
cross color channel effects, especially at higher fluorescent signals.  In these situations, 
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improper loading levels or inappropriate camera settings such as exposure time or gain, 
can result in saturation of the specific CCD elements and bleed into other channels.  The 
fluorophore and thus color choices used for the three part labeling are detailed in Figure 
4.11 and illustrate the spectral challenges in such an arrangement.  
 
 
Figure 4.11.  Three-Color Colocalization.  A) All three parts of the bead-based 
sandwich immunoassay are linked to fluorescent tags in the following studies.  The 
agarose bead substrate is coated with capture antibody/Alexa Fluor 647, which fluoresces 
in the red.  Antigen is identified by its Alexa Fluor 546 tag, an orange dye.  For confocal 
imaging, this fluorophores corresponds to a blue lookup table.  Finally, detecting 
antibody is identified by an Alexa Fluor 488 (green) tag.  B)  The excitation and emission 
specta of the three fluorophores mentioned above reveals overlap and the need for careful 
optical controls to prevent unauthentic signal. (Spectra in B is copyright and reproduced 
courtesy of Invitrogen/Life Technologies, Inc.) 
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Given the potential for cross talk limitations, it is important that careful study of 
control cases are completed to establish the limits of these studies.  The most problematic 
case was high intensity red signal from the capture antibody crossing into those pixels 
dedicated to green channel light collection.  Three approaches were used to reduce or 
eliminate the interference potential.  The most easily controlled variable in these 
experiments was the exposure time of the CCD camera. The DVC software allows 
integration times of 0.09 ms up to many seconds of exposure time to be collected.  
Response curves could be collected that show the signal intensity as a function of 
exposure time (data not shown).  250 ms of exposure time was ideal at eliminating red 
bleed into the green channel.  Second, was the amount of capture antibody on the bead.  
Figure 4.12 illustrates the differences between a high and low amount of capture 
antibody and Section 4.3.3 will give more results of these differences.  Finally, a 
background correction procedure, in which images were collected before and after a new 
experimental parameter, allowed only the specific fluorescence signal increase to be 
evaluated.  For example, after bead loading into flow chamber, image collection with the 
red (Alexa 647) and orange (Alexa 543) filter cubes revealed the amount of specific 
signal in red channel and bleed in orange.  After introduction of Alexa 543 labeled 
antigen, another image was recorded.  The difference between these two Alexa 543 
images was specific fluorescence from antigen.  As confocal images were taken after the 
entire immunoassay was completed, an alternative approach to controlling bleed was 
taken.  Here, careful sequential scanning was performed.  Although the optical design 
allows for the simultaneous collection of all three fluorescent images, the excitation laser 
lines at 488 nm, 543 nm, and 633 nm were increased in order to only excite one 
fluorophore at any given time.  Despite only one exciter being on, all three PMTs were 
simultaneous active with their settings tuned to ignore non-specific signal.   
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Figure 4.12. Three Color Imaging via Epifluorescent Microscope.  Signal bleed and 
cross talk were negated by reducing camera integration time, reagent concentration, and 
via background subtraction.  Optical settings: c.Ab. (647), gain 0, offset 0, 6 ms 
exposure; antigen (543) gain 5, offset -7.5, 1 sec exposure; d.Ab. (488) gain 5, offset -7.5, 
1 sec exposure.  Tabular results indicate signal present before next layer of 
immunocomplex was applied.  For orange and green signal, this is the amount of ―bleed‖ 
and is expressed parenthetically as a percentage of authentic signal.  Note that an 
additional set of images were collected at lower exposure time to eliminate optical 
saturation in the high concentration beads.   
4.4.3 Effect of Agarose Porosity on Assay Performance  
Having ascertained which bioligands give optimal signal as well as the preferred 
method to interpret photomicrographs, the next goal in understanding molecular level 
behavior of the NBC was a more detailed characterization of the agarose nano-net.  
Although previous studies in this group made casual relationships between agarose 
porosity and assay behavior, this work took a systemic approach.  A number of factors 
including the heterogeneous nature of the nano and microfibers and difficulty 
maintaining adequate bead hydration compounds accurate characterization of the agarose 
beads.  Furthermore, literature reports describing agarose is typically on slabs of agarose 
gel and not the bead structures used in the NBC.  Nevertheless, valuable information on 






 in which estimates of pore size in the 2% agarose gels used in 
Chapter 3 range between 100 and 400 nm.   
4.4.3.1 Agarose Permeability 
Typically, agarose gels are likened to other types of chromatography; models 
describing agarose use the notion of particles diffusing through a porous media, i.e. 
packed column.  Descriptors of agarose include the weight percent, fiber radius, 
permeability, and pore size.   Depending on the synthetic approach and rate of cooling the 
gel from liquid to solid phase, the weight percent of agarose most typically has the 
greatest influence on downstream analytical descriptors, and thus performance, of beads.  
Figure 4.10 more clearly illustrates differences between beads of different weight 
percentages.  As the weight percent increases, there is more solid phase in the gel and less 
void volume—a situation modeled by Darcy‘s permeability.
257
  Although commonly used 
in geology and petroleum engineering, this term has recently found to be appropriate for 
use in describing agarose and measures the ability of a pressure driven fluid to flow 
through porous media. 
258
    Using the method of Clague and coworkers, later refined by 
Deen‘s group, the Darcy permeability of agarose can be calculated using the estimates of 
agarose fiber radius provided by Berk.
258-260
  More explicitly, Equation (4.1) relates the 
Darcy permeability (κ) to the volume fraction of agarose (Φ) and radius of randomly 
oriented neutral fibers (r).   
 
This estimated r value, as presented by Pluen and Berk, is 3.3 ± 0.4 nm by Ogsten‘s 
method and 4.0 ± 0.5 via Brinkman‘s approach; a value of 3.5 nm was used for the 









Figure 4.13.  Bead Porosity Determines Function.  The agarose microspheres have 
pores of tunable porosity.  By selecting the percentage agarose in water during the 
synthesis, the immunoassay infrastructure may be tuned.  Here, SEM images for beads of 
0.5% (A), 2.0 (B), 4.0% (C), and 8.0% (D) reveal that pore size increases as percent 
agarose decreases.  Through this electron microscopy technique, pore size estimates were 
gleaned through distances between adjacent agarose nanometer scale fibers.  Green and 
pink arrows indicate representative measurements used to construct the green and pink 
curves in Figure 4.14B.  (These images collected and reproduction permission granted by 
Dr. Jorge Wong.)  
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Figure 4.14.  Characterization of Bead Porosity. (A)  Permeability of a model porous 
structure, based on agarose, decreases exponentially as weight percent of solid phase 
(agarose) increases.  A situation measured experimentally in (B).  Here, three different 
approaches measured the diameter of pores in agarose gels, a descriptor similar to 
permeability.  The atomic force microscopic (AFM) approach gives a tight cluster of pore 
sizes between 200-400 nm,
245
 while absorption-based, spectroscopy experiments 
(Absorbance) techniques show the exponential decay predicted by the model.
207
  Data 
from SEM images gathered in conjunction with this dissertation (SEM - UT) also 
correlate to the exponential reduction in pore size with increasing agarose concentrations 
predicted by model and agree nicely with the AFM published literature values.   
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The SEM images presented in Figure 4.13 were taken at 100,000 X magnification 
and specific regions of interest cropped and tiled.  Various pore sizes were measured by 
creating lines with width sufficient to bridge the gaps between the two adjacent agarose 
fibers nearest the surface of the bead.  This was repeated again at for a  smaller grouping 
of pores.  The microscope‘s built-in scaling tool converted average pixel widths into 
nanometers by (4.87 nm/pixel).  Values for the upper grouping of 616 ± 91, 415 ± 80, 
218 ± 25, and 109 ± 45 nm were obtained for the 0.5, 2, 4, and 8% (wt./wt.) agarose gels, 
respectively.  The smaller cluster is illustrated graphically.  While this method is 
potentially subjective and may not be representative of the hydrated, atmospheric 
pressurized beads, it does approximate nicely published literature values.  This data is 
displayed graphically in Figure 4.14B and correlates well with the experimental model of 
permeability.  Although the analytical descriptors between Figures 4.14A and 4.14B are 
different, their underlying function—to detail the porosity of the substance—is identical.  
Important here is the exponential decline in porous nature of both the model (y = 742.6e
-
0.41x 
) and the experimental data sets (y = 645.4e
-0.23x
) at higher concentrations of agarose.   
More detailed model sets should include information on capillary forces within 
the bead.  Further, permeability changes rapidly in response to pressure by Equation 4.2.   
 
Here, Q is amount of flow (volume/time), A is cross sectional area (62,000 µm
2
 for the 
NBC agarose beads), ΔP is pressure drop (determined by flow rate in NBC manifold), µ 
is viscosity of fluid, and L is length of flow path (280 µm in NBC-type beads). 
Intuitively, an increase in κ or external pressure (flow rate, ΔP) leads to a greater amount 
of fluid flowing through the bead.  Flow rate was one of the additional parameters 




   As stated in the introduction, this study monitored the increasing amount 
of fluorescently labeled antigen that penetrates a bead.  From this Figure 4.15 was 
prepeared that gave estimates for the pore sizes in these 2% agarose beads.
263
 The 
estimates gleaned from this study, bead pore size of roughly 140 nm again corresponds 
nicely to the estimates presented in Figure 4.14.  These different approaches to 
measuring pore sizes give two rough classes of pore sizes—between 100 and 200 nm and 
between 250 and 600 nm.  In actuality, both of these are likely true.  The SEM images 
above show that an extremely wide range of pore sizes are present.  Even though the 
SEM preparation method effectively shrinks the agarose, that there are a wide range of 
pore sizes, likely remains in the hydrated polymer used in NBC assays.  The impact this 
has on immunoassays performance is detailed below in a case study  
 
 
Figure 4.15.  Bead Porosity via Computation Fluid Dynamics. Here, additional details 
including pressure and bead size was used in tandem with a penetration depth versus time 




Figure 4.16.  Size Features of Immunoassay Components.  To illustrate the necessity 
to consider bead porosity in assay design, CEA
206
 (PDB ID = 1e07) (A) and IL 1-ß
264
 
(PDB ID = 1t4q) (C) antigens are displayed, drawn to scale.  Regardless of antigen size, 
IgG
150
 (PDB ID = 1igy) recognition element remains nearly identical in size (B).  D)  The 
larger size of CEA results from its increased molecular weight (* indicates glycosolated 
weight) and larger number of amino acids.  (Images reprinted in accordance with the 
policies of the Research Collaboratory for Structural Bioinformatics’ Protein Data Base 






4.4.3.2 Effects of Agarose Permeability and Antigen Size on Immunoassay 
In Figure 4.16, a space-filling model of the IgG molecule is shown in addition to 
two representative biomarkers—CEA, and interleukin-1beta (IL-1ß).  For all work in 
Section 4.3.3, fluorescently labeled, whole IgG molecules are used for both the capture 
and detection bodies; this design is the most commonly followed in previous NBC 
reports and verified by work in Section 4.4.1.
127, 130
  Although there is a large size 
difference between the two antigens presented here (22.7 nm in size or 162.6 kD), both 
immunoassays employ the same IgG structure basis for capture and detection.  By 
designing identical assay systems, the effect of antigen size and agarose porosity can be 
elucidated. 
Beads were prepared with 0.5 mg/mL capture antibody.  After overnight 
incubation and subsequent protein assays, it was found that the CEA beads were coated 
with 0.29 mg/mL of antibody and IL-1ß beads were coated with 0.22 mg/mL.  
Differences between the two include variance in the absolute number of beads transferred 
from stock vial to reaction vial, as well as reactivity of the dye.  This was performed for 
beads of 0.5%, 1%, 2%, and 4%.  Importantly, these beads were not cross-linked  
according to Wong‘s, typical, previous method.
199
   Rather than joining free hydroxyl 
groups together via divinyl sulfone to create agarose helices, these beads were used after 
initial glyoxal activation.  As a result, the 0.5% beads were highly incompatible with the 
MEMS-based NBC—an observation the correlates to the exponential change in behavior 
seen at low concentrations in Figure 4.14.  More specifically, their propensity to deform 
under pressure or fluid flow in the silicon chip as well as their resistance to handling by 
micro-manipulators under the bead-loading, dissection microscope, precluded their use in 
further studies.  Fortunately, the 1.0%, 2.0%, and 4.0% beads maintained a sufficiently 






Figure 4.17.  Analyte Size Affects Bead Behavior.   (A)  Three-color identification 
approach is used for two different size analytes.  (B) Signal from the larger CEA 
molecules (27 nm) signal remains on the exterior.  (C)  IL-1ß is a smaller, globular 
protein (5 nm) and allows for deeper penetration of immunoassay components.  (D) 
Regardless of bead porosity, all CEA antigen and detecting antibody remains in the thin 
layer on the bead exterior, unlike IL-1ß behavior (E) in which a gradual decrease in 
analyte is seen from exterior to interior.  (Please see Figure 4.15 for optical settings.) 
 
A wealth of information may be gleaned from Figure 4.17, in which penetration 
of capture antibody, antigen, and detecting antibody is monitored via red, blue, and green 
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fluorescence signal.  These confocal images capture the medial slice of the agarose bead 
and show differences between the two assay systems.   Key observations include the 
following: First, both systems have capture antibody coated throughout the entire bead 
substrate, a function of the overnight incubation of capture element and the bold, even 
tenacious, nature of plate rocker shaking.  Next, similar to Figure 4.10C, antigen 
penetration depth was determined by pixel width at half maximum. In the CEA system, 
penetration depths of 10.1 µm ± 2.0, 10.1 µm ± 2.0, and 8.5 µm ± 0.2, were observed for 
1%, 2%, and 4% agarose, respectively.  The IL-1ß beads exhibited antigen 
immobilization much deeper into the bead.  Penetration measurements indicate depths of 
78.0 µm ± 6.7, 57.1 µm ± 5.5, and 41.9 µm ± 1.7 are achieved for 1%, 2%, and 4% 
agarose, respectively.  Here, the extent to which IL-1ß molecules enter the bead matrix is 
substantially higher than the degree to which CEA antigen ingresses. The CEA antigen 
has a maximum dimension approximately 5 times that of IL-1ß antigen, and penetration 
depths approximately 5 times less, depending on bead substrate type.  Note that 
penetration depth increases with lower bead agarose percentage.  That is, less agarose 
implies larger pores, which allows antigen to suffuse deeper into the bead—this fortifies 
further the observations made in Figures 4.13 and 4.14 regarding bead porosity as a 
function of percent agarose.  Finally, it is noted that all the green signal (detecting 
antibody) present in both the CEA and IL-1ß systems are confined to regions overlapping 
with blue signal (antigen).   
Two important inferences may be drawn from this observation.  First, nearly 
complete detection of antigen bound on the bead, in both the CEA and IL-1ß assay 
systems, is achieved.  To determine analytically what percent of captured antigen is not 
later signaled by a detecting antibody, the technique of Bolte and Cordelières reported 
percentage overlap.
248
  In the CEA experiments, the amount of blue signal in green was 
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99.5% and the amount of green signal in blue is 97.9%.  Thus, less than 0.5% of all 
antigen that is immobilized on the bead is not later transduced as signal.  Furthermore, 
only 2.1% of green signal is present on the bead non-specifically.  The Pearson 
correlation between these two populations of pixels indicated a strong relationship at 
0.949.  The intensity coefficient quotient (maximum = 0.5) was also high at 0.493.  For 
the IL-1ß assay, percent blue in green in 95.9%; Pearson value is 0.887 and ICQ = 0.448.  
This lower degree of correlation is attributed to the larger number of pixels included in 
the analysis, i.e. more diffuse signal pattern.  Regardless, these experiments reveal the 
reliability of the assay parameters in detecting a very high percentage of captured analyte 
while preventing non-specific immobilization of the reconnaissance beacon.   
4.4.3.3 Antibody Concentration Effects on Immunoassay 
For the assay above, signal cross talk in epifluorescent imaging was compensated 
for by the correction methods described in Section 4.4.2.  This was designed to reduce 
the high fluorescent signal from the Alexa Fluor 647 capture antibody, which can 
introduce spectral bleeding and other interferences in the epifluorescent microscopy 
design.  To overcome these challenges, beads with capture antibody concentration of 
0.0096 mg/mL were prepared in addition to the 0.29 mg/mL beads.  This concentration 
was inspired by the reduced loading levels discovered through optimization studies of 
antibody fragments.  In Figure 4.18, the differences in signal distribution between the 
high and low capture antibody concentration beads illustrates the striking impact this 
factor has.  Again, information from all three sandwich immunoassay components may 
be gleaned.  First, capture antibody does not penetrate completely into the bead interior 
for the 2% and 4% low concentration beads, despite these beads‘ preparation identically 
to the high concentration population.  Because the 2% and 4% beads have more 
agarose—and thus more reactive sites—than 1% beads, they are capable of depleting 
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completely the reserve of labeled capture antibody present in the conjugation reaction 
vial.  This does not appear to be an effect of antibody size, but rather concentration.   
 
 
Figure 4.18.  Concentration affects bead behavior.   (A)  The three-color identification 
approach from Figure 4.2 is retained for two concentrations of CEA detecting antibody.  
(B) At high concentrations, signal remains on the exterior; however, at lower 
concentrations (C) the distance between capture elements increases allowing deeper 
penetration of immunoassay components.  (Please see Figure 4.20 for optical settings.) 
In addition to capture antibody distribution, substantial differences are seen in the 
antigen and detecting antibody apportionment between high and low concentration 
detecting antibody beads.  A drastic increase in both antigen and detecting antibody 
penetration is seen in the lower concentration beads.  Versus the approximately 10 µm 
penetration depths seen in the 0.29 mg/mL beads (vide supra), the 0.0096 mg/mL beads 
have penetration depths of 52.0 µm, 43.4 µm, and 20.2 µm for 1%, 2%, and 4% percent 
agarose, respectively (Fig. 4.19).  Two factors influence the trend towards less antigen 
penetration at higher concentrations of agarose in beads with little capture antibody.  First 
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is a lack of capture antibody to immobilize target in the interior.  Secondly, at higher 
concentrations of capture antibody, the immunocomplex occludes the agarose nano-
channels, a hypothesis below confirmed.     
 
 
Figure 4.19.  Line profiles of immunoassay components from Figure 4.18.  The 
behavior of detecting antibody is confined to the bead exterior at higher concentrations of 
capture antibody (A) than the isotopic distribution seen at lower concentrations (B). (C) 
This accumulation of detection body on the periphery of A is in sharp contrast to the 
capture antibody distribution seen in the same system.  (D)  At lower concentrations of 
capture antibody, the differences in bead potency may be seen.  In the 1% beads, there is 
an excess of capture reagent, allowing this signal to penetrate all the way to center.  In 
contrast, the 4% beads have more active sites, effectively depleting all of the reagent 
before penetration to center is possible.   
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4.4.3.4 Importance of Pressure Driven Flow 
Also important to consider here is fluid flow within the NBC system.  Figure 4.20 
illustrates flow paths typical for a 2% agarose bead within the silicon chip used in for 
these experiments.  The first two panels show the plan (xy) view and an elevation (xz 
plane).  Here, red arrows indicate the areas of highest flow.  Note the absence of arrows, 
and thus flow, through the bead interior—observations consistently with Figure 4.18 and 
4.19.  Indeed, Figure 4.20C indicates that nearly all of the active, pressure driven flow is 
above and around the bead with the blue bead itself, influenced by Fick‘s law of 
diffusion.  Smaller, more diffusive analytes such as ions and small molecules have a 









/s and below. The diffusion limited nature of the 
bead interior explains the observations made in Section 3.4.3 in which a quick flow rate 
of 1.1 mL/min for 1 minute was insufficient to remove enough unbound fluorescence to 
achieve the low backgrounds necessary for ultra-low detection limits even though this is 
effectively greater than 8,000 bead volumes of rinse material.  A 5 minute 0.2 mL/min 
gentle cleanse cycle was also needed to allow material deep within the bead adequate 
time to diffuse to bead surface where it was removed by pressure driven flow.  
 Additional work used a photofabricated stainless steel support structure to 
support the beads in lieu of the silicon MEMS structure indicates that the ‗round object in 
a square hole‘ approach has benefits.  Figure 4.20C illustrates the higher reflectivity of 
this material versus the nitride-coated silicon chip (Fig. 4.20D) as well as the round 
apertures versus square.  A complete understanding of the performance features of the 
two systems in side-by-side analysis could not be completed in the time constraints of 
this dissertation.  However, support structures that do not allow any flow diversion 
around the bead consistently causes bead deformation and bead extrusion through the 
opening.  In addition, beads with low agarose percentages or beads not highly cross 
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linked frequently passed through the openings at flow levels above 0.5 mL/min.  
Nevertheless, improved signal was sometimes observed as a greater amount of analyte 
was forced through the bead reactor by this method.  Ongoing work by other members of 
the McDevitt research community are exploring the effects of changing the physical 
dimensions of the chip support structure to determine the exact optimal geometry.   
 
Figure 4.20.  Chip Design Considerations.  Computational fluid dynamic (CFD) studies 
indicate that the vast majority of NBC flow when using the silicon MEMS chip is around 
the bead.  Red arrows in A (xz plane), B (xy plane), and E (xz plane expanded) indicate 
the most flow at 0.3 mL/min passes through the openings between bead and bottom of the 
well.  Indeed the convective flow indicated by red in D is in contrast to the mostly 
diffusive transport in the bead, shown in blue.  Although no CFD work has been done 
modeling the stainless steel support (C), observations made with the NBC suggest that it 
behaves very differently than the etched silicon chip (D). 
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4.4.3.5 Confocal Colocalization Imaging Controls 
The attentive reader will note the red fluorescent intensity in Figure 4.18B has 
intensity similar to Figure 4.18C, despite being nearly 30 times more dilute.  This is a 
result of the two images being captured under dissimilar optical settings on the Leica 
confocal microscope.  Quality image capture of these less fluorescent samples required 
more sensitive optical settings.  To confirm that the periphery-isolated patterning signal 
seen in the high concentration beads was a function of fluorochrome presence and not 
due to inadequate sensitivity of the photomultiplier tube detector, a series of images were 
captured at identical optical settings as the low concentration beads and presented in 
Figure 4.21.  Importantly, the intensity of this fluorescent signal increases, but the 
distribution does not.  It may therefore be concluded that the exterior-focused antigen and 
detecting antibody signal seen on the high concentration CEA beads is a true 
representation of the bioanalyte location and is not a photomicrographic optical artifact.   
To determine whether the blue and green channel signal seen in the 0.0096 
mg/mL capture antibody beads was a function of spectral bleed in the confocal 
microscope, the beads were analyzed prior to introduction of antigen and detecting 
antibody at the optical settings described in Figure 4.21.  The results of that experiment 
appear in Figure 4.22 indicating that the blue and green signal reported is indeed 
suggestive of the presence of the antigen and capture antibody and are not artifacts in the 













Figure 4.21.  Optical Settings Experiment for Verification of Signal.  In A, the same 
image is seen as in Figure 4.14B along with the optical settings needed for all three 
photomultiplier tubes on the confocal microscope.  B) Here also is the same specimen 
imaged at the more sensitive optical settings required for the lower concentration 
specimen from Figure 4.14C.  The similarity of the two images implies that the 
distribution differences seen in Figure 4.14 are not due to increased gain (sensitivity) or 




Figure 4.22.  Cross Talk Negative Control.  Beads only functionalized to capture 
antibody imaged at the optical settings detailed in Figure 4.14B with all three 
photomultiplier tubes.  That absence of signal in the green and blue channels implies that 
the presence of signal in the above experiments is genuine.   
 
4.4.3.5 Occlusion of Agarose Nanochannels  
Being assured that the observed signal was indeed a valid representation of the 
presence of immunocomplex, a further disambiguation of fluorescence patterns was in 
order.  Particularly interesting was the sharp difference between the low and high 
concentrations of capture antibody and the 0.0096 mg/mL beads‘ ability to allow analyte 
penetration and detection throughout more of the bead.  As Table 4.3 indicates, for the 
high concentration beads, only the outer shell (~ 40%) of the bead exterior is ever 
exposed to the entire assay sequence, with the remainder being effectively a void volume.  
This prevents maximum usage of the bead substrate and may be partially responsible for 
the plateau effect observed in high-level samples, e.g. Figure 3.6A.  Unfortunately, using 
only the dimensions of pore size is inadequate to explain the behavior observed.   
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As Figure 4.14B illustrates, the pore dimensions for agarose given by all three 
methods indicate that the 57 nm CEA immunocomplex (15 nm capture antibody + 27 nm 
antigen + 15 nm detecting antibody) should pass easily through all but the most stringent 
of pores.  Nevertheless, immunocomplex penetration is restricted to only the outermost 
regions of the bead and no difference was seen between 1%, 2%, and 4% beads.  
Equation 4.3 helps to explain further these observations.   
 
Here, d is the distance between capture antibody elements and is a function of the bead 
size as give by radius (rb, nm), amount of capture antibody conjugated to beads (j, g/mL), 
Avagadro‘s number (NA), molecular weight of the capture antibody (Mw, g/mol), and 
finally the number of beads per volume (Я, counts/mL).  For these experiments, Я was 
determined by Kepler‘s conjecture as summarized in Equation 4.4 where Vt is total 
volume of sample, p.e. is packing efficiency, and Vb is the volume of 1 bead.
266, 267
  For 
these experiments, it was found that 21,740 beads were estimated to be in 500 µL of 
sample.   
 
Using this value, and 280 µm beads and 155 kD IgG molecules, (4.3) can be decreased to 
the more manageable presentation in Equation 4.5, where the constant J condenses 
typical conditions of 280 µm beads and IgG capture/dection bodies into 64.3 nm
3
 *g/mL.   
 
With (4.5) and values of j determined by protein assay before and after reductive 
amination of capture antibody with beads, Table 4.3 was constructed to explain the 
relegation of signal to exterior in the high concentration beads.  At 0.29 mg/mL of 
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capture antibody, the distance between each recognition element is < 83 nm, a value large 
enough to allow one complete CEA immunocomplex to pass.  However, in the likely 
scenario that the bead chamber is lined with capture antibody, an 83 nm passage would 
be easily clogged with reagent material (Fig. 4.22). Two immunocomplexes have a total 
diameter of 114 nm—much larger than the distances between antibodies.  When the 
concentration of capture antibody is reduced in Table 4.3B, the distance between 
antibodies increases nearly three times to 237.5 nm.  This distance would theoretically 
allow deeper penetration of immunocomplex into the bead, an observation confirmed 
experimentally in Figures 4.18 and 4.19.  It may be further surmised that the pore size in 
all three beads is at least greater than the 114 nm length of two immunocomplexes.   
 
 
Figure 4.23. Occlusion of Nano-Channels. A and B) Agarose pore channels coated with 
detecting antibody.  Smaller bodies, however, such as IL-1ß (35 nm) shown in C, allow 
penetration deeper into the bead interior.  D) Larger immunocompelxes however, such as 
CEA (57nm) may block reagent transport in the agarose pores.   
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The hypothesis that the capture antibody is primarily responsible for occlusion of 
bead passageways is confirmed once again in Figure 4.10.  Here, the variable changes 
from concentration of capture antibody, to its size.  At the concentrations used in for 
these experiments (0.09 mg/mL), the distance between antibodies is 113 nm, just below 
the passage distance of the 114 nm CEA immunocomplex dimer.   As with the three color 
experiments, all antigen is relegated to the exterior, with the important exception of the 
Fab capture fragments.  Here, by reducing capture antibody by half, to 7.5 nm (recall Fig. 
4.3), a critical distance barrier is passed, allowing antigen to penetrate deeper into the 
bead.  The concentration of capture antibody needed to achieve this critical distance is 









Table 4.3.  Detecting Antibody Concentration Differences Affect Signal.  At higher 
concentrations of capture antibody (A) ~60% of the bead is unused for sandwich 
immunoassay.  No reagents besides capture antibody can penetrate into the bead center.  
This remains true regardless of bead porosity.  (B)  At a lower concentration, the distance 
between antibodies is increased allowing for more of the entire immunocomplex to 
penetrate.  Here, void volumes are reduced to zero; however, note the decreased 
epifluorescent signal intensity.  The * indicates the values is an estimate based on the 
trend fitting.  Data in § comes from Pernodet
245
 and ¶ is sourced to Narayanan.
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Importantly, in Equation 4.6, dimmuno is the size of the total immunocomplex. 
Thus, for the IL-1ß assay system, with whole IgG capture and detecting antibodies, the 
critical concentration of 1.50 mg/mL capture antibody begins occlusion. The experiments 
presented in Chapter 4 are well below this value and, indeed, show no resistance to 
reagent transfer.  It bears mentioning that the epifluorescent signal for the non-occluded 
bead is markedly lower than the higher concentration beads.  The epifluorescent signal 
for the low concentration 2% beads are approximately 18 times lower than the 0.2901 
mg/mL beads.  Therefore, in assays seeking low limits of detection, the higher 
concentration beads may be more appropriate as these beads concentrate further the 
 176 
analyte into a small region as they do not used entire bead volume.  Unfortunately, this 
same phenomenon may also decrease the linear dynamic range. 
4.4 SUMMARY AND CONCLUSION 
A study of molecular-level modeling with experimental verification is completed 
and the questions addressed in Section 4.1 may now be revisited.   
 The optimal reagents for Alexa Fluor-based immuonoassays in the agarose bead 
microreactors are identified to be whole IgG molecules for both capture and 
detection.  This is in contrast to the observations with QDs.   
 A substantial decrease in bead signaling capacity is observed for fragments of IgG1.  
This observation is attributed to a higher likelihood that the fragment is coordinated 
to either bead or fluorophore through an amine group in the antigen-binding site.  
Additionally, enzymatic cleavage may induce non-specific reductions or 
denaturations in antibody structure.   
 The use of Fab fragments for capture allow antigen and detecting antibody to 
permeate deeper into the bead, no increase in overall assay performance is observed.   
 Larger antigens are restricted to the bead exterior at isomolar concentration of capture 
antibody.  A direct dependence on size versus penetration into bead is observed.   
 Increasing weight percent agarose, increases the number of available functional 
groups in agarose lattice, but also decreases pore size.   
The observation here that whole antibodies are superior seems to be in conflict 
with the conclusions of Chapter 2 and 3 where antibody fragments gave best signal.  Such 
a conclusion need take into account the size effects of the reporter probe.  The larger QD  
size necessitated smaller fragments to be tailored to the agarose architecture.  Any loss of 
immunreactivity was compensated for by high QD fluorescent output for low limit 
analyte detection.  In contrast, whole antibodies need to be used for molecular 
experiments because the Fc regions contains a large number of the molecular 
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fluorophores.  Interestingly, both the IgG/Alexa and fragment/QD signaling bodies have 
sizes between 15-20 nm.   
Three-color colocalization experiments reveal that nearly complete detection of 
immobilized antigen is achieved with the NBC system.  Values of 99.5% detection 
typified the CEA assay.  In addition, the distribution of immunoassay components 
throughout the bead was found to be highly dependent on two key variables—the 
concentration of capture antibody and the size of the antigen target.  Decreasing either the 
antigen size or concentration of capture antibody allows a more monodisperse orientation 
of complex throughout the bead.  High concentrations and large antigen types give the 
ring structures commonly observed in both confocal and epifluorescent designs.  The 
derivation of a succinct equation to calculate the critical concentration of capture 
antibody to allow reagents complete access to bead interior may aid future researchers in 
designing experiments with optimal distribution of assay components.  Although 
montages of bead types have been used to expand the linear dynamic range of assays, the 
improved understanding of the molecular conditions affecting signal output presented 
here, may allow for even further increases in dynamic range, e.g. bead set #1 optimal for 
fg/mL range, bead set #2 optimal in pg/mL, and bead set #3 measures ng/m.  In addition, 
a variety of bead types are useful whenever a polymorphic analyte is being targeted.  For 
example, the CRP molecule is an inflammation marker studied previously by other 
McDevitt group members.
126
 At ng/mL levels the analyte behaves as a pentamer, 
however, as concentration falls into the pg/mL range, or in the absence of Ca
2+
, however, 
mostly monomers are observed.
127
 Having two bead types, one with smaller pores for the 
monomer, and one with large pores for the pentamer, all arrayed on a single chip would 
be very useful for extending the linear dynamic range of this immunoassay, beyond 
previous NBC experiments, and exponentially more than ELISA-based methods. 
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Figure 4.24.  Reagent Usage in Sandwich Immunoassay Systems.  The above 
comparison illustrates the fundamental differences between ELISA and the bead-based 
NBC for protein measurements.  By using a 3D versus 2D reaction vessel (A) and an 
intricate lattice of immobilization moieties versus a planar system (B), the NBC allows 
for a much higher density of reagent capture centers and thus a high capacity for 
reporting the presence of analyte (C).   
Chapter 4 offers additional insight on comparison of the bead-based NBC to 
ELISA systems.  In Figure 4.24, the differences are illustrated in a space-filling model.  
First of notice is the size difference.  A typical microtiter well has a diameter of 6.5 mm 
and a depth of 1 cm and comfortably contains a volume of 310 µL.  Some calculations 
allow for a best case estimate of the number of antibodies in this well.  For the monolayer 
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area of 1.33 cm
2




, approximately 9 x 10
11
 antibodies may 
be arranged in this space.  This value is the is an order of magnitude lower than the 9 x 
10
10
 copies of IgG antibody present in a agarose bead with an average uptake of 1 mg/mL 
protein out of reaction solution.  However, when volumes are considered (330 uL well 
versus 0.011 uL bead), the density of antibodies is 2.9/µm
3





 for the agarose system, nearly a 3,000 fold improvement in capture element 
density.  More importantly perhaps than this density, is that in the arrangement typical in 
NBC, this density contributes to the high avidity effects seen in the bead-based unit.   
Intuitively, the three-dimensional network of capture elements seen in Figure 
4.24Bii is highly efficient at not only capturing, but also retaining immobilized analyte in 
the reaction vessel.  In a monolayer, any antigen that becomes disassociated from the 
antibody has eight next-nearest neighbors on which to rebind.  In the bead, however, this 
number doubles to 16.  This doubling implies that the Koff  rate  is effectively negated and 
that a high amount of bound antigen is retained for a later signaling, an observation 
confirmed by other literature reports.
268, 269
 While it is true that this nano-net has the 
potential to increase non-specific absorption of fluorescent detecting antibody and 
increase assay background, the wash conditions (flow and time) described above 
effectively use both convection and diffusion to eliminate unbound detecting antibody.  
In addition, automated or manual sieving processes can select for smaller bead sizes in 
which the diffusion-limited behavior is reduced or eliminated.   
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Table 4.4.  Size Dependent Diffusion Time and Information Density.  The important 
effect size of reaction vessel has on system performance is illustrated above for a number 
of diffusion-limited hypothetical systems with dimensions and volumes listed above.  
Note that the ability to perform an increasingly larger number of assays in a shorter 
amount of time in a smaller amount of space.  ( td calculated by td = (d
2
/2D) where D is 





)  Please see Manz reference for additional insight.
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Table 4.4 gives one additional example of NBC assay performance versus ELISA 
to illustrate diffusion-limited differences.  Here, characteristic descriptors for the two 
methods are shown in comparison to two hypothetical devices, one larger and one 
smaller.  The theoretical maximum information density is nearly 10
10 
times larger for the 
bead based reactor as opposed to an ELISA plate.  Although, the ability to do a large 
number of assays on a small device array has not been completely exploited in the NBC, 
the efficiency with which this system captures analytes, as well as the high percentage of 
antigen captured that is later signaled, suggests that this approach to immunoassay 
building will continue to be explored by researchers seeking quality building blocks for 
POC biomedical analysis devices.   
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Dénouement: Conclusions, Outlook, and Future-Leaning Perspective  
As this work has studied improved methods to measure medically important 
analytes, it is now appropriate to revisit the specific questions proposed in Section 1.6.   
 Quantum dots from CdSe with a ZnS coat, peak emission at 655 nm and coated 
with a PEG based polymer, consistently gave the most intense, hydrophilic signal. 
 Conjugation methods linking QDs to monoclonal antibodies are specific to the 
application.  For cellular immunolabeling, a 2
o
 antibody approach was most 
effective while cellular labeling used direct covalent linkage of nanoparticle to 
antibody.  In both cases, antibody fragments complimented the steric size 
considerations of both the agarose bead and QD.   
 Non-specific binding and aggregation are reduced by careful selection of 
conjugation method and QD surface coating.  Avoid charged QDs to reduce non-
specific intereactions. Filtration of bioconjugate via 0.2 µm nylon filter 
immediately before labeling was key to minimizing aggregation.     
 Narrow emission filters (FWHM = 10-15 nm) are best suited for QDs; excitation 
at and below 425 nm is ideal.   
 The QDs are photostable up to 15 minutes of continuous excitation and give 30 
times more signal versus Alexa Fluor 488, which exhibits exponential signal 
decay in the time domain.   
 Successive line profile across the bead-based QD fluorescent signal yields the 
most sensitive response curves.  The SBR for cellular applications need be well 
above unity.  Background corrected images drastically improved signal quality.   
 The QD systems allows a single optical pathway to be used in multicolor channel, 
multiplexed experiments.  Demonstration of both inter-bead and intra-bead 
multiplexing is complete. 
 Limits of detection 60 times lower than ELISA methodology are achieved by 
using both an intense QD reporter as well as a fastidious approach to washing 
upon immunoassay completion—essential for low backgrounds. 
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 Whole IgG monoclonal antibodies in tandem with 2% agarose beads are the most 
appropriate building blocks in assay building with molecular fluorophores. 
 Recirculation of sample improves analyte capture 3-4 times, very important for 
low-level determinations.  The size of analyte and the concentration of capture 
antibody have important influence on reagent distribution and must be considered.  
The results of these questions may prove valuable to future researchers seeking to make 
improvements to this NBC assay design, but also to a broad class of life scientists seeking 
to integrate the attributes of hydrophobic nanoparticles into bioassay systems.  This work 
serves to engineer separate working parts with nano-level (nL, nm, ng) control of 
individual components with the potential for powerful new measurement devices. By 
carefully considering and defining the nanotechnological (QD), biological (antibody), 
and microfluidic (chip) components of the sensor, important advances in robust sensing 
have been made.  The processes necessary for highly efficient analayte capture and 
transduction in a microfluidic system is completed.   
As POC solutions become more commonplace and accepted in clinical settings, 
more applications may be envisioned.  Just as no diabetic could envision making regular 
trips to an outpatient hospital for glucose levels, so too may a number of assays currently 
confined to the laboratory be liberated.  Already, levels of electrolytes, blood gases, and 
cardiac markers are being measured at the POC, in spite of being limited by the resistance 
of some in the medical community to this new testing paradigm.  It should be understood 
that the goal of these handheld systems is to compliment other established methods, and 
not to reinvent those currently optimized.  Clearly, additional standardization studies are 
needed to give evidence to those in the practicing medical community of the validity of 
POC systems.  This work is the first to validate QD nanoparticles as reporter probes for 
these classes of analytes in a chip-based microfluidic ensemble.
131, 221
  Future work will 
focus on bring these advances to patients in need. 
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The majority of work presented here, employs the programmable, research-grade 
nano-bio-chip detailed in Figure 1.4A.  This assembly is ideally suited for empirical 
studies designed to determine the optimal design conditions of various reagent and 
reagent systems.  The modular, aluminum housing is convenient for initial studies 
determining such parameters as: labeling pathways between QD and bioligand, ideal 
antibody clones, QD vendor and emission maximum, flow rates and incubation times, 
and agarose porosity.  The screw-top aluminum housing allowed for quick exchange of 
fresh membranes for lymphocyte assays, and easy loading of fresh beads in between 
protein-based assays.   Unfortunately, the research grade NBC is not compatible with 
measuring samples in a clinic.   For truly integrated assays designs, an exploration of 
integrated systems was called for.  Medical clinicians and their support staff require a 
simple and reliable analysis scheme with the COMMAND QUALS characteristics 
mentioned in Section 1.4. 
The integrated labcard currently being optimized by research collaborators in this 
group, contains all elements required for a complete assay, integrated into a credit card-
sized device.  Liquid reagents are stored in blister packs while fluorescently tagged 
biorecognition moieties are stored in solid form.  Channels designed for mixing and fluid 
flow are built into this architecture.  These cards are built inexpensively from common 
materials including vinyl adhesive and assembled using conventional layering methods.  
The fluidic evolving design utilizes conventional computer animated drafting (CAD) 
software for simplicity and universality.  All cards are built in parallel, with 6-8 typically 
made from each page of laminate/vinyl adhesive design.  Figure D.1A illustrates the 
stratum of microfluidic pieces that combine to form the compact labcard in Figure D.1B.  
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Figure D.1.  Horizontal Cross Section of Compact NBC Labcard.  A variety of 
components condense to create the integrated NBC.  These include the buffer storage 
blister packs, fluid direction cavities, waste disposal reservoirs, and the analysis chamber.   
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Figure D.2.  Complete Assembly of Working Parts.  Many different components 
condense to create the integrated NBC (B), which contains the buffer storage blister 
packs, fluid direction cavities, waste disposal reservoirs, and the analysis chamber.  The 
two processor types (C) cited above (ii – Chapter 2, ii – Chapter 2 and 3) include the 
membrane-based, cellular processing unit (upper scheme i), for cellular assays, while the 
bead-based, chemical processing unit (lower scheme ii), is typified by protein assays.  
Both must bridge nanometer scale gaps between bioligand and signaling probe (E and F) 
to create bioconjugates for analyte fluorescence labeling (D) within the CPU.  Data 
contained in the samples and processed by the labcard is transcribed by a portable, self-
contained analyzer (A).   
 
One of the most important features of the POC solution detailed in this 
dissertation is its capability for analysis of both cellular and circulating disease markers.  
The modular and sui generis approach detailed in Figure D.2 is in sharp contrast to the 
―one assay, one chip‖ approach typically seen in the literature.   Chapter 2 detailed the 
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upper lymphocyte pathway of Figure D.2, while the lower scheme for proteins via 
agarose beads is described in Chapter 3 and 4.  Importantly, both types of analyses are 
easily integrated into the compact NBC labcard and interpreted by the standalone 
analyzer (Fig. D.2A).
223
   
 
 
Figure D.3.  Scaling and Moore’s Law Behavior.  The ability to bridge different gaps 
in scale (A) and combine the attributes of different layers results in an increasing number 
of analysis events on a small device footprint advances at a rate reminiscent of Moore‘s 
Law in the microelectronics industry (B).   
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This analyzer is currently under final revisions by a University of Texas 
commercialization partner and contains battery power supplies, signal capture and 
processing elements, readout display, memory for patient histories, and wireless 
communication features.  Each card is designed to be used for one patient samples.  After 
sample collection and introduction into the compact NBC, the labcard is inserted into the 
analyzer, similarly to a compact disk into a CD player.  Through manipulations of the 
fluidic cartridges, reagents are dispersed through the labcard according to design.  The 
integrated NBC is one of many contributions leading to behavior similar to Moore‘s Law 
in the electronics industry.  Here, the time needed to analyze a number of analytes on a 
single patient has decreased exponentially.  Figure D.3 illustrates in a general way, some 
of the major players in this space.  Owing to the theme of POC-type assay systems, time 
here is defined as time to perform the assay plus the shipping, or transport, time involved 
with the test.   
In conclusion, important advances are made in increasing the fidelity of the nano-
bio-chip POC sensor system of the McDevitt research community.  The inclusion of 
quantum dots made important increases in signaling capacity and limits of detection and 
allows a reduction in optical components typical of POC designs.  Although the field of 
POC systems is in its awkward adolescent phase, it remains of field of unlimited 
promise.
40
  The genomic, proteomic, and nanotechological advances of the past decade 
can only intimate where the ultimate future of biomedical devices may lie.  A continued 
movement toward singularity in medical diagnostic, imaging, and other analysis devices 
remains likely for the foreseeable future.    
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Appendix A: Optical Optimization—Emission and Excitation Filters  
Some of the initial experiments optimized the configuration of the Olympus BX2 
optical filter cubes.  Below is a representative example of such a systemic evaluation for 
the cellular NBC.  Two filter sets were used to examine one sample immobilized on a 3 
µm.  The signal and background were captured as explained in Section 2.4.2.  Although 
the signal remained nearly constant, the background was highly dependent on the 
emission optics.  Although both emission filters had peak transmittance at 560 nm, the 
one with a 40 nm bandwidth substantially increased the amount of background 
fluorescence relative to the filter with a 20 nm bandwidth.  Henceforth, filters with a 20 
nm bandwidth were used for all bead and membrane-based assays in the NBC.  This 
optimization was performed for each assay—the best results found are those listed in 
Materials and Methods for the respective experiments.   
 
 
Figure A.1.  Optimization of Excitation and Emission Optics.  These experiments 
reveals the importance of considering and evaluating carefully all optical assemblages 
used in conjucation with the NBC.   
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Appendix B: Reagent Optimization—Primary and Secondary Antibody 
Titration Experiments  
 
Figure A.2.  Optimization of Primary and Secondary Antibody Concentrations.  A) 
A constant volume secondary antibody was used in tandem with increasing volumes of 
primary.  Collected were total cell counts as well as non-specific (NS) aggregates outside 
of the cellular analysis parameters.  This NS value was used in tandem with background 
(B) counts to give a ratio of these events versus authentic cell counts.  Concentrations of 
reagents that minimized this parameter were needed.  B)  After 10 µg/mL was identified 
as the optimal quantity of primary antibody, the secondary antibody was similarly 
optimized.  Future experiments used 10 nM secondary antibody.  Two different camera 
exposure times were used, one and three seconds.   
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Appendix C: Sample Cellular Analysis Method via Java and ImageJ 
/






























run("Analyze Particles...", "minimum=70 maximum=500 bins=10 show=Masks 
display exclude clear"); 
initcountsr=nResults;totalcountsr=0; 
for (t=0; t<nResults; t++) { 
 
    W1[t]=getResult("Width", t); 
    H1[t]=getResult("Height", t); 
    circularity = getResult('Circ.', t); 
Xcoord[t]=getResult ("BX", t); 
Ycoord[t]=getResult ("BY", t); 
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   if (circularity>0.68) { 
  totalcountsr=totalcountsr+1; 
  run("Specify...", "width="+W1[t]+"  height="+H1[t]+"  
x="+Xcoord[t]+"  y="+Ycoord[t]+"  oval"); 




roiManager("Save", "C:\\Data\\Jesse\\2006\\100906\\"+k+"\\lp redCD3 ROIs 
"+j+"-"+i+".zip");        






run("Threshold", "thresholded remaining black"); 
run("Analyze Particles...", "minimum=70 maximum=500 bins=10 show=Masks 
display exclude clear"); 
selectWindow("ROI Manager"); 
selectWindow("Filter");close(); 
rename("Mask of Filter lp redCD3 "+j+"-"+i+""); 
open("C:\\Data\\Jesse\\2006\\100906\\"+k+"\\lp "+j+"-"+i+".tif"); 
roiManager("Open", "C:\\Data\\Jesse\\2006\\100906\\"+k+"\\lp redCD3 ROIs 
"+j+"-"+i+".zip");        
roiManager("Draw"); 
roiManager("Measure"); 


















run("Threshold", "thresholded remaining black"); 
run("Clear Results"); 
run("Analyze Particles...", "minimum=70 maximum=500 bins=10 show=Masks 
display exclude clear"); 
initcountsg=nResults;totalcountsg=0; 
for (t=0; t<nResults; t++) { 
    W1[t]=getResult("Width", t); 
    H1[t]=getResult("Height", t); 
    circularity = getResult('Circ.', t); 
Xcoord[t]=getResult ("BX", t); 
Ycoord[t]=getResult ("BY", t); 
   
   if (circularity>0.68) { 
  totalcountsg=totalcountsg+1; 
  run("Specify...", "width="+W1[t]+"  height="+H1[t]+"  
x="+Xcoord[t]+"  y="+Ycoord[t]+"  oval"); 
  roiManager("Add"); 
} 
} 
roiManager("Save", "C:\\Data\\Jesse\\2006\\100906\\"+k+"\\lp greenCD4 ROIs 
"+j+"-"+i+".zip");        






run("Threshold", "thresholded remaining black"); 
run("Analyze Particles...", "minimum=70 maximum=700 bins=10 show=Masks 





rename("Mask of Filter lp greenCD4 "+j+"-"+i+""); 
open("C:\\Data\\Jesse\\2006\\100906\\"+k+"\\lp "+j+"-"+i+".tif"); 
roiManager("Open", "C:\\Data\\Jesse\\2006\\100906\\"+k+"\\lp greenCD4 ROIs 
"+j+"-"+i+".zip");        
roiManager("Draw"); 
roiManager("Measure"); 
saveAs("Measurements", "C:\\Data\\Jesse\\2006\\100906\\"+k+"\\ Resultsgreenlp 





run("Image Calculator...", "image1=[Mask of Filter lp redCD3 "+j+"-"+i+"] 
operation=AND image2=[Mask of Filter lp greenCD4 "+j+"-"+i+"] create"); 
run("Analyze Particles...", "minimum=30 maximum=700 bins=10 show=Masks 
display exclude clear"); 
percentage=nResults/totalcountsr*100; 
print (" "+k+"   "+j+"-"+i+".tif"+"         "+initcountsr+"         "+totalcountsr+"         












run("Text...", "path='C:\\Data\\Jesse\\2006\\100906\\"+k+"\\Log of lp CD3CD4 
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